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ABSTRACT 
 
The hypothesis was that encapsulation of labile disulfiram (DS) in a high capacity 
nanoemulsion stabilized by quaternary ammonium palmitoyl glycol chitosan (GCPQ) could 
protect DS from degradation in the blood and increase its delivery to tumours. GCPQ was 
synthesized from glycol chitosan and characterized. GCP20Q11 polymer was chosen to be 
incorporated with DS in soybean oil into homogenous DS-GCP20Q11-E nanoemulsion. The 
nanoemulsions showed capability of oil-loading up to 50% v/v for a stable entrapment of high 
drug content. With increasing oil content (5 to 50%) the mean particle size increased, as did overall 
polydispersity (190 to 359 nm and 0.14 to 0.21, respectively). Transmission electron microscope 
(TEM) images showed existence of heterogeneous particles with a size below 100 nm. The drug 
load and colloidal stability were  improved in lower oil-content formulations stored at low 
temperature. Formulations showed highly positive particle surface charge (51 mV at pH 4.50), 
proving the ionic stability of the individual particles. DS-GCP20Q11-E showed marked 
cytotoxicity effect against human pancreatic cancer cell line (MIAPaCa-2) with enhanced activity 
seen in the presence of copper (IC50 of 0.37 µM compared to 34.17 µM with the nanoemulsion 
treatment without copper). In vivo oral pharmacokinetic (PK) study of DS-GCP20Q11-E showed 
low DS level (low area under curve (AUC)) in the mouse plasma compared to control group 
whereas the intravenous (IV) PK showed an improved AUC value with DS half-life of 17 minutes. 
DS-GCP20Q11-E anticancer activity against development of human pancreatic cancer xenograft 
tumour in mice revealed significant prolonged survival in animals treated with IV DS-GCP20Q11-
E or oral DS in soybean oil compared to control (no treatment). No toxicity or side effects were 
iv 
 
seen from the multiple administration of the nanoemulsion. In conclusion, DS-GCP20Q11-E 
nanoemulsion has the potential to be used or developed further for cancer therapeutic purposes. 
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1 Introduction 
 
Chapter 1 
 
Introduction 
 
1.1 Current cancer treatment 
Cancer is the leading cause of deaths worldwide with 8.2 million cancer-related 
death reported in 2012 (Forman and Ferlay, 2014). In the United Kingdom, 2.5 million 
people are estimated living with cancer and this number is predicted to increase up to 4 
million by 2030 (Maddams et al., 2012). This staggering numbers of cancer-associated 
mortality could mean that the current cancer treatment regime is not sufficient enough to 
combat the rapid and aggressive progression of cancer, despite of the widely diverse of 
advanced chemotherapeutic drugs available in the market. 
Patients who have early diagnosis of the tumours are usually subjected to localized 
treatment where surgery are performed to remove the malignant tissues. In the advanced 
stage of cancer where tumours have metastasized to other tissues, the common treatments 
after surgery is followed by the adjuvant therapy which involves chemotherapy, 
radiotherapy and immunotherapy.  The goal of adjuvant therapy is to reduce recurrence 
of the disease locally and systemically thus improving the survival rate of the patients 
(Chu and Sartorelli, 2015). 
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1.2 Issues with chemotherapeutic drug delivery 
The oral use of many chemotherapeutic drugs is hindered by their low 
bioavailability which can be frequently attributed to the low aqueous solubility and low 
intestinal permeability of the drug; i.e. Class 4 category compounds according to the 
Biopharmaceutical Classification System (Calleja et al., 2011). These low water 
solubility drugs are usually being absorbed slowly in the gut leading to variable or 
inadequate therapeutic concentrations reaching the systemic circulations (Savjani et al., 
2012).  
Due to bioavailability and also potential toxicity, the chemotherapeutic drugs tend 
to be administered parenterally. Once the drug is administered intravenously, the drug 
directly circulates throughout the body thus in principle giving access to the whole body. 
However, the drug level in the system is likely to rapidly drop due to various reasons such 
as metabolism in the liver and glomerular excretion by the kidney. This potentially limits 
the portion of the drug reaching the target sites, therefore reducing its medicinal effect. 
One of the major consequence in the use of chemotherapy drugs is the cytotoxic 
side effects resulting from the treatment. There is risk of side effects happening when part 
of the dose not reaching the target site thus toxic to the off-target tissues. Apart from 
killing the cancer cells, the drugs usually destroy surrounding healthy cells as well, 
especially the rapidly proliferating cells such in bone marrow, hair follicles, gonads and 
digestive tracts. This would later lead to occurrence of several adverse effects with 
symptoms such as fatigue, nausea, vomiting, loss of hair, impaired fertility, 
gastrointestinal disturbance and bone marrow suppression.  
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1.3 General issues with conventional drug delivery 
Suboptimal pharmacokinetics of conventional drugs is frequently related to the 
design and physicochemical property of the drugs, such as their chemical stability, 
dissolution rate, pKa and lipid solubility, all of which influence the drug’s absorption 
across the gut membrane upon oral administration (Ashford, 2013).  
Drug delivery systems (DDS) are commonly used to address the problems related 
to 1) poor solubility of the drug in aqueous solution causing the drugs to precipitate in 
aqueous medium; 2) rapid breakdown in vivo, causing loss of activity due to degradation 
upon contact with physiological pH or plasma proteins; 3) unfavourable 
pharmacokinetics, such as rapid drug clearance by the kidney and metabolic inactivation 
by the liver (Allen and Cullis, 2004). The problems with the conventional design of drugs 
have a major impact on the efficiency of chemotherapeutic drugs. In recent years, 
nanoparticulate delivery systems have created significant interest in the search of efficient 
way to improve the bioavailability of drugs. 
 
1.4 Nanotechnology in cancer medicine 
The word “nanotechnology’ was first introduced by Norio Taniguchi from Japan 
in 1974. The modern nanotechnology was initiated by the attention to colloid science and 
analytical tools such as the scanning tunnelling microscope in 1981 (Pathak, 2009). 
Application of nanotechnology in cancer medicine (cancer nanomedicine) is focusing 
more on creation of novel therapeutic and improving the state of current cancer treatment.  
Nanomedicine is a broad area involving the use of nanotechnology in medical 
application specifically for the use in pharmaceuticals, imaging agents and theranostics 
(Duncan and Gaspar, 2011) for the improvement in diagnosis, imaging, treatment and 
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prevention of the disease (Farokhzad and Langer, 2009, Moghimi et al., 2005). Main 
attractive benefits of nanomedicine are basically related to the nanoscale size, high 
surface area and functionalized surface of the material which enable it to access target 
sites in the human body and interact with the local tissues in a specific manner (Sainz et 
al., 2015, Sahoo et al., 2007).  
The involvement of nanomedicine in development of nanoscale drug delivery 
systems involves the use of nanoparticles. With size in range of one to several hundred 
nanometres, nanoparticles have been developed into various systems to create devices 
such as nanocarriers. Some of the well-known nanocarriers include polymeric 
nanoparticles, polymeric micelles, nanoemulsions, liposomes, and nanoshells (Ferrari, 
2005, Shah et al., 2010) (Figure 1). Nanocarriers usually act as a vehicle by either 
physically entrapping the drugs in or covalently bound to it. Characteristics required for 
an optimal nanocarrier design include high binding affinity, long circulating half-life, 
easy intracellular penetration, biocompatibility and high drug protection (Pathak, 2009). 
Application of nanomedicine in cancer therapies are directed to overcome issues 
such as nonspecific distribution of anticancer agents in the systemic circulation, 
unnecessary cytotoxicity to the non-cancerous cells and inadequate drug concentrations 
at the target tumour site (Misra et al., 2010). In recent years, nanocarriers have been 
utilized to improve the therapeutic efficacy of cancer treatment. Some examples of the 
chemotherapeutic drug-loaded nanocarriers available in the market include Abraxane® 
for paclitaxel, Caelyx®, Doxil®, Myocet® for liposomal doxorubicin (Green et al., 2006, 
Ellerhorst et al., 1999), Transdrug ® for doxorubicin nanoparticles and Daunoxome ® for 
liposomal daunorubicin (Fassas and Anagnostopoulos, 2005). 
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Figure 1: Schematic diagrams of several nanotechnology-based nanocarriers representing 
nanoshells, polymeric micelles, liposomes and nanoemulsions. 
 
1.5 Strategies in cancer nanomedicine 
Tumour physiology is different from the normal tissues. The vascularity of the 
tumours is highly heterogeneous. The tumours can be vascularized with blood vessels 
containing high proportions of endothelial cells, aberrant basement membrane and 
pericytes deficiency, while at the same time having open interendothelial junctions or 
transendothelial channels (size up to 400 nm in range) (Jain, 1997, Yuan et al., 1995). 
This would allow transport of macromolecules across the vasculature, including 
extravasation of nanometre-ranged particles from the main blood artery into the tumour 
microvasculatures. The lymphatic systems of the tumours are also abnormal, causing fluid 
retention and high interstitial pressure in the tumour as a consequence from the poor 
lymphatic drainage (Jain, 1987). The poor drainage system allows the particles that 
extravasate into the tumour to be retained in the malignant tissues. This combination of 
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leaky microvasculature and lack of intact lymphatic system contributes to the enhanced 
permeation and retention (EPR) effect, thus allow the strategy of passive targeting with 
the utilization of the nanoparticles (Arachchige et al., 2015, Maeda, 1992).  
Mononuclear phagocytic system (MPS) or also known as reticuloendothelial 
system (RES) is a major factor in elimination of most nanoparticles. MPS composed of 
monoblasts, promonocytes and monocytes which originated from the bone marrow, 
transported into peripheral blood as monocytes, and as macrophages in the tissues 
(Lasser, 1983). Kupffer cells in the liver and dendritic cells in the lymph nodes and spleen 
are also part of MPS. MPS is part of immunological defence mechanism responsible for 
removal of foreign materials such as harmful microorganisms (Halma et al., 1992). This 
elimination mechanism involves series of steps which include opsonization on the surface 
of the particles and phagocytosis of the opsonized materials by the macrophages and other 
mononuclear phagocytes (Owens and Peppas, 2006).  
Avoidance of MPS could be achieved by attaching shielding group on the particle 
surface to block electrostatic and hydrophobic attractions of opsonins from binding to the 
surface of the particles. Most widely used method is by covalently attaching poly(ethylene 
glycol) (PEG) chains to the particle surface, as the polymers are highly hydrophilic and 
typically neutral charge (Owens and Peppas, 2006). Hydrophilic particles are also more 
slowly opsonized compared to the hydrophobic ones (Carrstensen et al., 1992).  This 
could lead to longer residence of the nanoparticles in the systemic circulation and 
improves the pharmacokinetic property of the drug. 
Smaller size nanoparticles have more total surface area thus could allow more 
attachment to ligands such as peptides or monoclonal antibody for active targeting (Nie, 
2010). The smallest capillaries in human body is around 4 µm, therefore the particles are 
preferable to have sizes smaller than that in order to access locations by the intravenous, 
subcutaneous and intramuscular route. It was however reported that particles below the 
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size of 5 nm are rapidly cleared through renal clearance (Soo Choi et al., 2007) whereas 
particles of more than 1µm are prone to be trapped in the capillary beds of the liver and 
being taken up by the Kupffer cells (Illum et al., 1982, Caldorera-Moore et al., 2010). The 
size of spherical particles between 100-200 nm has the highest potential to stay longer in 
the circulation as they are small enough to avoid filtration in the spleen and large enough 
to avoid uptake by the liver (Petros and DeSimone, 2010), whereas particle size between 
10-100 nm could utilize the EPR effect at the tumour site (Danhier et al., 2010).  Polymer 
with molecular weight of around 15,000 Da is capable of stimulating the phagocytic 
activity whereas higher molecular weight polymer causes depression of the phagocytic 
activity of the MPS (Moghimi et al., 2001). Other benefits of small size particles include 
capability of cell membrane penetration and lysosomal escape after endocytosis (De Jong 
and Borm, 2008). 
Therefore, in general, the DDS for anticancer drugs should be designed with the 
following criteria; 1) able to extravasate the target tissues, for instance, via the passive 
targeting through the EPR effect; 2) able to avoid the elimination by the MPS; 3) able to 
maintain drug concentration at effective dose at the target sites for certain period of time; 
and 4) minimal off-sites drug accumulation (drugs able to selectively destroy the 
malignant cells without affecting the normal ones). 
 
1.6 Chitosan-based nanocarriers 
Nanoparticles made of biodegradable materials are more preferable as they are 
safer, low risk of toxicity and could be eliminated from the body through the natural 
process such as enzymatic degradation (Nair and Laurencin, 2007). In general, 
biodegradable polymers can be defined as the polymers that can be degraded and 
catabolized by microorganisms (bacteria, fungi, etc.) eventually into carbon dioxide and 
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water or other degradation products which are not harmful to the natural environment 
(Okada, 2002). Some of the presently available biodegradable polymers are made of 
polysaccharides (e.g. starch, chitosan, dextran and hyaluronic acid) and proteins (e.g. 
albumin, collagen and gelatine) (Piskin, 1995, Bohlmann, 2005, Chandra and Rustgi, 
1998). These types of natural polymers are abundance in nature, making them cost-
productive materials for the use as nanoparticles.  
 
1.6.1 Chitosan and chitosan-derived glycol chitosan 
Chitosan is a type of natural aminopolysaccharide copolymer of glucosamine and 
N-acetylglucosamine units. Chitosan is a product of the alkaline deacetylation of chitin 
(Figure 2), a substance second most abundant in nature after cellulose (Rinaudo, 2006) 
which can be found in the shells of many crustaceans. Chitosan is favourable because of 
its biodegradability, biocompatibility, positively charged and low immunogenicity (Sonia 
and Sharma, 2011, Kumar et al., 2004).  
The cationic property of chitosan is believed responsible for the mucoadhesive 
behaviour, as it is easily attracted to the negatively-charged mucin layer on the gut’s 
epithelium, thus improving the residence time of the drug at the gut wall and consequently 
increase the chance of drug absorption (Lehr et al., 1992). 
Since chitosan has a percentage of acetylation below 50%, it can only be dissolved 
in acidic solution with pH values below its pKa value of 6.5 by the protonation of the 
amine group on the C-2 position of the D-glucosamine unit (Rinaudo, 2006). This poor 
solubility of chitosan in neutral and basic aqueous solutions (around pH 7.5) is a 
restriction for absorption in the alkaline environment of the intestine. The chitosan 
structure however, contains many functional groups that can be chemically modified to 
9 
 
improve its solubility. The derivatization can utilize the primary amino group at the C-2 
position, or the hydroxyl group at C-6 of the glucosamine unit (Zambito, 2013). 
Glycol chitosan (GC) is one the derivatives of chitosan which is soluble in all pH 
values. GC is formed by reacting chitosan with ethylene glycol (Figure 2). The chemical 
modification of GC at the C-2 position, such as quaternisation and acylation, will improve 
properties of the polymer without changing the basic skeleton of chitosan.  
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Figure 2: The flow of formation from chitin to chitosan and eventually into glycol 
chitosan. 
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1.6.2 Quaternary ammonium palmitoyl glycol chitosan (GCPQ) 
Self-assembled polymeric micelles known as quaternary ammonium palmitoyl 
glycol chitosan (GCPQ) (Figure 3) are synthesized from glycol chitosan (Uchegbu et al., 
2001). GCPQ is made into a polymer which spontaneously forms micelles in aqueous 
solution. Modification of glycol chitosan into amphiphilic GCPQ involves addition of 
hydrophobic pendant side chains and hydrophilic group connecting to the amine group of 
the GC backbone, causing the polymer to form spherical micelles in aqueous solution.  
 
 
Figure 3: Quaternary ammonium palmitoyl glycol chitosan (GCPQ). The w, x, y and z 
represent the different monomeric repeating unit in the structure of GCPQ polymer as a 
result of random palmitoylation and quaternization at the amine group of glycol chitosan. 
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This polymer can be loaded with hydrophobic drugs such as griseofulvin, 
cyclosporine and propofol (Siew et al., 2012, Qu et al., 2006) in an aqueous media by 
using probe sonication method. The critical micellar concentration (CMC) is the 
concentration at which the micelles start to form (Fuguet et al., 2005). GCPQ has a low 
CMC value (Qu et al., 2006) which enables the nanoparticles to avoid premature 
disaggregation in the body fluid upon dilution and reach the target sites with full capacity 
of active drugs. 
Encapsulation within GCPQ polymers could protect the drug from gastric and 
intestinal degradation and could improve absorption in the gut (Lalatsa et al., 2012b). 
Amphiphilic chitosan is bioadhesive (Martin et al., 2002) and this criterion will allow 
adherence of the chitosan-derived nanoparticles to the mucus membrane in the gut. The 
small size of GCPQ nanoparticles provides high surface area for faster drug dissolution 
(Lalatsa et al., 2012a).  
Upon oral administration, GCPQ nanoparticles were able to promote drug 
transport by their adhesion to the mucus thus prolong the contact between loaded particles 
and absorptive enterocytes of the gastrointestinal tract (GIT) without disturbing 
intercellular tight junction permeability (Siew et al., 2012). In another study, GCPQ 
particles were proven to be absorbed in the GIT by the evidence of the particles being 
found within the villi of the ileum and duodenum which was presumably absorbed via the 
enterocytes. The particles had also been found in the intercellular spaces between 
hepatocytes in the liver, as well as in the gall bladder. Therefore, it was suggested that 
upon absorption via the enterocytes, GCPQ particles are transported to the liver via the 
venous blood in the villi or gut lymphatic vessels, later on to the gall bladder and 
presumably recirculated back to the GIT (Figure 4) (Lalatsa et al., 2012a). 
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Figure 4: Schematic diagram of proposed transport route for GCPQ nanoparticle 
formulation with peptide upon oral intake (reproduced from Lalatsa et al., 2012a with 
permission). 
 
Apart from enhancing oral drug absorption, GCPQ nanoparticles were also 
reported to promote brain delivery of neuropeptides known as leucine5-enkephalin 
(Lalatsa et al., 2012b). The same study also showed no accumulation of the particles in 
the lungs, suggesting GCPQ is capable to evade macrophage uptake by the 
reticuloendothelial system. Based on these properties, GCPQ should provide useful 
nanoparticles for delivery of drugs from the oral or intravenous route of administration 
into the tumours. 
 
1.7 Disulfiram as a potential chemotherapeutic drug 
The search continues for novel potent anticancer drugs capable of selectively 
killing cancer cells without harming the normal cells. In addition to looking at the 
development of novel chemical entities, there is also considerable interest in exploring 
the anticancer potential of existing drugs with known safety profile.  
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Disulfiram (DS) has been used for the treatment of alcoholism since the year of 
1947 (Chick, 1999). The drug inhibits the activity of aldehyde dehydrogenase in the liver 
thus preventing the conversion of the highly reactive and toxic acetaldehyde into acetic 
acid. The serendipitous observation of the remission of breast cancer in a patient treated 
for alcoholism with disulfiram (Lewison, 1977) has led to an interest of DS as a candidate 
for the potential repurposing as an anticancer drug.  
Disulfiram, chemically known as bis(diethylthiocarbamoyl)disulfide (Figure 5) is 
the first medication approved by U.S. Food and Drug Administration (FDA) for the 
treatment of chronic alcohol dependence. The treatment of alcoholism works when DS 
blocks the activity of aldehyde dehydrogenase (ALDH), an enzyme responsible for 
transforming acetaldehyde into acetate (Johansson, 1992). The inhibition of ALDH stops 
the oxidation of acetaldehyde, causing rapid formation of acetaldehyde in the blood 
resulting in the disulfiram-alcohol reaction (DAR). DAR is recognised by the moderate 
to severe side effects such as sweating and flushing on the upper chest and face (flush 
syndrome), nausea and vomiting, tachycardia, vertigo and blurred vision (Wright and 
Moore, 1990). The drug itself will not treat the addiction but the discomfort of DAR will 
encourage the abstinence towards drinking alcohol.   
 
 
 
Figure 5: Chemical structure of disulfiram 
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1.7.1 Anticancer properties of disulfiram 
Years after the discovery of disulfiram, more scientific evidence of DS having 
anticancer properties has emerged. Studies have reported that DS has the cytotoxic effects 
against several types of cancer, such as pancreatic (Dalla Pozza et al., 2011, Kim et al., 
2013), brain (Liu et al., 2012), prostate (Lin et al., 2011) and skin cancer (Cen et al., 
2004). The anticancer property of metal-chelating DS is heightened when given to the 
patients in combination with metal, in particular, copper (Cvek, 2011). The cytotoxicity 
effect of DS given with copper appears to happen through inhibition of proteasome 
pathway leading to the induction of apoptosis activities in human cancer cell lines (Chen 
et al., 2006). There are other mechanisms of actions responsible for the anticancer effect 
of disulfiram which has been described later in this report in Table 1. 
Copper ions are abundant in the human body and can be readily found in the 
stomach. The copper ions, Cu(II), could spontaneously combine with DS at its thiol 
groups, as well as with DS main metabolite, diethyldithiocarbamate (DDC), to form a 
much more stable compound known as copper-DDC (CuDDC) (Johansson and 
Stankiewicz, 1985). CuDDC is a neutral and hydrophobic metabolite of DS and is rapidly 
absorbed in the gut. Despite its stability, CuDDC is however rapidly degraded back into 
DDC and copper in the blood stream (Johansson, 1992). As proposed by Cen et al. (2004), 
the copper-disulfiram (CuDS) complex (Figure 6) can be synthesized by reacting DS and 
copper chloride (CuCl2) in unbuffered aqueous solution, followed by extraction in organic 
solvent such as anhydrous chloroform. The rapid reaction yields a dark brown precipitate 
which is hydrophobic and acidic with pH lower than 3. This stoichiometric product has 
been proven to have toxicity effect against melanoma cell line A375 as well as prostate 
cancer cell line DU145. Even though copper is known to be a cofactor in the tumour 
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angiogenesis (Duan et al., 2013), the role of Cu in promoting the toxicity effect of DS 
against cancer cells seems to outweigh the role of Cu in promoting the tumour growth. 
 
 
Figure 6: Proposed structure of copper-disulfiram complex (CuDS) after reaction of 
copper with disulfiram in unbuffered aqueous solution (Cen et al., 2004). 
 
 
The metabolism of DS in humans is well-known (Figure 7) (Eneanya et al., 1981, 
Johansson, 1992) ensuring the safety of DS usage and this is a distinct advantage to 
repurpose of DS as a chemotherapy drug. About 80 to 95 percent of the orally ingested 
DS is absorbed in the GIT to be metabolized into DDC by the endogenous thiols and the 
glutathione reductase in the blood within four minutes (Cobby et al., 1977). The acidic 
condition in the stomach can also metabolize DS into the less stable DDC through the 
reduction process. DDC is polar, hydrophilic and decomposes rapidly into carbon 
disulfide and diethylamine (Eneanya et al., 1981). DDC in the bloodstream reaches the 
liver and undergoes methylation during the Phase II metabolism into S-methyl-N,N-
diethyldithiocarbamate (MeDDC) by the action of S-methyl-transferase and later on into 
S-methyl-N,N-diethylthiocarbamate (MeDTC). Further oxidation process by the 
microsomal cytochrome-P450 produces S-methyl-N,N-diethylthiocarbamate sulfoxide 
(MeDTC sulfoxide) and S-methyl-N,N-diethylthiocarbamate sulfone (MeDTC sulfone). 
MeDTC sulfoxide and MeDTC sulfone are prone to carbamoylate the sulfhydryl of 
glutathione and produce S-(N, N-diethylcarbamoyl) glutathione or simply known as 
carbamathione (Faiman et al., 2013).  
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Figure 7: Disulfiram and its metabolic pathways in humans. DDC = 
Diethyldithiocarbamate; MeDDC = S-methyl-N,N-diethyldithiocarbamate; DTC = 
Diethylthiocarbamate; MeDTC = S-methyl-N,N-diethylthiocarbamate. 
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In the literature, DS has been reported to have various activities which have been 
studied thoroughly in both in vitro and in vivo models, as well as in human clinical trials. 
Table 1 summarizes some of the properties of disulfiram contributing to its anticancer 
activity.  
Only DS, DDC and combination of copper with either DS or DDC possess the 
activity of anticancer effect against the tumour cells. Since the CuDDC is less stable than 
the CuDS, it is sensible to consider utilizing DS or combination of DS and copper to 
create nanoparticles that could enhance their delivery to the target sites in the tumours. 
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MECHANISM OF 
ACTION 
ACTIVITY EXPERIMENTAL 
MODEL 
DRUG LEVEL PUBLICATION 
Induces  reactive 
oxygen species (ROS), 
activates Jun N-terminal 
kinases (JNK) and p38 
pathways 
Cytotoxicity on 
glioblastoma multiforme 
stem-cell like 
In vitro 10 µM DS + 1 µM Cu Liu et al., 2012  
Blocks the activity of P-
glycoprotein membrane 
pump  
Increased sensitivity of P-
gp-transfected cells to 
vinblastine and colchicine 
and inhibited P-gp’s 
verapamil-stimulated 
ATPase activity  
In vitro; 
In vitro 
100 µM DS;  
0-200 µM DS 
Loo and Clarke, 2000;  
Loo et al., 2004 
Potent inhibitor of 
nuclear-factor kappa B 
(NF-κB), a key pro-
survival factor in cancer 
cells  
Inhibiton of NF-κB in 
Jurkat T cells; growth 
inhibition of colorectal and 
breast cancer cell line and 
breast cancer stem cells 
In vitro;  
in vitro;  
in vitro; 
in vitro; 
in vitro, in vivo,  
100 µM DS;  
0-40 µM DS;  
10 µM DS + 1 µM Cu;  
1 µM DS +Cu;  
1 µM DS + 10 µM Cu, 
75 mg/kg DS + 8 mg/kg 
Cu 
Schreck et al., 1992;  
Wang et al., 2003;  
Liu et al. 2012;  
Liu et al. 2013;  
Liu et al. 2014 
Synergistically enhances 
gemcitabine cytotoxicity, 
reverses gemcitabine 
resistance in  colon and 
breast cancer cell lines 
In vitro 0-6 µM DS+Cu Guo et al., 2010 
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Inhibits breast cancer stem 
cells and enhances 
cytotoxicity of paclitaxel 
in breast cancer cell lines  
In vitro 1µM DS and 1µM Cu Yip et al., 2011 
Induces apoptosis Apoptosis in melanoma 
cells, multiple myeloma, 
acute myeloid and 
lymphoblastic leukaemia 
In vitro;  
in vitro;  
in vitro, in vivo;  
 
in vitro 
25-50 ng/ml DS;  
0.17 µm + 1 µm Cu;  
5-20 µM DS+Cu, 50 
mg/kg DS;  
0.1-5 µM DS + 0.2-2 
µM Cu 
Cen et al., 2002;  
Cen et al., 2004;  
Chen et al., 2006;  
 
Conticello et al., 2012 
Apoptosis in Jurkat cells 
by the caspase activity  
In vitro 5-50 µM DS  Nobel et al., 1997 
Apoptosis in breast cancer 
cell line MDA-MB-231 by 
inhibition of  proteasome 
activity 
In vitro 5-20 µM DS+Cu Chen et al., 2006 
Reduces angiogenesis Retards growth of C6 
glioma and Lewis lung 
carcinoma in mice 
In vitro;  
in vivo 
1-10 µM DS;  
13-30 ug/mouse DS 
Shian et al., 2003; 
Marikovsky et al., 
2002 
Inhibits expression of 
matrix 
metalloproteinase 2 
(MMP-2) and 
metalloproteinase 9 
(MMP-9) 
Invades human 
osteosarcoma cells 
In vitro; 
In vitro 
0-20 µM DS;  
1-10 µM DS 
Cho et al., 2007;  
Shian et al., 2003 
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Inhibits activating 
transcription 
factor/cyclic AMP-
responsive element 
binding protein in metal 
dependent manner 
Reduces hepatic 
metastases and ocular 
melanoma 
In vitro, in vivo 0.15-5 µM DS + 0.2-10 
µM Cu 
Brar et al., 2004 
Inhibits DNA 
methyltransferase by 
demethylating gene 
promoters and 
reactivating the 
expression of 
epigenetically silenced 
genes  
Inhibits prostate cancer 
cell growth 
In vitro, in vivo 100 nM DS, 10-40 
mg/kg DS 
Lin et al., 2011 
Impairs the activity of 
endogenous arylamine 
N-acetyltransferase 1 
(NAT-1)  
Growth inhibition of 
human lung cancer cells 
In vitro 8-30 µM DS Malka et al., 2009 
Inhibits the expression 
of polo-like kinase 1 
(PLK1) in glioblastoma 
multiforme (GBM) cells 
Inhibits the growth of 
temozolomide resistant 
GBM cells without 
affecting normal human 
astrocytes, blocks self-
renewal of the BT74 and 
GBM4 primary cell lines 
In vitro 50-500 nM DS Triscott et al., 2012 
 
Table 1: Various properties of DS  reported in the literature.  
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1.7.2 Disulfiram role against cancer stem cells 
Another DS feature that is gaining interest lately is its potential activity against 
the cancer stem cells. Cancer stem cells (CSC), similar to normal stem cells, have the 
capability of self-renewal (Lobo et al., 2007). Self-renewal enables the stem cell to divide 
and produce another stem cell that remains undifferentiated and possesses the same 
development and replication capabilities, while the other daughter cells undergoes 
proliferation and differentiation to tissue-specific cells. It was proposed that CSC can 
arise from either the normal stem cells (Fialkow, 1990, Lapidot et al., 1994) or from the 
progenitor cells that can give rise to self-renewing cancer stem cells (Reya et al., 2001, 
Clarke and Fuller, 2006). There is possibility that the tumour recurrence is caused by the 
treatment failure to eliminate the CSC and assumption is that the typical cancer treatments 
only shrink the bulk of the tumour cells without destroying the source of the cancer, i.e. 
the CSC. 
ALDH activity has been recognized as a universal marker for the CSC. In 
particular, ALDH1A1 was the first one found among the 19 ALDH isoforms that is 
responsible for the CSC activity, while other isoforms (e.g. 1A2, 1A3, 1A7, 2*2, 3A1, 
4A1, 5A1, 6A1 and 9A1) was discovered later for their expression in CSC (Muzio et al., 
2012). The detection of ALDH activity can be done using the aldefluor assay by 
measuring the fluorescent aldehyde substrate (Marcato et al., 2011, Ginestier et al., 2007, 
Storms et al., 1999). First ALDH-positive CSC isolation was the leukemia stem cells 
(Cheung et al., 2007) and later in the same year from breast cancers (Ginestier et al., 
2007). This was later followed by the discovery in many types of cancer including 
pancreatic, prostate, brain, liver and lung (Jiang et al., 2009, Li et al., 2010, Ma et al., 
2008, Rasheed et al., 2010, Rasper et al., 2010). 
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DS is known for blocking the activity of ALDH enzyme which prevents the 
transformation from acetaldehyde into acetate. This specific property of DS has made it 
a strong candidate for the activity inhibition or elimination of the CSC in the 
chemotherapeutic treatments. Several studies have been done to investigate the activity 
of DS against the CSC in different types of cancer. For glioblastoma multiforme (GBM), 
it was reported that DS with copper (DS/Cu) markedly inhibits the proliferation of glioma 
stem cells (GSC) (Hothi et al., 2012) with enhanced effect seen in combination with 
temozolomide (Lun et al., 2016). Liu et al. (2012) reported the GBM stem-like cell 
population was abolished by the cytotoxicity effect of DS and copper complex. Along 
with the complex enhancement on the activity of gemcitabine, the cytotoxicity was likely 
due to inhibition ALDH and NFkB pathway and the induction of reactive oxygen species 
(ROS).  
DS was found cytotoxic against the breast cancer stem-cell like (BCSC) with and 
without presence of copper (Kim et al., 2016, Liu et al., 2013, Robinson et al., 2013, Yip 
et al., 2011). In another breast cancer study, the DS in liposome was able to block the 
hypoxia-induced NFkB activation of the BCSC and specifically targeted the BCSC 
population in both in vitro and in vivo (Liu et al., 2014). The DS anti-CSC activity was 
also seen against the ovarian cancer stem-like cells (Rezk et al., 2015).  
The present study focused on the DS activity against pancreatic cancer. CSC was 
reported to cause the therapeutic resistance in pancreatic ductal adenocarcinoma (PDAC) 
(Hermann et al., 2007) and demonstrated resistance against gemcitabine and 5-
fluorouracil (Hermann et al., 2007, Jimeno et al., 2009). Terminal ductal cells were 
reported as pancreatic/stem progenitor cells with ALDH1A1 expression in mice (Rovira 
et al., 2010, Strobel et al., 2007). Kim et al. (2013) reported DS to have significant 
cytotoxicity against the human PDAC-derived, MIAPaCa-2 and CFPAC-1 cell lines 
(high positive ALDH1A1 expression), without mortally affecting the normal pancreatic 
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epithelial cell line, hTERT-HPNE. The study also reported DS oral administration 
selectively eliminates ALDH1A1 cell in the xenograft tumours and inhibits the tumour 
growth upon combined treatment with low-dose gemcitabine. 
Therefore, it is hypothesized that the DS formulation with GCPQ would curb the 
pancreatic CSC activity. Repurposing the use of DS as an adjuvant anticancer drug is 
worthwhile as it is inexpensive, easily available and has negligible adverse effects 
compared to the classical chemotherapeutic drugs. This can also avoid the expensive and 
time-consuming development process of new anticancer drugs that involves the costly 
pre-clinical and clinical testing (Chong and Sullivan, 2007).  
 
1.8 Formulation of disulfiram with GCPQ polymers 
The oral administration of DS is preferable as patients can easily take the drug by 
mouth. The oral drug preparation is also at cheaper cost. The main issue in repurposing 
the use of DS as chemotherapeutic oral drug are the short half-life of the drug in the acidic 
gastric fluid and in the blood circulation (Johansson, 1992), while the highly hydrophobic 
property of the drug hinders its dissolution in aqueous bodily fluid which affects its 
absorption in the gut. Ultimately, to ensure the delivery of the drug molecules to reach 
the target tumours, the active form of DS must be able to pass the gut epithelium in intact 
form after an oral administration. 
We hypothesized that GCPQ would encapsulate the hydrophobic DS within the 
interior part of the nanoparticles and form stable particles. The nanoparticles would allow 
more drug absorption in the gut by protecting the drug from degradation in the acidic 
condition of the stomach and from metabolism or degradation by the enzymes present in 
the liver and in the blood circulation, respectively. Hence the drug could be transported 
through blood or lymphatic circulation into the tumour site and released for the activity 
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against the malignant tissues. In order to produce a stable and robust formulation, 
fundamental approaches were taken such as thorough formulation characterization done 
both in in vitro and in vivo to ensure the optimum criteria of nanoparticles were achieved.  
In literature, formulations of several types of DS-loaded nanocarriers have been 
published (Table 2) which include lipid emulsion, lipid nanocapsule, polymeric micelles, 
poly(lactic-co-glycolic acid) (PLGA) nanoparticle, liposome and mixed nanoparticle. 
Most of the formulations were made to improve DS stability in blood circulation and to 
improve the delivery of the drug to the tumour site by prolonging the DS-loaded 
nanoparticle’s circulation and half-life, as well as developing the nanoparticle’s 
controlled release. Almost all of the DS-loaded nanocarriers were reported to have 
encouraging effects on attenuating the cancerous progression in comparison to the free 
drug of which studies were done either in vitro or in vivo, or both.  
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NANOCARRIER PUBLICATION FORMULATION 
Lipid emulsion  Chen et al., 2015 DS in oleic acid and soybean lecithin in 
medium chain triglycerides (MCT) as oil 
phase; glycerol, F68 and water as aqueous 
phase; both phases subjected for high-
pressure homogenization 
Lipid nanocapsule  Zhang et al., 2015 Phase-inversion method of DS with MCT, 
Kolliphor HS15, Lipoid S75 and sodium 
chloride 
Polymeric micelles Duan et al., 2013 Micelles and DS co-dissolved in 
dimethylformamide (DMF) followed by 
addition into water  
Löbler et al., 2009 PEG5000-b-PCL5000 dissolved in DS-
DMF solution, then added dropwise into 
phosphate buffered saline 
Poly(lactic-co-
glycolic acid) 
(PLGA) nanoparticle 
Fasehee et al., 2016b DS in PLGA or PLGA-PEG-folate dissolved 
in dimethylsulfoxide followed by addition 
into water 
Hoda et al., 2015 Nanoprecipitation of DS with PLGA, 1% 
Pluronic 188, PS80 and Triton X-100 
Hoda et al., 2016 Addition of PLGA and DS in acetone into 
water containing 1% polysorbate 80, 
followed by evaporation and centrifugation 
Zembko et al., 2015 DS and PLGA mixture undergoes solving 
casting or heating compression method to 
produce DS-loaded wafers 
Wang et al., 2016 Emulsion-solvent evaporation method of 
PLGA and DS in dichloromethane and 
cyanomethyl diphenylcarbamodithiote 
aqueous solution into oil-in-water emulsion, 
followed by evaporation and centrifugation 
to obtain purified nanoparticles 
Liposome  Buckiova et al., 2012, 
Löbler et al., 2009  
Reverse-phase evaporation method of DS 
with lipid stock (eggPC, DSPE-PEG-2000 
and TRITC-DHPE) 
Mixed nanoparticle  Song et al., 2016a,  
Song et al., 2016b 
Nanoprecipitation method of methoxy 
poly(ethylene glycol)-b-poly(lactide-co-
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glycolide)/poly(ε-caprolactone (mPEG-
PLGA/PCL) and DS mixture in DMF 
and water 
 
Table 2: DS-loaded nanocarriers and its brief formulation description. 
In order to find the most ideal and suitable type of DDS for utilization of DS and 
GCPQ in cancer therapy, two forms of nanoparticle formulations were investigated which 
were the polymeric micelles and nanoemulsion.  
 
1.8.1 Polymeric micelles  
Polymeric micelles are nanoparticles formed from amphiphilic copolymers that 
self-assembled in aqueous solution, forming inner hydrophobic core and outer 
hydrophilic layer based from the hydrophilic block of the copolymer (Sahoo and 
Labhasetwar, 2003). The inner micellar core is where the hydrophobic drug molecules 
are loaded. Application of polymeric micelles to be loaded with hydrophobic drugs and 
improve the drug delivery has been reported frequently in the literature (Lalatsa et al., 
2012c). Generally, polymeric micelles improve dissolution of hydrophobic drugs by 
increasing their aqueous levels and the encapsulation is also increased with the increase 
of polymer hydrophobicity (Qu et al., 2006). 
Several advantages of polymeric micelles are 1) better thermodynamic stability 
mostly from the intertwined polymer chains in the inner core (Xu et al., 2013), leading 
the low critical micellar concentration of the system thus rendering it more stable and able 
to avoid the rapid in vivo dissociation (Jones and Leroux, 1999, Rapoport, 2007); 2) 
narrow size distribution in nanometre range, owing to their unique core-shell structure 
which segregates the hydrophobic segments from the outer aqueous exterior. This makes 
them an ideal drug carrier system for the avoidance of the MPS and renal exclusion 
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following intravenous administration thus enhance the drug’s bioavailability in the 
tumours (Gothwal et al., 2016). 
Polymeric micelles have been used to improve drug delivery of sparingly soluble 
chemotherapeutic drugs (Wang et al., 2005). The micelles can be characterized based on 
their coatings which can be made of anticancer drugs, sugars or tumour-specific 
antibodies. The coatings enable the nanoparticles to target and bind the cancer cells, 
followed by the release of drug molecules (Gregoriadis and Florence, 1993, Miyata et al., 
2011).  
Some of the known biodegradable and biocompatible micelles for cytotoxic drug 
delivery are the utilization of non-toxic polymers such as PEG as the basic structure for 
the outer hydrophilic layer and PLGA as the base for the hydrophobic core (Gothwal et 
al., 2016). The polymeric micelles of PEG and PLGA conjugated with doxorubicin, 
paclitaxel or docetaxel have been reported (Yokoyama et al., 1990, Yoo and Park, 2001, 
Cheng et al., 2007). 
 
1.8.2 Nanoemulsions  
By definition, an emulsion is a system consisting of two immiscible liquid phases, 
one of which is in the form of fine droplets (the dispersed phase) distributed uniformly 
throughout the other (continuous phase) (Eccleston, 2013). Emulsions are classified as 
oil-in-water (O/W) when oil droplets are dispersed in the aqueous medium, or water-in-
oil (W/O) when the internal phase is formed by water. Emulsions are thermodynamically 
unstable. This is due to the high surface free energy which is caused by the high interfacial 
area between the dispersed phase and continuous phase droplets. Upon contact, the 
droplets coalesce to reduce the total interfacial area thus reducing the total surface energy. 
This leads to the phase separation (Attwood, 2013).  
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In order to kinetically stabilize the emulsions, emulsifying agents (emulsifiers) are 
added to help maintain the dispersion state after cessation of the agitation. The emulsifiers 
that are also known as surface active agents (surfactants), act by forming electrostatic or 
mechanical barrier at the droplet interface thus providing an interfacial film. The 
interfacial film increases droplet to droplet repulsions by introducing electrostatic or steric 
repulsive forces between the dispersed droplets (Eccleston, 2013, Attwood, 2013).  
Emulsions, in particular the macroemulsions, have a wider range of droplet 
diameter with the range of 0.1 to 100 µm (Attwood, 2013), whereas nanoemulsions are 
colloidal systems with droplets in nanometre range (10-300 nm). Nanoemulsions, which 
are also known as submicron emulsion or ultrafine emulsion, usually involve the use of 
oil, surfactant, co-surfactant and aqueous medium as the ingredients. The common O/W 
formulations involves the addition of surfactant to help lower the surface tension between 
oil and water and to prevent the coalescence during high-energy sonication procedure 
(Lovelyn and Attama, 2011).  
A nanoemulsion drug delivery system is a promising way to enhance oral 
absorption of poorly soluble anticancer drugs such as paclitaxel, etoposide and 
doxorubicin (Tiwari and Amiji, 2006, Ganta and Amiji, 2009, Zhang et al., 2011, Mohan 
and Rapoport, 2010). For medicinal purposes, colloidal dispersion in nanometre range 
such as nanoemulsions is favourable for several reasons such as; 1) better stability to 
particle aggregation and gravitational separation thus prevents creaming and 
sedimentation during storage as well as avoidance of flocculation and creaming (Tadros 
et al., 2004); 2) large surface area of nanoparticles promotes rapid drug release thus 
increase the drug bioavailability. Nanoemulsions has the capacity to be loaded with large 
amount of hydrophobic drugs in the oil core (Lovelyn and Attama, 2011). This could 
avoid unnecessary toxicity from the use of high amount of surfactant needed to stabilize 
the higher amount of drug in the formulation. 
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1.9 Objectives of the study 
The general objective of the study is to develop a DS nanoparticle formulation 
with ideal characteristics that could protect the drug, improve its delivery to the target 
sites and have a significant effect on the progression of the tumour. The specific 
objectives of the study are as follows: 
 To synthesize glycol chitosan-based polymer GCPQ and to characterize the 
modification of the polymer based on the molecular weight, degree of 
palmitoylation and degree of quaternisation 
 To develop DS nanoparticle formulation using GCPQ polymer that has the ideal 
characteristics such as high drug load, particle size at nano-range diameter and 
small particle size distribution 
 To characterize the formulation based on the stability in various in vitro 
environments such as different temperatures, pH buffers and simulated biological 
fluids 
 To determine the cytotoxicity effect of the DS nanoparticle formulation against 
human pancreatic cancer cell lines 
 To determine the pharmacokinetic profile of the DS nanoparticle formulation in the 
mouse model  
 To determine the anticancer property of the DS nanoparticle formulation against 
development of xenograft tumour of pancreatic cancer in mouse model. 
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2 Quaternary ammonium palmitoyl glycol chitosan (GCPQ) 
 
Chapter 2 
 
Quaternary ammonium 
palmitoyl glycol chitosan 
(GCPQ) 
 
2.1 Overview 
GC was modified into amphiphilic GCPQ polymer by conjugating hydrophobic 
palmitic chains and creating hydrophilic regions with quaternisation at the free amine 
group of the GC sugar backbones. This type of polymeric micelles has hydrophobic group 
with a chain length of 16 carbons that allows self-aggregation and behaves like a polysoap 
(soluble polymers bearing pendant amphiphilic or hydrophobic groups) (Uchegbu et al., 
2001). Acid degradation of GC allows the control of molecular weight while preserving 
the primary amine group on the repeating sugar unit.  
GCPQ is able to self-assemble at neutral pH because GC itself is soluble at neutral 
pH. GCPQ has the CMC in micromolar range (6-100 µM) (Qu et al., 2006) compared to 
other block copolymers, such as Pluronic block copolymer which has the CMC in 
millimolar range (Dwyer et al., 2005). The low CMC value helps to prevent premature 
disaggregation upon dilution in biological fluid, thus improving the micellar stability in 
the gastrointestinal fluid and blood circulation.  
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2.2 Synthesis of GCPQ 
The synthesis of GCPQ involves four main stages (Figure 8); acid degradation of 
GC, palmitoylation (acylation) of degraded GC with palmitic acid ester, quaternisation of 
palmitoylated GC with methyl iodide at the primary amine and removal of iodide from 
the newly formed quaternary ammonium product (Uchegbu et al., 2001) to produce N-
palmitoyl, N,N,N-trimethylamino, N,N-diethylamino, N-monomethylamino, 6-O-glycol 
chitosan (quaternary ammonium palmitoyl glycol chitosan, GCPQ). 
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Figure 8: Reaction scheme for the synthesis of GCPQ. 
Glycol chitosan  
Acid degradation 
Degraded glycol chitosan 
Palmitoylated  
glycol chitosan 
 Reaction with 
Reaction with 
CH3I 
GCPQ 
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2.2.1 Materials  
Two batches of GCPQ were synthesized. The first batch (GCP10Q11) was 
synthesized using glycol chitosan (GC) supplied by Chitomerics whereas the second 
(GCP20Q11) batch was synthesized using GC from Sigma Aldrich. 
 
Item Supplier 
Glycol chitosan 
Lot number: 
120M1438V 
081M1560V 
 
 
Chitomerics Limited, Coventry, UK 
Sigma Aldrich, Missouri, USA 
Palmitic acid N-
hydroxysuccinimide ester 
Sigma-Aldrich Company Limited, Dorset, UK 
Sodium iodide 
Sodium bicarbonate 
Methyl iodide 
N-methyl-2-pyrolidone 
Sodium hydroxide 
Resin (Amberlite IRA-96) 
Hydrochloric acid  Fisher Scientific Limited, Leicestershire, UK 
Absolute ethanol 
Diethyl ether 
Visking seamless cellulose 
dialysis membrane 
Medicell International Limited, London, UK 
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2.2.2 Degradation of glycol chitosan 
For acid degradation of GC, 2 g of GC was dissolved in 152 ml 4 M hydrochloric 
acid and incubated in 50⁰C water bath with shaking at 125 rpm for 24 hours. On the next 
day, the degraded GC (dGC) solution was cooled in a fridge for 10 minutes to bring it to 
room temperature before the exhaustive dialysis process against water. In the dialysis 
procedure, the dGC solution was transferred into seamless cellulose dialysis membranes 
with molecular weight cut-off (MWCO) 3500 Dalton. The tubes were then submerged in 
distilled water in 5 L conical flask and stirred. The water in the flask was changed 6 times 
in 24 hours, leaving at least 1 to 2 hours between changes. After 24 hours, the content of 
each membrane was emptied into a large beaker. Each membrane was rinsed with purified 
water to ensure no polymer was lost. The dialysed solution was poured into 60 ml freeze-
drying bottles until 80 % full. Top of each bottle was covered with parafilm and small 
holes were pierced through the parafilm. The bottles containing dGC were placed in 
minus 20⁰C for at least an overnight to freeze the solution prior to the freeze drying 
process. The solution was freeze dried (ScanVac CoolSafe, LaboGene ApS, Lynge, 
Denmark) until white, cotton-like solid was obtained. 
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2.2.3 Palmitoylation of degraded GC 
 After degradation, every 500 mg dGC was dissolved in 24 ml absolute ethanol 
and 76 ml Milli-Q water (MilliQ Integral Water Purification System, Millipore 
Corporation, Massachusetts, USA) added with 376 mg sodium bicarbonate. For every 
500 mg dGC, 792 mg of palmitic acid N-hydroxysuccinimide ester (PNS) was dissolved 
in 150 ml absolute ethanol. The whole process involving PNS must be protected from 
light. The PNS solution was then transferred into a 1 L separating funnel wrapped with 
aluminium foil. The dGC solution was added with PNS solution in drop wise manner and 
with continuous stirring. The cloudy mixture produced was then left to stir for another 72 
hours. The ethanol in the solution was removed by rotary evaporator at 50 to 52⁰C under 
reduced atmospheric pressure.  
The remaining aqueous phase was extracted by adding diethyl ether three times 
the amount of the aqueous phase in a 1 L separating funnel (Figure 9). The solution was 
mixed by slow swirling movement of the funnel followed by intermittent release of 
pressure build-up from ether evaporation in the funnel. The funnel was left in upright 
position using a stand for at least 30 minutes to allow three distinct phases to separate. 
Among the three layers, only two bottom layers were collected (fatty and aqueous layers) 
while the top layer (organic ether layer) was discarded. The two layers collected was then 
added with new diethyl ether solution and extraction process was repeated twice more 
(three extractions in total).  
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Figure 9: Separation of the solution into three different layers was done in separating 
funnel to extract the aqueous and fatty layer from the solution. 
 
The cloudy aqueous solution was dialyzed exhaustively against water (as 
described previously in the dialysis process for degradation of GC) using dialysis 
membrane with MWCO 12,000 to 14,000 Dalton. After the 6 changes of water in 24 
hours, the solutions were subjected for freeze-dry once again until cotton-like solid 
substance was obtained. 
 
  
Organic ether layer 
Fatty layer 
Aqueous layer 
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2.2.4 Quaternisation of palmitoylated dGC (PGC) 
 Each 300 mg PGC was dispersed in 25 ml N-methyl-2-pyrolidone (NMP) in a 
conical flask capped with glass stopper and stirred vigorously overnight until a foamy 
dispersion was produced. In the next step, for each 300 mg PGC, 45 mg sodium iodide, 
0.44 ml methyl iodide and 40 mg sodium hydroxide were dissolved in 4 ml absolute 
ethanol and added into the PGC dispersion. All of the ingredients were stirred in pre-
heated oil bath at 36⁰C under a nitrogen atmosphere for 3 hours. The nitrogen atmosphere 
was obtained by filling a balloon with nitrogen gas and clamping it closed. Once the 
balloon was placed on top of the flask in the oil bath, the clamp was released and the 
balloon sealed in place with parafilm.  
After 3 hours, the product was precipitated by adding diethyl ether into a conical 
flask and left for overnight. On the following day, a brown precipitate formed at the 
bottom of the flask. The diethyl ether was carefully decanted to avoid polymer loss. The 
precipitated product was washed with 300 ml diethyl ether twice more. The resultant solid 
was dissolved in 100 ml water (for every 400 mg PGC) and dialyzed exhaustively against 
water (the same dialysis method as before) using MWCO membrane 7,000 Dalton. 
 
2.2.5 Removal of iodide 
 A column was prepared by packing 100 ml Amberlite IRA-96 in a 1 L separating 
funnel. The column was washed with 150 ml 1 M hydrochloric acid followed by 8 L of 
Milli-Q water or more until a neutral pH was obtained. The funnel was left wet overnight 
with the tap closed. On the following day, the column was washed with another 2 L of 
water. With the tap closed, the dialysate was added into the funnel and it was then allowed 
to pass the column slowly. Once it reached the end of the column by gravitational force, 
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the solution was collected directly into freeze dry bottles. The column was washed with 
water in amount equal to twice of the column volume plus the dialysate volume or until 
the brown solution was no longer seen collected into the bottles. The solution was let 
frozen in the -20⁰C freezer and freeze-dried until white cotton-like product obtained.    
 
2.3 Characterization of GCPQ 
2.3.1 NMR spectroscopy 
Nuclear magnetic resonance (NMR) spectroscopy is a method for identifying 
compound and determining structure of organic compounds. The NMR method is based 
on utilization of magnetic momentum produced by spinning of magnetic nuclei at its 
nuclear axis. The spinning motion is termed as spin quantum number (I), of which is 
determined by the even or odd number of neutrons and positively charged protons in the 
nuclei. Only nuclei with half-integral I (I =1/2), such as in 1H and 13C, are suitable for 
NMR measurement as they have uniform charge distribution on the nuclear surface (Ning, 
2005). 
When a magnetic nucleus is placed in a large static magnetic field and subjected 
to pulses of electromagnetic radiation, such as radio frequency (RF), the energy absorbed 
by the nucleus causes transitions (flipping orientations) from lower to higher energy state, 
or the other way around. The frequency of absorbed energy is directly proportional to the 
magnetic field strength, thus allowing the modern Fourier transform spectrometer to be 
used for scanning the RF (Jones and Mulloy, 1993). This energy absorption induces a 
voltage detectable by tuned coil of wire which later translates into signals displayed as 
free induction decay. Relaxation happens when the spin system returns to thermal 
equilibrium where RF pulses are no longer present. The energy for flipping and thus 
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production of NMR signal is basically the energy difference between the two nuclear 
orientations which depends on the magnetic field strength (James, 1998).  
Chemical shift (δ) shows the peak position for a particular functional group in 
parts per million (ppm) unit in the NMR spectrum. The chemical shift is the difference 
between position of the signal of interest and the reference standard at 0 ppm (James, 
1998). Tetramethylsilane is commonly used as the standard for 1H measurement because 
it resonates at higher frequency than most other nuclei, having only single peak and can 
be removed easily from the sample (boiling point = 27°C) (Ning, 2005). The area of the 
peak represents the number of nuclei contributing to the signal. Deuterium solvent (e.g. 
deuterated methanol) is usually used to dissolve the samples. Since deuterated solvent has 
the spin value of 1 (I = 1), it has a completely different frequency from the 1H isotope 
thus avoiding solvent-sample signal interactions (Williams and Fleming, 1995). 
 
2.3.2 Molecular weight of GCPQ 
The measurement of GCPQ’s molecular weight was done using the gel 
permeation chromatography (GPC). GPC (Moore, 1964) is also known as size exclusion 
chromatography. It is a type of liquid chromatography in which the separation mechanism 
relies solely on size of the polymer molecules in solution rather than chemical interactions 
between the particles and the stationary phase.  
The long chain polymers when dissolved in solvent would normally coil up to 
form coil formation that resemble a ball of strings and behave like tiny spheres. The 
hydrodynamic size of the spheres depends on the molecular weight of the polymers, with 
higher molecular weight polymers coil up to form larger spheres. These coiled polymers 
are then introduced into the mobile phase and flow through the pores of the GPC column. 
Large spheres that are unable to enter the pores are carried straight through the mobile 
41 
 
phase, whereas small spheres that fit the pores are retained in the stationary phase before 
eventually eluted out of the column at different rate depending on the size of the spheres 
(Agilent Technologies, 2015). 
As a result, small coiled polymers that can enter many pores would take a long 
time to pass through the column, therefore exit the column slowly. Large coiled polymers 
that cannot enter the pores leave the column quickly, whereas the intermediate size coiled 
polymers leave the column in between these examples (Bly, 1970). This also means larger 
spheres (higher molecular weight polymers) eluting first, followed successively by 
smaller spheres (lower molecular weight polymers). As the spheres exit the column, 
elution behaviour of the samples is displayed in a chromatogram, which shows the 
volume of materials exited the column at any one time. The chromatogram data is then 
compared to a calibration that shows elution behaviour of polymer with known molecular 
weight.  
Calculations of molecular weight in GPC are based on distribution. The amount 
of particles is counted at every weight in the distribution to calculate average value for 
the whole sample. This calculated average is known as number average molecular weight 
(Mn)  and the other molecular weight average used is known as weight average molecular 
weight (Mw). It is common to see Mw value greater than Mn unless the polymer is 
completely monodisperse. The ratio of Mw to Mn is used to calculate polydispersity index 
(Mw/Mn) as indication of the polymer’s molecular mass range (Agilent Technologies, 
2015). 
 Standard GPC detectors are not able to count number of molecules eluted from 
the column, meaning that the weight averages cannot be measured directly. Therefore, 
concentration of molecules on weight/volume basis is measured using concentration 
detector, which measures the differential refractive index (dRI). In combination with the 
refractive index detector, static light scattering detector can be used, such as multi-angle 
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laser light scattering (MALLS) detector (Trathnigg, 1995). MALLS detector works under 
the principal that scattering beam of light as it strikes a polymer molecule enables the 
instrument to directly measure the molar mass when the refractive index increment 
(dn/dc) is known. This gives a response directly proportional to the molecular weight of 
the polymer molecules.  
 
2.3.3 Materials 
Item Supplier 
Deuterated methanol, CD3OD Cambridge Isotope Laboratories, Inc, Massachusetts, 
USA 
Sodium acetate anhydrous Sigma-Aldrich Company Limited, Dorset, UK 
Glacial acetic acid Fisher Scientific Limited, Leicestershire, UK 
Methanol Fisher Scientific Limited, Leicestershire, UK 
Polyethersulfone (PES) 
syringe filter 
Merck Milipore Limited, Cork, Ireland  
 
2.3.4 Methodology 
2.3.4.1 Level of palmitoylation and quaternisation of GCPQ 
Nuclear magnetic resonance experiments (1H NMR) of GCPQ were performed 
using Bruker AMX 400 MHz spectrometer (Bruker Instruments, Coventry, UK). GCPQ 
solution was prepared by dissolving 3 mg GCPQ in 0.7 ml CD3OD. The level of 
palmitoylation (P%) and quaternisation (Q%) were determined by comparing the 
palmitoyl methyl protons (δ = 0.89 – 0.90 ppm) and the quaternary ammonium methyl 
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protons (δ = 3.45 ppm) respectively with the sugar methine/methylene protons (δ = 3.50 
– 4.40 ppm) (Qu et al., 2006).  
 
 
 
 
2.3.4.2 Gel permeation chromatography 
The molecular weight of GCPQ was determined by gel permeation 
chromatography-multiangle laser light scattering (GPC-MALLS). The measurement was 
done using Dawn Heleos II MALLS detector (λ=658 nm), Optilab rEX interferometric 
refractometer (λ=658 nm) and quasielastic light scattering (QELS) detectors (Wyatt 
Technology Corporation, Santa Barbara, USA). The mobile phase used was a mixture of 
acetate buffer (0.5 M anhydrous sodium acetate, 0.2 M glacial acetic acid, pH 4.8) and 
methanol at ratio 35:65 v/v. The GCPQ samples prepared were filtered (0.2 µm PES 
syringe filter) prior to injection into POLYSEP-GFC-P 4000 column (300 x 7.8 mm, 
Phenomenex, UK) coupled with POLYSEP-GFC-P guard column (35 x 7.8 mm, 
Phenomenex, UK) using Agilent 1200 series autosampler (Agilent Instruments, 
Stockport, UK) at loading concentration of 5 mg/ml and flow rate of 0.7 ml/min. Dn/dc 
was determined by preparing stock solutions of 0.1, 0.2, 0.3, 0.4, 0.5 and 0.6 mg/ml 
GCPQ in the mobile phase and injecting one stock solution at a time into the Optilab 
instrument. The data were analysed using ASTRA for Windows version 5.3.4.14 software 
(Wyatt Technology Corporation). 
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2.3.5 Results and discussion 
2.3.5.1 Level of palmitoylation and quaternisation of GCPQ 
Based on the calculation from the formula, the level of palmitoylation (P %) and 
quaternisation (Q %) for both batches of GCPQ are displayed in Table 3. 
Polymer P % Q % 
GCP10Q11 
 
P % =   1.18 / 3 
34.11/9 
 
Q % =   3.89 / 9 
  34.11/9 
 
GCP20Q11 P % =   1.80 / 3 
27.22/9 
 
Q % =   3.04 / 9 
  27.22/9 
 
 
Table 3: Level of palmitoylation and quaternisation (P% and Q%, respectively) of 
GCP10Q11 and GCP20Q11 (GC source: Chitomerics and Sigma Aldrich, respectively). 
 
 These P% and Q% values were used in naming the GCPQ batches accordingly for 
easy reference in the upcoming experiments. Based on the results, both batches of which 
were synthesized using the same method but of different sources of GC had different level 
of palmitoylation. GCP20Q11 of GC from Sigma had twice the amount of P% of 
GCP10Q11 albeit same ratios of palmitic acid were used in both syntheses. This might 
due to the higher degree of N-acetylation of the GC from Chitomerics compared to the 
GC from Sigma, resulted in less primary amine group available for the conjugation with 
palmitic chain. Besides, the conjugation reactions occurred quite randomly in between 
batches of GCPQs and this had caused a difficulty to reproduce or replicate the exact 
same polymer configuration more than once. 
Determination of palmitoylation and quaternisation degree enables the estimation 
of the hydrophobicity and hydrophilicity of the polymer. It is important as a way of 
 x 100 = 10.38 % 
x 100 = 19.88 % 
x 100 = 11.40 % 
x 100 = 11.24 % 
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predicting the aggregation capability of the polymer and its stability upon micellization 
in aqueous media. The CMC value of GCPQ is highly influenced by the level of 
hydrophobic constituent of the polymer, with lower CMC values were observed with 
higher amount of hydrophobic molecules (Qu et al., 2006, Tanford, 1978). GCPQ 
polymer aggregation is influenced by the entropy gain from the interaction of water 
molecules with the hydrophobic C16 chains on the polymer, which at the same time also 
improves the stability of the micellar formation due to the high apolar surface area (Siew 
et al., 2012).  The 1HNMR spectra for the GCP10Q11 and GCP20Q11 which are shown 
in  Figure 10 and Figure 11, respectively, confirmed the formation of GCPQ polymers. 
The chemical structure of the GCPQs are labelled with P% and Q% to show the random 
reactions of palmitoylation and quaternisation calculated per 100 glycol chitosan 
monomers into percentile unit. The presence of a distinct peak at 3.15 ppm means more 
free amine group in GCP10Q11, which further proved that there was less palmitoylation 
in this batch of polymer compared to GCP20Q11. 
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Figure 10: 1HNMR spectrum of GCP10Q11 in CD3OD. 
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Figure 11: 1HNMR spectrum of GCP20Q11 in CD3OD 
 
 
 
 
 
 
 
48 
 
2.3.5.2 Molecular weight of GCPQ 
The two batches of GCPQ showed two different values of average molecular 
weight with 15,100 Da for GCP10Q11 and 24,890 Da for GCP20Q11. Both Mw and Mn 
for GCP20Q11 showed higher values compared to the Mw and Mn of GCP10Q11 (Table 
4). These higher values of molecular weight in GCP20Q11 could be related to its higher 
level of palmitoylation (P%), which remarks the higher acylation of the primary amine 
group with the palmitic acid chain thus adding more molecular weight or mass to every 
subunit of the GCPQ polymer in comparison to the lower palmitoylated GCP10Q11. The 
Mw / Mn polydispersity ratio for both batches at 1.18 and 1.24 for GCP10Q11 and 
GCP20Q11, respectively can be considered as in narrow distribution since the common 
values for synthetic polymer is between 1.2 and 3. The dn/dc for GCP10Q11 and 
GCP20Q11 was 0.1763 ± 0.0043 ml/g and 0.1399 ± 0.0053 ml/g, respectively.  
 
Polymer 
Molecular weight determination 
Mw (Da) Mn (Da) Mw/Mn 
GCP10Q11 15, 100 12, 790 1.180 
GCP20Q11 24, 890 20, 110 1.238 
 
Table 4: Molecular weight of GCPQs based on weight average molecular weight (Mw), 
number average molecular weight (Mn) and polydispersity index (Mw/Mn) of the polymer. 
 
Both GCPQ chromatograms showed good overlap of light scattering (red) and 
differential refractive index (blue) peaks. The additional peaks of dRI signals displayed 
after 15 minutes represent the exclusion limit of the column (Figure 12). 
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Figure 12: An example of chromatogram of light scattering (red line), quasi-elastic light 
scattering (pink line) and differential refractive index (blue line) detector signals used in 
ASTRA software in determination of GCPQ molecular weight. 
 
2.4 Conclusion 
The current synthesis methodology applied was successfully able to produce 
GCPQ polymers regardless of different sources of glycol chitosan used in the synthesis. 
Different level of palmitoylation polymers enabled more choices of GCPQ batches to be 
used for nanoparticle formulations. 
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3 Disulfiram nanoparticle formulation 
 
Chapter 3 
 
Disulfiram nanoparticle 
formulations 
 
3.1 Overview 
Two types of nanoparticle preparations have been attempted in the search of the 
most ideal type of nanoparticle formulation that can highly load the hydrophobic and 
labile disulfiram and remain stable upon exposure to various external factors. The first 
approach was to formulate DS with GCPQ into polymeric micellar nanoparticles. 
Application of polymeric micelles to be loaded with hydrophobic drugs and improve the 
drug delivery has been reported frequently in the literature (Lalatsa et al., 2012c). 
 Self-assembled GCPQ polymeric micelles had been used to be loaded with 
hydrophobic drugs such as griseofulvin and cyclosporine A (Siew et al., 2012), AZD6244 
(selumetinib) (López-Dávila et al., 2016) and celecoxib (Mennini et al., 2014) in an 
aqueous media using probe sonication method. In order to improve solubility and 
permeability of amphotericin B for oral delivery, GCPQ was added into an alkaline 
solution of the drug to create the polymeric micellar nanoparticles (Serrano et al., 2015). 
Generally, polymeric micelles improve dissolution of hydrophobic drugs by increasing 
their aqueous levels and the encapsulation is also increased with the increase of polymer 
hydrophobicity (Qu et al., 2006). 
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The second approach was to create nanoemulsions with main ingredients DS-in-
oil and GCPQ in aqueous medium. Unlike the polymeric micelles formulations, 
preparation of high capacity nanoemulsions using only GCPQ as the emulsifier has never 
been attempted in our laboratory. The surfactants are usually of amphiphilic structure 
with hydrophilic and hydrophobic moieties commonly called the heads and tails, 
respectively. This specification makes the GCPQ amphiphiles a possible polymeric 
surfactant for the formation of stable emulsions. 
 
3.2 Nanoparticle characterization analysis 
3.2.1 Principle of the methodologies used in nanoparticle 
characterization 
3.2.1.1 HPLC 
 Physicochemical characterization is one of the fundamental aspects for 
determination of the safety, efficiency and biodistribution of the nanoparticle 
formulations The most important criterion is the ability of nanoparticle to be able to 
encapsulate or attach maximum amount of drug. The content of the drug in the 
nanoparticle formulations is commonly measured using high-performance liquid 
chromatography (HPLC). HPLC is a rapid, simple and robust method especially for the 
analysis involving highly hydrophobic drugs. 
HPLC is one of the chromatographic methods that can be used to provide 
quantitative and qualitative information of chemical substances based on the compound 
separations in a liquid medium under a set of conditions (Meyer, 2006). A common setup 
of a HPLC system consists of solvent reservoir, transfer line, high-pressure pump, sample 
52 
 
injection instrument, column and detector (Figure 13). The system is usually connected 
to a computer equipped with software to control the data acquisition and analysis.  
A standard HPLC run is commonly initiated with the solvent (mobile phase) from 
the solvent reservoir continuously pumped throughout the system until all parts are 
equilibrated, followed by injection of the samples into the mobile phase at the injection 
valve. The separation of various compounds in the sample takes place within the column, 
and separated sample components leave (eluted) from the column at different times, 
which will be scanned by the ultraviolet (UV) detector (Snyder et al., 2010b). The detector 
signal is plotted against time which is interpreted by the software to produce a 
chromatogram. 
 
 
Figure 13: Schematic diagram of an HPLC system. 
 
The choice of right column is fundamental for efficient separation of samples. 
Reversed-phase chromatography (RPC) is the most commonly used HPLC mode for 
analysing hydrophobic drugs. RPC features a nonpolar column in combination with polar 
mixture of water and organic solvent as the mobile phase. The column in RPC is usually 
consist of porous silica particles creating pores that are attached with C18 groups as the 
stationary phase.  
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When the samples in the mobile phase flow through the column, the molecules of 
mobile phase are not retained thus leave the column the quickest. The differential 
migration (different speed at which the solute molecules migrate through the column) of 
the compounds in the sample forms the basis of the chromatographic separation. As the 
solute molecules move through the column, they occupy a volume which is called a band. 
The width of this solute-volume (band-width) is measured as it leaves the column and 
recorded in the chromatogram as a peak. Time of the band leaves the column is interpreted 
as the peak retention time for that particular solute, and concentration of the solute in the 
sample is proportional to the area or height of the peak (Snyder et al., 2010a).  
 
3.2.1.2 Particle size and particle size distribution with DLS analysis 
Another important criterion of nanoparticle formulations is to ensure the particle 
size is small and within the nanometre scale, as well as having narrow size distributions. 
This characterization can be done using dynamic light scattering (DLS) analysis or also 
known as photon correlation spectroscopy (PCS) (Hall et al., 2007). The principle of DLS 
measurement is based on the Brownian motion of particles in suspension that is caused 
by thermally induced collisions between suspended particles and solvent molecules. Once 
the particles illuminated with a laser, the intensity of the scattered light fluctuates 
depending on the size of the particles. Analysis of the intensity fluctuations determines 
the Brownian motion velocity which is defined by translational diffusion coefficient (D). 
D is converted into particle size using Stoke-Einstein equation: 
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The diameter measured using DLS is called hydrodynamic diameter, which refers 
to the diameter of the sphere that diffuses at the same speed as the particle being 
measured. Apart from the actual size of the particle, determination of hydrodynamic 
diameter also depends on the particle shape, particle surface structure and ionic strength 
in the medium. 
  
 
Figure 14: Illustrations of hydrodynamic diameter for various size and shape of particles. 
 
Polydispersity index (PDI) is the measurement of heterogeneity of particle sizes 
in a mixture. Monodisperse or uniform particles have the same sizes, shapes and masses 
while a polydisperse or non-uniform collection of particles have inconsistent sizes, shapes 
and masses. 
 
3.2.1.3 Visual analysis of nanoparticles with TEM 
Transmission electron microscope (TEM) is able to provide a higher resolution 
and greater detail view of the nanoparticles shape and morphology at the nanometre scale. 
This imaging technique is usually used altogether with DLS for size measurement as DLS 
usually gives larger particle size compared to the values measured from TEM images 
(Hall et al., 2007). TEM works based on the principle of electron beam deflection and 
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diffraction from the particles where high-vacuum and thin sample sections are needed for 
the beam to penetrate.  
 
3.2.1.4 Particle surface charge with DLS analysis 
For optimal design of therapeutic nanoparticles, surface charge or known as zeta 
potential of a particle is also a fundamental parameter as it is known to affect dispersion 
stability. Zeta potential is a measure of charge repulsion or attraction between particles or 
electrostatic magnitude in a liquid suspension. For instance, in the development of 
nanoemulsions, information of the droplet charge is crucial as the negative ones are 
cleared more rapidly from the blood than neutral and positively charged (Eccleston, 
2013).  
When a charged particle is suspended in a liquid filled with cations and anions, 
the opposite charge will be attracted to the surface of the particle. A positively charged 
particle attracts negative ions in the liquid, and vice versa. Ions closest to the particle 
surface are strongly bound to the charged particle whereas ions further away are loosely 
bound forming a diffuse layer, forming two layers of ions which is known as electrical 
double layer. Ions in the diffuse layer will also move along with the particle when it moves 
in the liquid, but ions just outside the layer’s boundary do not travel together. This 
boundary is called the slipping plane. The potential that exists between the particle surface 
and the dispersing liquid at the slipping plane is the zeta potential (Figure 15). 
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Figure 15: An illustration of the zeta potential at the surface of a negatively charged 
particle measured by DLS.  
 
3.2.2 Ideal criteria of nanoparticle formulations 
The aim of characterization is to ensure the obtained nanoparticle formulations 
have high amount of drug content inside or attached to the particles, nanometre range of 
particle size and narrow particle size distribution (preferably PDI value of less than 0.5). 
The formation of nanoparticles is further confirmed with visual examination of the TEM 
images for the particle size and shape distributions. The zeta potential is measured to 
determine the ionic strength of the particles formed whether the charge is weakly- or 
highly- positive, or weakly- or highly- negative. The stability of physicochemical 
properties of the nanoparticles were studied upon ingredient adjustments to the 
formulations, effect of storage and exposure to different pH environments and biological 
fluids. 
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3.2.3 Materials 
Item Supplier 
Methanol, HPLC grade Fisher Scientific Limited, Leicestershire, UK 
 Ethanol, HPLC grade 
Hexane, HPLC grade Sigma-Aldrich Company Limited, Dorset, UK 
 
3.2.4 HPLC analysis 
3.2.4.1 Instrumentation 
One reverse phase Phenomenex Onyx Monolithic C18 column (4.6 x 100 mm) 
connected with a guard column (4.6 x 5 mm) was used on Agilent 1200 series HPLC 
(Agilent Technologies, Wokingham, UK) equipped with a quaternary pump, degasser, 
autosampler and UV detector. The mobile phase used was a mixture of methanol and 
Milli-Q water at 80:20 v/v ratio. The flow rate was 1.0 ml/min with column temperature 
at 30⁰C and injection volume of 5 µl. The DS peak was measured at wavelength 275 nm. 
The software used for HPLC data analysis was Agilent Chemstation. 
 
3.2.4.2 HPLC method validation 
Validation of bioanalytical methods is fundamental in order to ensure the 
reliability, quality and reproducibility of the data analysis and the findings that come out 
from it (Tiwari and Tiwari, 2010). The HPLC method was validated based on selectivity, 
linearity, accuracy and precision. The selectivity was determined by analysing samples 
of DS in ethanol at lower limit of quantification (LLOQ) level. The linearity was 
determined by plotting the calibration curve for disulfiram standards of the drug 
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concentration versus peak area response (y = ax + b). The accuracy and precision of the 
assay method was determined for both intra-day and inter-day variations using the quality 
control (QC) samples. The precision of the assay was determined by analysing the 
repeatability and reproducibility of the assay. Repeatability refers to running the analyses 
on the same day in rapid succession (within-run precision or intra-day), whereas 
reproducibility is by running the assay on separate days when laboratory conditions may 
vary (between-run precision or inter-day) (Vogel, 1989). The accuracy was expressed as 
percentage of relative error (%RE), while precision as percentage of coefficient of 
variation (%CV).  
%RE = ((Found DS – Added DS)/Added DS) x 100 
%CV = (Standard deviation / Mean of found DS) x 100. 
 
3.2.4.2.1 Preparation of standards and quality control solutions for method validation 
 
The stock standard solution was prepared by dissolving DS in methanol to create 
a stock solution of 100 µg/ml. Six standard solutions at 7.5, 5.0, 2.5, 1.0, 0.5 and 0.25 
µg/ml of disulfiram in methanol were prepared by serial dilutions. Two QC solutions 
were also prepared at the concentrations of 0.75 and 6.0 µg/ml. All samples were prepared 
in triplicate.  
 
3.2.4.2.2 Selectivity 
The selectivity (specificity) of the method was proven by the chromatograms 
showing distinct peak of DS at retention time 1.58 minutes (Figure 16). The LLOQ was 
found to be at 0.25 µg/ml. 
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Figure 16: HPLC chromatogram shows disulfiram peak at LLOQ of 0.25 µg/ml with 
retention time at 1.58 minutes. 
 
3.2.4.2.3 Linearity 
The linearity of the calibration curve (Figure 17) was analysed using linear 
regression analysis from which the linear regression equation was obtained. The 
calibration curve was linear in the range concentration of 0.25 to 7.5 µg/ml with 
regression equation of y = 8.8749x – 0.6759 with R2 value of 0.9989. The lower limit of 
detection (LLOD) was found to be at 0.15 µg/ml (Table 5). 
 
DS 
concentration 
range 
Linear regression 
Coefficient of 
correlation (R2) 
LLOD 
(µg/ml) 
LLOQ 
(µg/ml) 
0.25 – 7.5 
µg/ml 
y = 8.8749x - 
0.6759 
0.9989 0.15 0.25 
 
Table 5: Linearity of disulfiram standards by HPLC method. The linear regression 
equation was obtained from three calibration curves. 
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Figure 17: The linear calibration curve of disulfiram obtained from the DS standards. 
 
3.2.4.2.4 Accuracy and precision 
The intra-day and inter-day for determination of accuracy and precision are 
displayed in Table 6. Both %RE and %CV showed values below 15%, which is 
acceptable by the Food and Drug Administration (FDA) (2001) guidance. 
 
 Intra-day Inter-day 
Added DS 
(µg/ml) 
Found DS ± SD %RE %CV  Found DS ± SD %RE %CV  
0.75 0.7522 ± 
0.0113 
0.2963 1.4979 0.7631 ± 
0.0251 
1.7467 3.2892 
6.0 5.9316 ± 
0.0815 
-1.1396 1.3742 5.8911 ± 
0.0124 
-1.815 0.2105 
 
Table 6: Precision and accuracy of the HPLC assay method for disulfiram (DS). SD = 
standard deviation of the three replicates. 
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3.2.4.3 Drug encapsulation efficiency for nanoparticle formulation 
The amount of DS encapsulated in the nanoparticles was determined as drug 
entrapment (DE%), which was the percentage amount of drug found (drug content) in 
proportion to amount of drug added in preparation of the formulation.  
 
 
 
The drug was measured using the same HPLC instrumentation as in the method 
validation. Sample for analysis was prepared by diluting 10 µl formulation in 490 µl of 
either absolute methanol (micellar formulation) or ethanol (nanoemulsions) to create 50 
times dilution solution. 
 
3.2.5 Dynamic light scattering (DLS) analysis 
Nanoparticle size (Z-average, ZAve), polydispersity index and zeta potential of 
the nanoparticle formulations were measured using Malvern Zetasizer Nano ZS ZEN3600 
(Malvern Instruments Ltd, Worcestershire, UK) fitted with 633 nm (red) laser. Samples 
were prepared by diluting 10 µl formulation in 990 µl Milli-Q water in order to meet the 
data quality criteria set by the DLS equipment. 
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3.2.6 Transmission electron microscopy (TEM) analysis 
Preparation of the samples for TEM imaging was performed by placing a small 
amount of the nanoparticle formulation (± 10 µl) on a carbon coated grid and negatively 
stained with uranyl acetate (1% w/v). Images of the samples were then captured using 
FEI CM129 BioTwin transmission electron microscope (Philips, Eindoven, The 
Netherlands) and advanced microscopy technique (AMT) digital camera. 
 
3.2.7 Statistical analysis 
Statistical analysis was performed using IBM SPSS Statistics for Windows, 
Version 22.0 (IBM Corp, Armonk, New York, USA). Comparison of more than two 
groups was done using One-way ANOVA with Tukey’s multiple comparison test for the 
post-hoc analysis, whereas comparison between two groups was done using Independent-
samples t-test (Student’s t-test). Data were presented as mean ± standard deviation with 
significance value of p < 0.05. 
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3.3 Formulation of DS into micellar nanoparticles 
3.3.1 Formulation of DS with GCP10Q11 
3.3.1.1 No drug pre-dissolution step 
3.3.1.1.1 Methodology 
In a brief experiment to determine solubility of DS in water, 5 mg of DS was added 
into 1 ml Milli-Q water and left to stir at room temperature for 24 hours. The solution was 
then centrifuged and the supernatant was sampled for HPLC measurement. The DS 
solubility in water was found to be 4.34 ± 0.01 µg/ml, slightly higher solubility than 
previously reported (4.09 µg/ml at 25°C) (Yalkowsky and He, 2003).  
The nanoparticle formulations were prepared based on the assumption that GCPQ 
would improve the solubility of highly hydrophobic DS in aqueous medium. The 
formulations were prepared by mixing DS crystals into pre-dissolved GCP10Q11 in 
Milli-Q water (pH 5.5) with drug to polymer ratio of 1 to 5 (1:5 w/w) and 1 to 10 (1:10 
w/w) in 1 ml aqueous solution. The 1:5 and 1:10 formulations were prepared in 1 ml 
volume. Therefore, 5 mg or 10 mg GCPQ were dissolved in 1 ml deionized water 
respectively in glass vials, creating a transparent aqueous solution. One milligrams DS 
were then added into the vials containing GCPQ solution to create 1 mg/ml DS (DS-
GCP10Q11) formulations. The formulations were sonicated using an ultrasonic 
disintegrator at amplitude 5 (Soniprep 150 Plus, MSE, U.K.)  until the drug was dissolved 
or homogenization was achieved. The formulations were then centrifuged at 10,000 g for 
10 minutes to separate the encapsulated drug from the non-encapsulated drug. The 
supernatant which contains the drug-loaded nanoparticles was measured for DE%, 
particle size and PDI. All measurements were done in triplicate and mean values were 
recorded. 
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3.3.1.1.2 Results 
Table 7 shows the drug content, DE%, size of particles and PDI of the supernatant. 
Solid crystals of DS were seen in TEM images (Figure 18) and upon naked eye 
observation at the bottom of the vials after sonication, indicating the drug was not fully 
solubilized even after 1-hour sonication. This could explain the low drug content in the 
supernatant, which was 0.94 % and 2.26 % of the added drug for 1:5 and 1:10 
formulations, respectively. The size of particles of the two formulations was considered 
small and closely similar to each other. The PDI values were also acceptable although 
1:10 had higher value compared to the 1:5 formulations. 
 
SAMPLES 
DRUG 
CONTENT 
(µg/ml) 
DE% SIZE (nm) PDI 
1:5 
DS-GCP10Q11 
9.35 ± 0.05 0.94 168.3 ± 2.5 0.29 ± 0.01 
1:10 
DS-GCP10Q11 
22.61 ± 3.56 2.26 165.9 ± 5.4 0.40 ± 0.05 
 
Table 7: Drug content, DE%, particle size and PDI values for 1:5 and 1:10 DS-
GCP10Q11 formulations prepared with no drug pre-dissolution step. Data were presented 
as mean ± SD (n = 3). 
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Figure 18: The TEM image (top) is the nanoparticles formed after the sonication of DS 
with GCP10Q11. The image (bottom) shows the example of DS crystals seen in the 
formulations. All images were captured before centrifugation. 
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3.3.1.2 Drug and polymer pre-dissolved in solvent 
The results from the previous attempt of DS-GCP10Q11 formulations suggest the 
low drug encapsulation was caused by the insolubility of the drug in solution therefore 
leads to low amount of free drug that can be encapsulated by the polymer. The next 
approach was to ensure the drug was completely dissolved prior to the addition into the 
GCPQ solution to increase the amount of free drug available in the aqueous solution.  
Methanol was chosen since both DS and GCPQ polymer can be solubilised in it. 
 
3.3.1.2.1 Methodology 
Two milligram DS were mixed with either 10 or 20 mg GCP10Q11 in a glass vial 
and dissolved in 2 ml methanol by vortex to create the 1 mg/ml of drug formulation. Once 
dissolved, the solvent was removed by evaporation using a vacuum concentrator (Savant 
SpeedVac, Asheville, USA) equipped with refrigerated vapour trap (Savant RVT400, 
Asheville, USA). The resultant paste-like substance after the evaporation was then 
reconstituted in 2 ml Milli-Q water and sonicated for 15 minutes to achieve homogenous 
dissolution and to create small size particles. The formulations were then centrifuged at 
10,000 g for 10 minutes. As previously done, the supernatant which contains the drug-
loaded nanoparticles was measured for drug content, particle size and PDI. All 
measurements were done in triplicate.  
 
3.3.1.2.2 Results  
Table 8 shows the drug content, DE%, size of particles and PDI of the 
formulations. After sonication, cloudy and homogenous dispersion was seen in the 
formulations without signs of drug crystal at the bottom of the glass vials. However, after 
settling the formulations in upright position for approximately 5 minutes, sedimentation 
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of large particles was formed and seen accumulated at the bottom of all formulations. 
This could indicate most of the drug and polymer aggregated together and formed large 
particles which later accumulated by the force of gravity. This could also explain the low 
level of encapsulated drug in the supernatant, which was 1.28 % and 2.21% of the added 
drug for 1:5 and 1:10 formulations, respectively. The size of particles was also considered 
small for both formulations. The PDI values were also acceptable for a homogenous 
distribution of particles. 
 
SAMPLES 
DRUG 
CONTENT 
(µg/ml) 
DE% SIZE (nm) PDI 
1:5 
DS-GCP10Q11 
12.78 ± 0.08 1.28 208.0 ± 6.8 
0.30 ± 
0.03 
1:10 
DS-GCP10Q11 
22.15 ± 0.08 2.21 274.8 ± 14.2 
0.33 ± 
0.04 
 
Table 8: Drug content, DE%, particle size and PDI values for 1:5 and 1:10 DS-
GCP10Q11 formulations prepared whereby drug and polymer pre-dissolved in solvent. 
Data were presented as mean ± SD (n = 3). 
 
3.3.1.3 Conclusions for DS formulation with GCP10Q11 
The polymeric micellar formulations of DS with GCP10Q11 was unable to give a 
high drug load (less than 3% DE%) although the particle sizes (166 – 275 nm) and particle 
size distributions (PDI = 0.3-0.4) were within acceptable range. The next approach was 
then to formulate DS with higher palmitoylation GCP20Q11 for the attempt to increase 
the drug encapsulation. 
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3.3.2 Formulation of DS with GCP20Q11 
We hypothesized that the dissolution and encapsulation of hydrophobic DS could 
be elevated with the use of higher palmitoylation GCPQ. Therefore, formulations using 
GCPQ with higher palmitoylation level GCP20Q11 (P% = 19.88%, Q% = 11%) were 
made. The preparation steps and methods of analyses for the formulation of DS with 
GCP20Q11 were the same as have been done in the preparation of DS-GCP10Q11. 
 
3.3.2.1 No drug pre-dissolution step 
 
3.3.2.1.1 Results  
 
Table 9 shows the mean drug content, size of particles and the PDI values of the 
DS-GCP20Q11 formulations. The added drug for each formulation was 1 mg/ml (1000 
µg/ml). Similar to the DS-GCP10Q11, there were also solid crystals of DS seen at the 
bottom of the vials even after the 1 hour which explains the low amount of drug 
encapsulated by GCPQ (1.92% and 3.48% of the added drug for 1:5 and 1:10, 
respectively). The PDI values of 0.6 or more for both formulations were considered high 
for nanoparticle formulations. However, the particle sizes were acceptable for the 
optimum nanoparticle criteria.   
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Table 9: Drug content, DE%, particle size and PDI values for 1:5 and 1:10 DS-
GCP20Q11 formulations prepared with no drug-predissolution step. Data were presented 
as mean ± SD (n = 3). 
 
3.3.2.2 Drug and polymer pre-dissolved in solvent 
3.3.2.2.1 Results  
 Table 10 shows the mean drug content, DE%, size of particles and the PDI values 
of the DS-GCP20Q11 formulations. The added drug for each formulation was 1 mg/ml 
(1000 µg/ml). Similar to the DS-GCP10Q11 formulations (prepared with the same 
method as these ones), there were also sedimentation seen in the formulations shortly 
after the sonication and is also presumed to be the reason of the low level of encapsulated 
drug in the formulations (2.13% and 3.81% of the added drug for 1:5 and 1:10, 
respectively). The PDI values for the 1:10 formulations were found higher than 0.6. In 
fact, the overall PDI values for DS formulations with GCP20Q11 were higher than the 
ones with GCP10Q11 (approximately 0.3-0.4 vs. 0.5-0.6). This suggests the use of higher 
palmitoylation GCPQ in the formulations would produce higher polydispersity in 
nanoparticle size distributions. 
 
 
SAMPLES 
DRUG 
CONTENT 
(µg/ml) 
DE% SIZE (nm) PDI 
1:5 
DS-GCP20Q11 
19.17 ± 0.31 1.92 159.3 ± 8.2 0.59 ± 0.04 
1:10 
DS-GCP20Q11 
34.76 ± 0.27 3.48 112.4 ± 1.1 0.68 ± 0.01 
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SAMPLES 
DRUG 
CONTENT 
(µg/ml) 
DE% SIZE (nm) PDI 
1:5 
DS-GCP20Q11 
21.30 ± 0.65 2.13 294.7 ± 0.03 
0.53 ± 
0.07 
1:10 
DS-GCP20Q11 
38.09 ± 0.18 3.81 143.9 ± 6.01 
0.62 ± 
0.04 
 
Table 10: Drug content, DE%, particle size and PDI values for 1:5 and 1:10 DS-
GCP20Q11 formulations prepared whereby drug and polymer pre-dissolved in solvent. 
Data were presented as mean ± SD (n = 3). 
 
 
3.3.3 Discussion for micellar formulations 
GCPQ which can act as a drug solubilizer (Uchegbu et al., 2001) was hypothesized 
to be able to dissolve the highly hydrophobic disulfiram in aqueous solution and form 
micellar nanoparticles. However, the results revealed that even after such a strong 
sonication power applied to break apart the disulfiram solid crystals into smaller sizes for 
easy dissolution, macroscopic form of disulfiram crystals were still detected indicating 
the incomplete dissolution of the drug even in the presence of GCPQ. The solvent 
evaporation method by which dissolving the drug in methanol to form free DS to enable 
encapsulation by the GCPQ micelles was also found failed to achieve high encapsulation 
of the drug within the particles. 
At 1:10 ratio, the DS-GCP20Q11 formulations were found to have higher 
percentage of DE% compared to the DS-GCP10Q11 formulation at the same drug to 
polymer ratio. This shows the higher palmitoylation GCPQ is capable to entrap more 
drugs compared to the lower palmitoylation level. However, the PDI values of 0.6 or more 
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for DS-GCP20Q11 formulations were considered high compared to the DS-GCP10Q11 
formulations (PDI range = 0.3 – 0.4). This shows the use of GCPQ polymers with higher 
palmitoylation level produces more polydisperse (heterogenous) size of nanoparticles. 
The log P for disulfiram is 3.88 (Hansch et al., 1995) with molecular weight (MW) 
of 296.54. In literature, formulations of GCPQ with many hydrophobic drugs were 
reported to have higher drug encapsulation. GCPQ (P% = 21.6, Q% = 6.4, MW = 11,350 
Da) formulations with celecoxib (Log P = 3.9, MW = 381.37) at 1:5 drug to polymer ratio 
was able to encapsulate between 14.8% and 15.8% w/w drugs, whereas at 1:10 ratio, the 
drug encapsulation was between 21.1% and 32.1% w/w depending on the sonication 
power during the preparation of the nanoparticles (Mennini et al., 2014). For comparison, 
the P% of the GCPQ used in the study was almost similar to GCP20Q11. In addition, the 
log P for celecoxib is also closely similar to the log P of disulfiram. Yet, the DE% of 
celecoxib by GCPQ was much higher compared to the formulation of DS with GCPQ. In 
another study, formulation of GCPQ (MW = 10, 159 Da) with cyclosporine A (log P = 
4.3, MW = 1202.61) and griseofulvin (Log P = 2.18, MW = 352.77) had 15% and 3% 
drug entrapment, respectively (Siew et al., 2012).  
 
3.3.4 Conclusions for micellar formulations 
The polymeric micelle formulations of DS with both GCP10Q11 and GCP20Q11 
produced nanoparticles had low DE% value (< 4%), although formulation with the latter 
polymer produced higher than 3% DE% for the 1:10 ratio formulations. This showed a 
trend of higher drug load in formulation with higher palmitoylated GCPQ. 
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3.4 Formulation of DS and GCPQ into nanoemulsions 
 
Based on the previous experiments, the polymeric micelle formulations were 
unable to give high encapsulation efficiency of DS. Nevertheless, one definite conclusion 
can be derived from those experiments is that the use of higher palmitoylated GCPQ gives 
a higher hydrophobic drug entrapment, as had been previously suggested in other GCPQ 
nanoparticle formulations (Qu et al., 2006). This also led to the hypothesis of using highly 
hydrophobic vehicle or excipient for the drug, such as oil, would give a possibility of high 
drug entrapment in the polymers. The combination of oil and water will produce a 
colloidal system known as emulsion, and with addition of surfactant and application of 
energy, nanoemulsion is formed.  
Some of the O/W emulsions available commercially are for oral and intravenous 
routes. Medicinal oral O/W emulsions have been used for treatment of constipation (e.g. 
Emulsoil® and Neoloid® for castor oil) and as food supplement (e.g. Scott’s® emulsion 
for fish liver oil). Intravenous O/W lipid emulsions such as Intralipid® is used in clinical 
practice to provide calories and essential fatty acids to the patients. Onxol™ is one 
example of paclitaxel intravenous emulsion used for treatment of cancer. 
There are two common types of O/W colloidal dispersions; microemulsions and 
nanoemulsions. By definition, a microemulsion is a thermodynamically stable colloidal 
dispersion consisting of small particles dispersed homogenously within an aqueous 
medium, which can be formed spontaneously when the components are mixed in 
appropriate ratios (McClements, 2012). Meanwhile, nanoemulsion is a 
thermodynamically unstable (but kinetically stable) colloidal dispersion consisting two 
immiscible liquids, with one of the liquids being dispersed as small spherical droplets in 
the other liquids. Nanoemulsion usually requires high energy methods for the formation 
of the particles by utilizing devices such as ultrasonic or high pressure homogenizers 
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(Anton and Vandamme, 2011). This means the major difference between these two types 
is mainly based on the thermodynamic stability. In terms of droplet size, both types are 
of particles within the nanometre range with microemulsion average droplet size is 
between 5 – 140 nm (Attwood, 2013).  
  Vegetable oil, which majorly consists of triacylglycerols (Ayorinde et al., 2000) 
has been used widely in preparation of nanoemulsions (Adamczak et al., 2013). It was 
reported DS can be solubilised in olive oil (Brar et al., 2004). The use of edible vegetable 
oil is a good candidate in oral drug formulation as it is safe to be administered via the 
enteric route (Chung et al., 2001). Soybean oil, for instance, is already one of the accepted 
excipient for oral drug formulation (Strickley, 2004). In the experiments ahead, 
preparation of the formulations involves dissolution of DS in soybean oil prior to the 
addition into GCPQ solution, followed by agitation by ultrasonic disintegrator to create 
homogenous distribution of nano-sized emulsions. 
 
3.4.1 Solubility of DS in different types of oil 
It is crucial to choose the type of oil that can dissolve high amount of DS to 
minimize the use of oil as excipient in the formulation. Several types of edible oil that are 
listed as pharmaceutical excipients (Rowe et al., 2006) were chosen for determination of 
DS solubility. 
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3.4.1.1 Methodology 
An excess amount of DS (~ 100 mg) was added into 1 ml of oil of either cotton 
seed, olive, rapeseed, safflower, sesame, castor or soybean oil (Sigma Aldrich, Missouri, 
USA) and left to stir overnight at room temperature. Samples were prepared in triplicate 
for each type of oil. On the next day, the drug-in-oil dispersion was centrifuged at 10,000 
g for 15 minutes to accumulate the large undissolved drug crystals at the bottom of the 
tubes. The clear supernatant was then collected and filtered with 0.45 µm PES syringe 
filter to remove any small undissolved drug crystals in the supernatant. The drug 
concentration was then measured using HPLC. For HPLC measurement, the oil samples 
were diluted (25 times dilution) in hexane followed by further dilution (50 times dilution) 
in ethanol to ensure the concentration of samples were within the concentration range of 
the calibration curve.  
 
3.4.1.2 Result 
Table 11 shows concentration of DS measured in each type of oil. Soybean oil 
showed highest DS solubility (~ 21 mg/ml) whereas castor oil showed the lowest DS 
solubility. Therefore, soybean oil was chosen to be used in the formulation. 
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OIL TYPE DRUG CONTENT (mg/ml) 
Cotton seed 15.40 ± 0.92 
Olive 12.58 ± 0.66 
Rapeseed 11.63 ± 0.44 
Safflower 14.54 ± 0.63 
Sesame 13.87 ± 2.36 
Castor 2.90 ± 0.64 
Soybean 21.12  ± 1.04 
 
Table 11: Solubility of DS in various types of oil. 
 
3.4.2 Stability of DS in soybean oil 
The stability of DS dissolved in soybean (SB) oil over a period of time was 
examined. The stock of DS in SB oil was prepared at 20 mg/ml. After the addition of 20 
mg DS into 1 ml oil, the stock was heated at 50°C while stirring to speed up the 
solubilisation of DS crystals. The stock was then let to cool to room temperature and 
observed for signs of recrystallization. The stock was prepared in triplicate and kept at 
room temperature (22 to 24°C with 12-hour light and dark cycle). Samples of oil were 
taken at Day 0 (fresh preparation), 1, 3, 6 and 8 and analysed for drug content using 
HPLC.  Oil samples were diluted in hexane (20 times dilutions) followed by ethanol (50 
times dilution) prior to the HPLC measurements.   
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Figure 19: Amount of DS detected in oil samples from DS in soybean oil stock made at 
20 mg/ml at Day 0, 1, 3, 6 and 8. Data were presented as mean ± SD (n = 3). 
 
 
No drug recrystallization was observed in all DS stocks after being cooled to room 
temperature. Statistical analysis showed no significant change in DS concentration in the 
SB oil medium over the period of 8 days in comparison with the amount of drug on Day 
0 (p>0.05) (Figure 19).    
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3.4.3 Formulation of DS with GCP20Q11 at 5% oil 
Based on assumption concluded from previous experiments using GCPQ polymer 
with higher palmitoylation, the attempt of DS formulation with GCPQ into 
nanoemulsions was made with GCP20Q11. The DS-GCP20Q11 nanoemulsions (DS-
GCP20Q11-E) were made at 1 to 5 and 1 to 10 drug to polymer ratio (w/w) in 1 ml volume 
(Table 12). GCP20Q11 was dissolved in Milli-Q water prior to the addition of DS in SB 
oil. After the addition, the formulations were sonicated using ultrasonic disintegrator at 
amplitude 5 (Soniprep 150 Plus, MSE, U.K.) until homogenization was achieved which 
was 5 minutes. The resulting dispersion of 5% oil v/v DS-GCP20Q11-E was a uniform 
and milky white in colour (Figure 20). All formulations were prepared in triplicate. As 
GCPQ is able to act as surfactant or emulsifier itself, no additional surfactant was added 
to stabilize the formulations. 
 
DS-
GCP20Q11-E 
Amount of 
DS (mg) 
Amount of 
GCP20Q11 
(mg) 
20 mg/ml 
DS stock 
(µl) 
GCP20Q11 
in Milli-Q 
water (µl) 
Final 
volume 
(µl) 
1:5 1 5 50 950 1000 
1:10 1 10 50 950 1000 
 
Table 12: Table of ingredients for preparation of 5% oil v/v DS-GCP20Q11-E 
formulations.  
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Figure 20: GCP20Q11 micelles (a) appeared as a clear suspension, whereas 5% oil DS-
GCP20Q11-E formulation (b) appeared as a milky-like emulsion. 
 
3.4.3.1 Drug content of DS-GCP20Q11-E 
Table 13 shows the amount of drug detected in the DS-GCP20Q11-E 
formulations. The result shows higher DE% (87%) in the 1:10 formulations compared to 
only 30% DE% in 1:5 formulations after 5 minutes’ sonication. This suggests the use of 
higher amount of GCPQ enables higher amount of particles (droplets) formed that are 
stabilized by the polymer. The low DE% in 1:5 formulations might be due to inadequate 
GCPQ to support formation of more stable particles. Although phase separation was not 
seen in the formulation, physical instability such as creaming might have occurred, where 
the less dense oil droplets rise to the surface to form a thin upper layer of cream, causing 
lesser amount of drug in the sampled emulsions.  
 
 
 
a b 
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DS-GCP20Q11-E 
Amount of DS 
(µg/ml) 
Drug content 
(µg/ml) 
DE% 
1:5 1000 304.36 ± 126.51 30.4 
1:10 1000 868.25 ± 27.01 86.8 
 
Table 13: Drug content and DE% of the 1:5 and 1:10 DS-GCP20Q11-E formulations after 
5 minutes’ sonication. Data were presented as mean ± SD (n = 3). 
 
 
In order to improve the encapsulation efficiency, the next attempt was to prolong 
the sonication time. Therefore, the newly prepared 1:5 and 1:10 DS-GCP20Q11-E 
formulations were sonicated for 15 minutes instead of 5 minutes. Table 14 shows the 
amount of drug detected in the DS-GCP20Q11-E formulations after 15 minutes’ 
sonication. 
 
DS-GCP20Q11-E 
Amount of DS 
(µg/ml) 
Drug content 
(µg/ml) 
DE% 
1:5 1000 952.60 ± 3.91 95.2 
1:10 1000 1018.46 ± 12.73 101.8 
 
Table 14: Drug content and DE% of the 1:5 and 1:10 DS-GCP20Q11-E formulations after 
15 minutes’ sonication. Data were presented as mean ± SD (n = 3). 
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After a longer sonication time, the DE% for both 1:5 and 1:10 was seen to increase 
dramatically. The DE% for 1:5 formulations were increased 3 times the value of the 
formulations when sonicated for 5 minutes (from 30% to 95%). The excess of detected 
drug (slightly more than amount of added drug) in the 1:10 formulations might due to the 
pipetting error during sampling. 
 
3.4.3.2 Particle size, polydispersity index and zeta potential of DS-GCP20Q11-E 
Table 15 shows the average particle size, PDI value, zeta potential and pH for the 
1:5 and 1:10 DS-GCP20Q11-E formulations sonicated at both 5 and 15 minutes. Based 
on the results, longer sonication time produced smaller size nanoparticles and lower PDI 
values for both 1:5 and 1:10 formulations.  
Sonication for a longer time at high power provided more agitation force to break 
the oil phase into more droplets at much smaller size. With the GCPQ acting as a cationic 
surfactant, the nanometre droplets (particles) formation was maintained due to the 
increase in interfacial area and decrease in interfacial tension (Solans et al., 2005).  
The DS-GCP20Q11-E formulations at 1:10 drug to polymer ratio containing 5% 
oil content and sonicated for 15 minutes (Figure 21) was the formulation of choice for its 
high DE% and small particle size and PDI values.  
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DS-GCP20Q11-E 
Sonication 
time 
(minutes) 
Size (nm) PDI 
Zeta 
potential 
(mV) 
pH 
1:5 5 375.7 ± 5.5 0.29 ± 0.07 N/A N/A 
1:10 5 380.2 ± 3.0 0.49 ± 0.04 N/A N/A 
1:5 15 201.7 ± 0.4 0.13 ± 0.02 49.9 ± 3.0 4.96 
1:10 15 183.2 ± 5.9 0.17 ± 0.01 50.9 ± 1.3 4.54 
 
Table 15: Average particle size, PDI value, zeta potential and pH of 5% oil DS-
GCP20Q11-E formulations. Data were presented as mean ± SD (n = 3). N/A = data not 
available.  
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Figure 21: Schematic diagram for the preparation of 1:10 drug to polymer ratio of DS-
GCP20Q11-E at 5% oil v/v. 
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For further confirmation of the particle size distributions for this formulation, the 
intensity, volume and number weighted distribution of the particle size were measured. 
Figure 22 shows the three types of particle size distribution graphs for triplicate 
measurements of the 1:10 formulations. The size distribution histograms are displayed as 
relative intensity of light scattered by particles (Y-axis) against the logarithmic size 
classes (X-axis). 
 
 
(a) 
 
 
(b) 
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(c) 
 
Figure 22: The distribution of particle size populations for 1:10 DS-GCP20Q11-E 
formulation, 5% oil sonicated for 15 minutes, based on the (a) intensity, (b) volume and 
(c) number weighted distributions. 
 
The basic measurement for DLS is the intensity weighted distributions (including 
the Z-average), from which the number and volume weighted size distributions are 
calculated by default in the DLS instrument. The transformation from intensity into 
volume and number is based on assumptions: 1) all particles are spherical, homogenous 
and having equivalent density, 2) the optical properties are known, such as the refractive 
index of the sample dispersant. The graphs (Figure 22) show the intensity, number and 
volume weighted particle size distributions of DS-GCP20Q11-E at 5% oil having 
unimodal distribution of particle size. The volume and number distributions should only 
be used to estimate relative amount of particles in separate peaks. Since there were no 
distinct additional peaks in the aforementioned distribution graphs of this formulation, 
only the intensity weighted distribution is being considered for determination of the 
particle size. A small additional peak seen at 500 nm for the intensity weighted graph 
might due to the presence of large foreign particles (e.g. dust) in the cuvette or that entered 
during sample preparation.  
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From the zeta potential results, the DS-GCP20Q11-E at 5% oil showed highly 
positive charged formulations at an acidic pH of 5. This indicates stable formulations in 
which the particles repel each other because of the strong charges thus ensuring the 
dispersion stability by avoiding occurrence of aggregation or flocculation in the 
formulation. The positive surface charge of the nanoparticles was probably due to GCPQ 
hydrophilic substituent, where in this case owed to the presence of the trimethyl 
ammonium groups (Uchegbu et al., 2004). 
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3.4.3.3 TEM images of DS-GCP20Q11-E 
 TEM images showed formation of spherical particles in the formulations. The 
GCP20Q11 micelles (as control) were seen as a collection of very small particles with 
diameter of less than 30 nm (Figure 23). Another control formulation was made by 
vortexing together GCP20Q11 aqueous suspension and empty 5% v/v soybean oil 
(without drug) vigorously (no sonication). This particular control showed two populations 
of sizes; one with the smaller size ranged between 20 to 40 nm, and the other one was at 
bigger size in range of 100 to 900 nm (Figure 24). The DS-GCP20Q11-E particles at 1:10 
ratio sonicated for 15 minutes were seen heterogeneous with size between 9 to 100 nm in 
diameter (Figure 25). 
The overall size of the DS-GCP20Q11-E particles appeared bigger than the size 
of the GCP20Q11 micelles with no drug. This could indicate the encapsulation of the 
drug by the GCPQ polymer, positioning the oil droplets at the core and increasing the size 
of the DS-GCP20Q11-E particles. It was also noticed that the size of DS-GCP20Q11-E 
particles seen in the TEM images appeared smaller compared to the size detected using 
DLS. The smaller size in TEM images might be caused by the shrunken nanoparticles 
due to the drying process of the sample prior to the imaging. Apart from that, 
hydrodynamic size measured by DLS instrument is usually larger than the actual size of 
the particle itself since the particle surface structure and ionic strength could add extra 
nanometres into the hydrodynamic particle size. 
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Figure 23: GCP20Q11 at 10 mg/ml in MilliQ water. The size of GCPQ micelles shown 
here are between 12 to 23 nm in diameter. Left: 46,000x magnification, Right: 93,000x 
magnification. 
 
   
Figure 24: GCP20Q11 at 10 mg/ml dissolved in MilliQ water and added with empty 5% 
v/v/ soybean oil. The size of particles is seen heterogeneous with size between 20 to 40 
nm, whereas the bigger size was between 100 to 900 nm in diameter. Left: 135,000x 
magnification, Right: 65,000x magnification. 
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Figure 25: DS-GCP20Q11-E 1:10, 5% oil . The particle size was heterogeneous between 
9 to 100 nm in diameter. Left: 46,000x magnification, Right: 93,000x magnification. 
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3.4.4 Formulation of DS with GCP20Q11 at different amount of oil 
The ability of GCPQ polymer to encapsulate high amount of drug is important to 
ensure the minimum use of polymer with the drug to reach the effective dose required for 
the administration in animal subjects later in the project. Therefore, the current 
experiment was to evaluate the maximal amount of drug/oil that can be stabilized by 
GCPQ at different ratios of oil/polymer in the formulation.  
 
3.4.4.1 Determination of maximum oil content for DS-GCP20Q11-E 
 
In the attempt to determine the maximum amount of oil the GCPQ is able to 
contain, separate DS-GCP20Q11-E formulations were made containing either 5, 10, 15, 
20, 25, 30, 35, 40, 45, 50 or 55% oil v/v. Table 16 summarizes the preparation of DS-
GCP20Q11-E formulations at different amount of oil. Amount of GCP20Q11 was fixed 
at 10 mg/ml in all formulations. The GCP20Q11 was dissolved in Milli-Q water prior to 
the addition of DS in SB oil. After the addition, the formulations were sonicated using 
ultrasonic disintegrator at amplitude 5 (Soniprep 150 Plus, MSE, U.K.) for 15 minutes. 
All formulations were prepared in triplicate.  
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Oil content 
v/v (%) 
Amount of 20 
mg/ml DS in 
SB oil (µl) 
Amount 
of DS 
(mg) 
Amount of 
GCP20Q11 
(mg) 
GCP20Q11 
in Milli-Q 
water (µl) 
Final 
volume 
(µl) 
5 50 1 10 950 1000 
10 100 2 10 900 1000 
15 150 3 10 850 1000 
20 200 4 10 800 1000 
25 250 5 10 750 1000 
30 300 6 10 700 1000 
35 350 7 10 650 1000 
40 400 8 10 600 1000 
45 450 9 10 550 1000 
50 500 10 10 500 1000 
55 550 11 10 450 1000 
 
Table 16: Table of ingredients for preparation of DS-GCP20Q11-E from 5 to 55% oil v/v 
formulations. 
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In this preliminary experiment, the freshly prepared formulations were placed in 
a long, thin and clear glass tubes (Figure 26) to allow better visibility of the oil layer 
forming at the top surface of the unstable colloidal dispersions. The oil layer formed from 
the excess of oil that cannot be contained by the polymer. 
 
 
Figure 26: DS-GCP20Q11E formulations at different amount of oil in glass tubes for oil 
layer observation. The oil layer in the 55% oil content formulation is clearly visible in the 
picture after 24 hours at room temperature. 
 
Based on the observation, only DS-GCP20Q11-E formulation at 55% oil content 
showed a clear visible layer of oil after the formulation left to stand at room temperature 
for 24 hours. There was no oil layer observed in other formulations. For further 
confirmation and better visibility of the excess oil layer formation in the high oil-content 
formulations, 20 µl of 1 mg/ml Nile red dye solution (Sigma Aldrich, Missouri, USA) 
was added into 500 µl of each formulation. The formulations were then mixed thoroughly 
by high speed vortex and centrifuged at 17,000 g for 45 minutes to induce phase 
separation. 
Upon addition of the dye, the milky white colour of the formulations turned to 
pink. After the centrifugation, only 55% oil content formulation showed three distinct 
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layers while others showed only two layers’ formation. The 3 layers in the 55% oil content 
were comprised of free oil layer (top layer), particle layer (middle layer) and water layer 
(bottom layer), whereas the 2 layers in other formulations were comprised of only particle 
and water layers (top and bottom layer, respectively) (Figure 27).  
 
                    
 
 
Figure 27: DS-GCP20Q11-E formulations at 50 and 55% oil content stained with Nile 
red before and after centrifugation. Three distinct layers can be seen in 55% oil 
formulation. 
 
 
The Nile red is lipophilic and water insoluble, therefore it needs to be in lipophilic 
environment. This behaviour gave the oil and particle layers a translucent and opaque 
pink colouration, respectively, which in the latter was due to the scattered light by the 
particles giving it a turbid feature. The attraction of the dye to the particle layer was 
probably due to hydrophobic palmitic chain of the particles as well as to the oil content 
inside the particles. The clear and transparent hydrophilic water layer showed there was 
no presence of the dye.  
As this preliminary result showed formulations at 55% oil content is incapable of 
encapsulating the whole amount of oil added, the endpoint amount of oil that can be added 
Before centrifugation After centrifugation 
Oil layer 
Particle layer 
Water layer 
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into the formulation for a stable formulation was between 51 to 54% oil. At this point, the 
highest amount of oil that can be used to form a stable DS-GCP20Q11-E nanoemulsion 
is 50% v/v. In theory, the disperse phase in an emulsion can occupy up to 74% of the 
phase volume, but common pharmaceutical emulsion usually contain only between 10-
30% disperse phase (Eccleston, 2013). This suggest GCP20Q11 is a good emulsifier for 
being able to stabilize up to 50% of the oil-loaded particles. 
 
3.4.5 Characterization of DS-GCP20Q11-E at different amount of oil  
DS-GCP20Q11-E formulations at 5, 10, 20, 30, 40 and 50% v/v oil content was 
prepared as described previously (Table 16) in triplicate. All freshly prepared 
formulations with different oil content (Figure 28) were characterized by measuring the 
mean drug content, DE%, particle size and PDI values.  
 
 
Figure 28: The milky-white appearance of freshly prepared DS-GCP20Q11-E 
formulations at (from left) 5, 10, 20, 30, 40 and 50% v/v oil content. The formulations 
appeared thicker and denser towards the higher amount of oil content. 
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The drug content graph shows the trend of increasing amount of DS detected 
towards the increasing amount of oil added into the formulations. This drug content was 
later interpreted into DE% to determine the encapsulation efficiency of GCPQ polymer 
on the different amount of oil. The result shows all formulations having almost 100% 
drug entrapment with no significant difference of entrapment percentage between the 
different oil content formulations (P > 0.05) (Figure 29). 
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Figure 29: Drug content (left) and DE% (right) for the freshly prepared DS-GCP20Q11-
E formulations at 5, 10, 20, 30, 40 and 50% oil content. The mean values for each type of 
formulations were labelled on top of the bars. Data were presented as mean ± SD (n = 3). 
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* Significant compared to mean particle size of any other formulations with different oil content 
Figure 30: Particle size of freshly prepared DS-GCP20Q11-E formulations at 5, 10, 20, 
30, 40 and 50% oil content. Data were presented as mean ± SD (n = 3). 
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The particle size was in a range of 166 to 351 nm and was seen increased with 
higher amount of oil in the formulation (Figure 30). The mean particle size was found 
significantly different among the different oil content formulations (P < 0.05). On the 
other hand, all formulations showed low PDI (less than 0.3), even though the values for 
5% oil was significantly higher than 10 and 20% oil formulations and 40% oil 
significantly higher than 10% oil formulations (Figure 31). 
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a Significant compared to mean PDI value of 5% oil content formulations  
b Significant compared to mean PDI value of 10% oil content formulations  
Figure 31: PDI values of freshly prepared DS-GCP20Q11-E formulations at 5, 10, 20, 30, 
40 and 50% oil content. Data were presented as mean ± SD (n = 3). 
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TEM images of DS-GCP20Q11-E at 40% and 50% oil content showed formation 
of heterogenous particle size in the range of between 300 to 500 nm in diameter (Figure 
32a and b, respectively). These values are almost similar as indicated by the DLS 
measurements (mean values of 314.7 and 350.6 nm for 40% and 50% oil content, 
respectively). The particles were also seen tightly packed together especially in the 50% 
oil formulation. The reason was probably that more amount of oil causing more particles 
to be formed by GCPQ up to a point where there was hardly free space for the particles 
to move around, which could explain the higher viscosity observed in higher oil content 
formulations. 
Formulations at 55% oil which exceeds the maximum amount of oil that can be 
added into the formulations, showed appearance of large droplets of oil (more than 1 µm) 
(Figure 32c). This was probably parts of the oil phase which were not encapsulated by 
the polymer merged together because of no free polymer left available for the formation 
of nanoparticles. 
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Figure 32: TEM images of DS-
GCP20Q11-E at 40% (a), 50% (b) and 
55% (c) oil content. 
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3.4.6 Stability of DS-GCP20Q11-E upon storage 
The stability of DS-GCP20Q11-E formulations at 5, 10, 20, 30, 40 and 50% oil 
content was tested upon storage at different temperatures by measuring the changes in 
drug entrapment, particle size and PDI value over a period of time. The formulations were 
kept at either room temperature (RT) by placing them on the bench in the lab, or at 4°C 
by placing them in the fridge. Samples were taken for analysis on Day 0 (day of 
preparation), 1, 2, and 8. The statistical analysis used to compare the values between days 
within a group was One-way ANOVA, followed by Tukey’s HSD for the post-hoc 
analysis. 
 
3.4.6.1 Changes in drug entrapment 
Based on the result, the formulations were more stable when stored at 4°C as only 
5, 10 and 20% oil formulations had significantly reduced DE% within the 8 days’ period, 
compared to all formulations having significant DE% reduction at RT (Figure 33). At 
4°C, formulations containing 30% oil and above showed no significant reductions in drug 
entrapment up until 8 days. This suggests such amount of oil in the formulations is 
optimum for the polymer to retain the DE% to a longer period of time. The lower 
temperature plays a role in giving more DE% stability by the GCPQ polymer. As 
explained in Section 3.4.3.1, there was possibility of unseen creaming or flocculation 
(clusters of particles behave as a single kinetic unit) occurring in the nanoemulsions over 
time, causing sampling of the area with less particles in the formulation thus decreased 
the DE% measurement. 
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* Significant compared to mean DE% on Day 0 in its respective group 
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* Significant compared to mean DE% on Day 0 in its respective group 
 
Figure 33: DE% of DS-GCP20Q11-E formulations at different oil content stored at 4°C 
(DE% 4°C, top) and RT (DE% RT, bottom) on Day 0, 1, 2 and 8. Data were presented as 
mean ± SD (n = 3). 
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3.4.6.2 Changes in particle size 
The pattern of the graphs (Figure 34) shows the more oil content in the 
formulation, the bigger the size of the particles. Despite the significant change in size, all 
formulations at both temperatures showed no large increase or decrease in values 
compared to the fresh preparation (change of size was observed less than half of the size 
on Day 0).  
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* Significant compared to mean particle size on Day 0 in its respective group 
Figure 34: Particle size of DS-GCP20Q11-E formulations at different oil content stored 
at 4°C (Particle size 4°C, top) and RT (Particle size RT, bottom) on Day 0, 1, 2 and 8. 
Data were presented as mean ± SD (n = 3). 
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3.4.6.3 Changes in PDI value 
In general, mean PDI values (Figure 35) for 5% oil content showed better stability 
at RT compared to 4°C. Significant increase in PDI was seen at earlier days for both 10% 
and 20% oil content formulations when stored at RT compared to storage at 4°C. There 
was no change observed in 30% oil content formulations at both temperatures throughout 
the study. Formulations of 40% oil content showed only significant increase in PDI on 
Day 8 at RT, whereas 50% oil content at both temperatures showed significant fluctuation 
on the PDI values until end of the study. 
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Figure 35: PDI values of DS-GCP20Q11-E formulations at different oil content stored at 
4°C (PDI 4°C, top) and RT (PDI RT, bottom) on Day 0, 1, 2 and 8. Data were presented 
as mean ± SD (n = 3). 
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3.4.7 Stability of DS-GCP20Q11-E in acidic and basic pH 
3.4.7.1 Overview 
The experiment was done to analyse the influence of highly acidic or highly basic 
pH on the particle size and PDI value of the DS-GCP20Q11-E nanoparticles. Such 
changes in bulk pH conditions are typically encountered in the gastrointestinal tract, blood 
circulation and in the tumour where it could affect the morphology of the particles.  
 
3.4.7.2 Materials 
Item Supplier 
Hydrochloric acid Fisher Scientific Limited, Leicestershire, UK 
Sodium hydroxide Sigma-Aldrich Company Limited, Dorset, UK 
 
3.4.7.3 Methodology 
One millilitre of DS-GCP20Q11-E at 5% oil content was prepared as described 
previously. As a control, 10 mg/ml of GCP20Q11 suspension was prepared by dissolving 
10 mg of the polymer in 1 ml of MilliQ water. The formulations and GCP20Q11 
suspensions (in triplicate) were titrated with either 0.1 M hydrochloric acid (HCl) or 0.1 
M sodium hydroxide (NaOH) solution to create the highly acidic (pH 1.7) or highly basic 
(pH 11) condition, respectively.  Both formulations and control were then sampled 
immediately for the DLS measurement, as described previously.  
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3.4.7.4 Results  
 
 Particle size (nm) and pH 
Fresh preparation Acidic condition Basic condition 
DS-GCP20Q11-E 195.7 ± 2.3 
pH 4.4 
215.8 ± 0.7 
pH 1.67 
192.2 ± 1.4 
pH 10.9 
PDI value and pH 
Fresh preparation Acidic condition Basic condition 
0.24 ± 0.004 
pH 4.4 
0.33 ± 0.01 
pH 1.67 
0.24 ± 0.01 
pH 10.9 
GCP20Q11 
(control) 
Particle size (nm) and pH 
Fresh preparation Acidic condition Basic condition 
156.0 ± 1.2 
pH 4.53 
152.6 ± 32.1 
pH 1.73 
125.7 ± 13.1 
pH 11.1 
PDI value and pH 
Fresh preparation Acidic condition Basic condition 
0.59 ± 0.15 
pH 4.53 
0.46 ± 0.07  
pH 1.73 
0.49 ± 0.06 
pH 11.1 
 
Table 17: The particle size, PDI values of DS-GCP20Q11-E and GCP20Q11 suspensions 
in highly acidic and basic pH condition. Data were presented as mean ± SD (n = 3). 
 
3.4.7.5 Discussion and conclusion 
Based on the result in Table 17, statistical analysis showed no significant changes 
in particle size and PDI value in both DS-GCP20Q11-E and GCP20Q11 suspensions 
when it is adjusted into highly acidic and basic environment when compared to the 
unaltered fresh preparation (p > 0.05). It was noticed that the PDI values for GCP20Q11 
suspension was large (0.50 – 0.60). This might due to the way the polymeric suspension 
was prepared of which the GCPQ suspension was not sonicated after completely 
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dissolved in Milli-Q water compared to the formulations where it was sonicated to reach 
homogeneity. There was no aggregation observed in all formulations that might have led 
to flocculation or cracking (phase separation) of the nanoemulsion, although it was 
expected to happen in the highly basic environment where the abundant presence of OH- 
ions might neutralize the positive charged particles, leading to instability of the particle 
structure. This perhaps attributed to the highly charged GCPQ particles outweighing the 
effect of the counter ions introduced into the formulations. In conclusion, both the DS-
GCP20Q11-E and GCP20Q11 were stable in highly acidic and basic environment. 
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3.4.8 Stability of DS-GCP20Q11-E in buffers 
The next experiment carried out was to determine the stability of DE% of the DS-
GCP20Q11-E in HCl (pH 1.2) and phosphate (pH 6.8) buffers.  
 
Materials 
Item Supplier 
Potassium chloride Sigma-Aldrich Company Limited, Dorset, UK 
 Monobasic potassium 
phosphate 
Sodium hydroxide 
Hydrochloric acid Fisher Scientific Limited, Leicestershire, UK 
 
3.4.8.2 Methodology 
HCl buffer was prepared by mixing together 50 ml of 0.2 M potassium chloride 
and 85 ml of 0.2 M HCl solution in a 200 ml volumetric flask. Milli-Q water was then 
added into the volumetric flask to prepare 200 ml HCl buffer at pH 1.2. Phosphate buffer 
was prepared by mixing 50 ml of 0.2 M monobasic potassium phosphate with 22.4 ml of 
0.2 M NaOH solution in a 200 ml volumetric flask. Milli-Q water was then added into 
the flask to create 200 ml phosphate buffer at pH 6.8. 
The stability of DS-GCP20Q11-E in the buffer was determined by assessing the 
DE% of the formulation in the buffer over a period of time. DS-GCP20Q11-E at 5% oil 
content (DS concentration = 1 mg/ml) was freshly prepared and 400 µl of this formulation 
was added into 3600 µl of either the HCl or phosphate buffer (DS concentration = 100 
µg/ml) with solutions at room temperature (22-24°C). Samples were taken (50 µl) at 0 
minutes (right after addition), 30 minutes, 1, 2 and 4 hours after the addition (t = 0, 0.5, 
1, 2 and 4, respectively) and diluted with 950 µl ethanol (20 times dilution). The samples 
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were then centrifuged at 1,000 g for 10 minutes to sediment any large particles such as 
salt present in the samples. Without any further sample dilution, the drug content in the 
supernatant was then measured with HPLC.  
 
3.4.8.3 Results  
The results showed no significant decrease of DE% for formulation incubated in 
phosphate buffer (pH 6.8) up to 4 hours, whereas the significant decrease was seen in HCl 
buffer (pH 1.2) only at t = 4 hour (Figure 36).  
 
* Significant compared to mean DE% at t = 0 hour 
Figure 36: DE% of DS-GCP20Q11-E in HCl and phosphate buffer at t = 0, 0.5, 1, 2 and 
4 hours. Buffers were at room temperature at the time of measurement. Data were 
presented as mean ± SD (n = 3). 
 
3.4.8.4 Discussion and conclusion 
Colloidal stability depends on the balance of attractive and repulsion interactions 
between particles. The repulsion of particles might be attributed to the electrical charge 
around the particles and/or attached polymer layers on the particle surface which causes 
electrostatic and/or steric stability, respectively. Presence of salts could increase the 
electrolyte concentration in the particles’ environment which leads to compression of the 
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electrical double layer. This causes the energy barrier to decrease or disappear, leading 
the Van der Waals attraction to induce aggregation of the particles (Schramm, 2006). HCl 
buffer could imitate the highly acidic environment in the stomach where chloride was 
found as the dominating ion at concentration range between 48 to 173 mM in the fasted 
state (Lindahl et al., 1997).  
Despite the presence of salts, the formulation was able to maintain its colloidal 
stability. In conclusion, it could be summarized that with the presence of 0.2 M salt in the 
acidic and neutral buffer, DS-GCP20Q11-E is stable and able to withhold the drug 
loading for as long as 2 and 4 hours, respectively. 
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3.4.9 Stability of DS-GCP20Q11-E in simulated biological samples 
3.4.9.1 Overview 
The crucial point of an oral drug formulation is the ability to withstand the 
variation in pH level and exposure to various enzymes and bile salts in the GIT. This 
experiment was conducted as an in vitro test to study the effect of the physicochemical 
environment of the GIT on the digestive stability of the formulations. In other words, it 
was also to study the GIT fluid effect on the stability of the polymer structure that 
encapsulates the drug to protect it from degradation.  
 The simulated gastric fluid (SGF) and simulated intestinal fluid (SIF) were used 
as an imitation to the human GIT fluids. These two fluids are more commonly used to 
study the drug dissolution in the gut (Marques et al., 2011). SGF represents the acidic 
environment in the stomach which is more adequately reflects the physiological 
conditions of the fasted-state fluid (Vertzoni et al., 2005), whereas the SIF represents the 
conditions in the small intestine. Pepsin enzyme, a digestive protease simulates closely 
the fasting conditions in the stomach (Vertzoni et al., 2005). On the other hand, pancreatin 
enzyme that is added into the SIF contains many enzymes such as amylase, trypsin, lipase, 
ribonuclease and protease to imitate more of the activities happening in the small intestine 
(Das and Lin, 2005). 
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3.4.9.2 Materials 
Item Supplier 
Sodium chloride Sigma-Aldrich Company Limited, Dorset, UK 
 Potassium dihydrogen 
phosphate 
Sodium hydroxide 
Pepsin powder from porcine 
gastric mucosa 
Pancreas powder from 
pancreatin of porcine 
pancreas 
Dimethyl sulfoxide 
Hydrochloric acid Fisher Scientific Limited, Leicestershire, UK 
 
3.4.9.3 Methodology 
3.4.9.3.1 Preparation of simulated gastric fluid  
SGF was prepared as described in British Pharmacopoeia (2013) and consist of 2 
g sodium chloride, 3.2 g pepsin powder and later on added with 80 ml 1M hydrochloric 
acid to make 1 L of SGF solution, pH 1.2. 
3.4.9.3.2 Preparation of simulated intestinal fluid  
SIF was prepared as described in British Pharmacopoeia (2013) by mixing 77 ml 
of 0.2 M sodium hydroxide, 250 ml of 6.8 g potassium dihydrogen phosphate and 10 g 
pancreas powder to make 1 L of SIF solution at pH 6.8. 
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3.4.9.3.3 Experimental procedure 
DS-GCP20Q11-E formulations containing 5% oil and 1 mg/ml DS were prepared. 
As for control, 1 mg/ml of DS was prepared in 2% dimethyl sulfoxide (DMSO). An 
amount of 400 µl of the formulations or control was added into 3.6 ml of either SGF or 
SIF to make ratio of 1 to 10 (drug to SGF or SIF) and maintained in 37⁰C water bath. The 
drug content was assessed at several time points after the addition into the SGF or SIF; 
right after the addition (t = 0) and at 30 minutes, 1 hour, 2 hours and 4 hours post-addition 
(t = 0.5, 1, 2 and 4, respectively). At each time point, 50 µl of the SGF or SIF solutions 
were taken and diluted in 950 µl ethanol (added drug concentration = 5 µg/ml).  The 
samples were then centrifuged at 1,000 g for 10 minutes. The supernatant was collected 
and subjected for HPLC analysis and the pellet was discarded. All samples were prepared 
in triplicate. 
 
3.4.9.4 Results 
As shown in Figure 37, the stability of DS in SGF was improved greatly when it 
is incorporated with GCP20Q11 with no significant degradation throughout the 4 hours’ 
period whereas DS in DMSO (control) was significantly degraded over time. Meanwhile 
in SIF, the DS content was seen decreasing gradually over time in both control and DS-
GCP20Q11-E samples. 
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a, b, c Significant compared to drug content at t = 0 for DS in SGF, DS in SIF and DS-GCP20Q11-
E in SIF, respectively. 
 
Figure 37: The stability of DS following incubation of the DS-GCP20Q11-E formulation 
or the drug alone (control) in SGF and SIF up to 4 hours at 37⁰C. The drug concentration 
in the graph was normalized by using percentages. Data were presented as mean ± SD (n 
= 3). 
 
3.4.9.5 Discussion and conclusion 
The SGF solution did not seem to affect the drug content of DS-GCP20Q11-E up 
to 4 hours’ incubation, indicating the GCPQ polymer is capable of protecting the drug 
from digesting activity of the pepsin enzyme and the low pH environment in the SGF. 
The DS-GCP20Q11-E formulation is however unstable in SIF as the drug concentration 
was seen to decrease over time. The loss of the drug content could indicate that the 
multiple enzymes affect the structure of the GCPQ polymers causing the release of the 
encapsulated drug into the SIF thus degraded upon contact with the pancreatin enzyme or 
113 
 
the high pH. As a conclusion, the DS-GCP20Q11-E formulation is suitable to be used for 
protection of DS against degradation in the stomach. 
 
3.4.10 Conclusions for nanoemulsion formulation 
The encouraging criteria of the nanoemulsion formulations (e.g. high drug load) 
and its stability in the low pH environment provide enough reasons for the nanoemulsion 
to be chosen for further studies in the in vitro and in vivo model. Apart from giving an 
insight of the possible protection of the drug content when the formulations are given to 
the animal subjects later in the project, the information on the stability of the formulations 
in different environments also allows us to set the right condition for the preparation of 
the formulation prior to the dosing process for the in vivo experiments.  
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4 Disulfiram nanoemulsion in vitro cytotoxicity 
 
 
Chapter 4 
 
Disulfiram nanoemulsion in 
vitro cytotoxicity 
 
4.1 Overview 
In vitro cell-based cytotoxicity assays are employed to allow quick compound 
screening to determine effects on cell proliferation and toxicity. One of the ways to assess 
cell survival upon exposure to test compounds is by measuring the general metabolism or 
the enzymatic activity of the cells. There are handful of tetrazolium compounds that have 
been used for detection of viable cells. One tetrazolium compound known as MTT (3-
[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide) has been used widely in 
laboratory as a homogenous cell viability assay developed for 96-well plate format. 
The MTT reduction assay is based on conversion of MTT reagent by mitochondrial 
activity of living cells into formazan crystals, thus the level of product is proportional to 
the relative number of viable cells (Mosmann, 1983). The tetrazolium salt MTT is 
positively charged and can penetrate eukaryotic cells by cellular uptake via plasma 
membrane potential (Berridge et al., 2005). After the incubation of yellow MTT reagent 
with the cells for 1 to 4 hours, the amount of purple coloured formazan crystals formed is 
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later measured with plate reader spectrophotometer to record the changes in absorbance 
at 570 nm. 
The principal of this colorimetric assay is that mitochondrial activity of most viable 
cells are usually constant, therefore higher mitochondrial activity linearly related to 
higher number of viable cells (van Meerloo et al., 2011, Denizot and Lang, 1986). The 
precise cellular mechanism of MTT reduction into formazan is still unknown, but it is 
likely by mitochondrial succinate dehydrogenase (Slater et al., 1963), or involving the 
transfer of electrons to MTT from nicotinamide adenine dinucleotide (NADH) coenzyme 
generated in the mitochondria (Stockert et al., 2012, Berridge et al., 1996) (Figure 38). 
 
 
Figure 38: Conversion of MTT reagent into formazan by NADH coenzyme. 
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4.2 Materials  
Item Supplier / Manufacturer 
MIAPaCa-2 American Type Culture Collection, Rockville, 
Maryland, USA. 
Dimethyl sulfoxide Sigma-Aldrich Company Limited, Dorset, UK 
 Copper (II) chloride 
Dulbecco’s Modified Eagle’s 
Medium (DMEM), high 
glucose with L-glutamine and 
sodium bicarbonate (D5796) 
Fetal bovine serum 
Dulbecco’s Phosphate 
Buffered Saline 
Thiazolyl blue tetrazolium 
bromide 
Triton X-100 
Hanks’ Balanced Salt 
Solution, 10X 
Gibco Life Technologies, Paisley, Scotland 
 
Sodium pyruvate, 100 mM 
Trypsin-
ethylenediaminetetraacetic 
acid (EDTA), 0.25%, phenol 
red 
Glucose intravenous infusion 
50% w/v 
Hameln Pharmaceuticals Limited, Gloucester, UK 
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4.3 Methodology for MTT assay 
The cytotoxic effect of DS and DS-GCP20Q11-E, with and without the presence 
of copper was determined in the human pancreatic cancer cell line MIAPaCa-2.  
 
4.3.1 Cell preparation in 96-well plate 
Freshly thawed MIAPaCa-2 cells from cryopreservation were grown for at least 2 
weeks prior to the experiment. The complete growth medium used for the cells was 
sterile-filtered DMEM added with 10% v/v fetal bovine serum and 1 mM sodium 
pyruvate. The cells were maintained in carbon dioxide (CO2) incubator with environment 
set at 5% CO2 and temperature at 37°C. 
For propagation, cells that were grown in 75 cm2 cell culture flask were detached 
from the bottom of the flask by rinsing the cells first with phosphate buffered saline (PBS) 
followed by adding 3 ml of trypsin-EDTA for detachment and incubation in CO2 
incubator for 3 minutes. The flask was then shaken to completely detach the cells. After 
confirmation of full detachment by examination under the light microscope, the cells were 
immediately added with 7 ml complete growth medium to neutralize the activity of 
trypsin-EDTA. The cell suspension was then mixed thoroughly with serological pipette 
to break the clumps of cells into individual cells. The number of cells was then counted 
by measuring 200 µl cell suspension with a flow cytometer (MACSQuant®, Miltenyi 
Biotec GmbH, Bergisch Gladbach, Germany) or haemocytometer. 
The cells were seeded at 500 cells in 200 µl volume per well (2,500 cells/ml) into 
sterile flat bottom 96-well plate using multichannel pipette. For each plate, only the inner 
60 wells were used (Figure 39) for the assay, avoiding the outer wells that are prone to 
evaporation and contamination from the outside air. The cells were then kept in the CO2 
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incubator for 3 days to allow the cells to be in log phase growth by the time the treatment 
was applied. 
 
 
Figure 39: Sixty wells (highlighted in red box) from a 96-well plate used in the assay.  
 
4.3.2 Drug treatments 
Four different types of treatments were tested against the MIAPaCa-2 cells, as 
summarized in Table 18. 
 
GROUP TREATMENT 
DS DS in 2% DMSO 
DS-GCPQ DS-GCP20Q11-E, 5% oil content 
DS + Cu DS in 2% DMSO with copper chloride (CuCl2) 
DS-GCPQ + Cu DS-GCP20Q11-E, 5% oil content with CuCl2 
 
Table 18: Four different groups of treatments for the MTT assay. 
 CuCl2 solution was prepared in PBS at a concentration equimolar to the DS 
molarity (1 mg DS = 3.37 x 10-6 moles = 0.45 mg CuCl2). Prior to the drug addition, the 
medium in the plate (cell plate) was replaced with fresh 100 µl/well growth medium. Ten 
119 
 
different concentrations for each type of treatment were achieved by serial dilution from 
500 µg/ml (highest concentration) to 5 x 107 µg/ml (lowest concentration). The drug 
dilutions for each treatment type were prepared in a new sterile plate (drug plate, 
containing no cells) (Figure 40) at double the final concentration of the intended drug 
concentration for incubation with the cells (200 µl/well). After the dilutions, only 100 µl 
of the drug solution in medium from each well in the drug plate was added into the cell 
plate (already containing 100 µl fresh medium) to achieve the intended drug 
concentration.   
 
Figure 40: Drug dilutions (yellow box) was done in a new plate (drug plate, containing 
no cells). Lane 1 was added with the highest drug concentration and serially diluted 
towards Lane 10 (20 µl from previous well into 180 µl fresh medium in the next well ~ 
10 times dilution) to get ten different concentrations of drug in one plate. Five wells (5 
replicates) were allocated for each concentration. Red box was for positive control (total 
cell death) and green box for untreated cells.  
 
Three plates were prepared for each type of treatment. The cells were incubated 
with the treatment for 4 hours in the CO2 incubator. After the incubation, drug solutions 
were removed and cells were washed three times with PBS. Cells were then added with 
200 µl/well fresh growth medium and left in the CO2 incubator overnight.  
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4.3.3 Addition of MTT reagent and formazan dissolution 
MTT solution was prepared by dissolving 5 mg/ml of thiazolyl blue tetrazolium 
bromide powder in PBS protected from light, followed by filtration with 0.22 µm syringe 
filter to remove dust and foreign particles. The MTT solution was then further diluted 
with growth medium to create 0.5 mg/ml MTT solution. For positive control, growth 
medium in allocated 5 wells (Figure 40) were replaced with 200 µl of 1% Triton-X 
solution and incubated for 10 minutes or until all cells were dead. After the removal of 
the Triton-X, the rest of the medium in all wells were removed and replaced with the 0.5 
mg/ml MTT solution. The plates were then incubated for 2 hours in the dark inside the 
CO2 incubator.  
After 2 hours, formation of purple formazan crystals in the wells was confirmed 
with examination under an inverted light microscope. The MTT solution in the wells was 
then removed and replaced with 100 µl DMSO per well to dissolve the crystals. The plate 
was placed on the shaker for 10 to 15 minutes to completely dissolve the crystals. The 
absorbance of each well was then measured using ELX808TM Absorbance Microplate 
Reader (Bio-TEK Instruments Inc., Winooski, Vermont, USA) at wavelength 570 nm.  
 
4.3.4 Determination of cell viability and IC50 of the treatments 
Percentage of cell survival upon each treatment was calculated as below: 
a) Mean absorbance calculation of 5 wells in positive control (p) 
b) Subtraction of p value from the absorbance of each treated well (t) 
c) Mean absorbance calculation of 5 wells in untreated group (u) 
d) Transformation of absorbance value into viability figure for each well: 
Viability of cells (V%) = [( t – p ) / u ] x 100  
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e) Calculation of V% mean and SD values of 5 wells for each drug concentration 
The mean and SD values of V% for each concentration was then used in scatter 
plot graph to create a dose-response curve for determination of half-maximal inhibitory 
concentration (IC50) for each type of treatment. 
 
4.3.5 Statistical analysis 
Statistical analysis was performed using IBM SPSS Statistics for Windows, 
Version 22.0 (IBM Corp, Armonk, New York, USA). Data was analysed using One-way 
ANOVA, with Tukey’s multiple comparison test for the post-hoc analysis. Data was 
presented as mean ± standard deviation with significance value of p < 0.05. 
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4.4 Results and discussion 
Dose-response curve plotting the cell viability (Figure 41) of MIAPaCa-2 cell 
lines after exposure to DS, DS-GCPQ, Cu + DS and Cu + DS-GCPQ and determination 
of the IC50 for each treatment were done using OriginPro 2016 software (OriginLab 
Corporation, Massachusetts, USA).  
 
     
     
Figure 41: Dose-response curve of MIAPaCa-2 cell viability after treatment with DS (a), 
DS-GCPQ nanoemulsions (b), DS with copper (c) and DS-GCPQ nanoemulsions with 
copper (d) for 4 hours. 
 
 
a) b) 
d) c) 
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aSignificant compared to IC50 of DS and DS-GCPQ 
Figure 42: Summary of IC50 obtained from dose-response curves of all four treatments.  
   
The results showed that IC50 for MIAPaCa-2 cells treated with DS in the presence 
of copper ion with or without GCPQ encapsulation were significantly lower than groups 
treated without copper (Figure 42).  This showed that copper highly enhanced the potency 
of the DS in the cytotoxic activity against the cancer cell lines. This effect of copper on 
DS activity has been reported previously against melanoma, myeloma, and breast cancer 
cell lines (Chen et al., 2006, Chen and Dou, 2008, Conticello et al., 2012, Yip et al., 2011). 
A pattern of lower IC50 was also seen in groups with drug + GCPQ when comparing it to 
the group treated with the same drug but without GCPQ, although none of the difference 
was statistically significant. Cells that are treated with DS-GCPQ nanoemulsion and 
copper showed a remarkably low IC50 value which was almost 10 times the effect seen in 
cells treated with Cu + DS. 
Kim and his colleagues (2013) explored in detail the effects of DS on ALDH 
positive human pancreatic ductal adenocarcinoma cell lines. One of the findings was 
MIAPaCa-2 cell lines to have the highest expression of ALDH compared to several other 
human pancreatic cancer cell lines such as CFPAC-1, PANC-1 and AsPc-1. Since DS can 
irreversibly block the activity of ALDH, this supports the choice to use MIAPaCa-2 in 
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the present study as it is the most suitable pancreatic cell line to be used for determination 
of DS nanoemulsion activity on ALDH-expressed cells.  Kim et al. however reported a 
much lower IC50 (0.77 µM) for treatment of DS alone against MIAPaCa-2 cell lines 
compared to our study (43.66 µM). This could have attributed to the 12 hours’ drug 
incubation with the cells in his study in comparison to only 4 hours in our study. Besides, 
Kim et al. performed the viability assay using water-soluble tetrazolium salt dye (EZ-
Cytox Enhanced cell viability assay kit). This type of assay was claimed to be more 
sensitive and precise than MTT-based assay since the step of MTT reagent removal prior 
to addition of DMSO is omitted therefore avoids the risk of accidentally removing the 
formazan-contained cells from the wells.  
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4.5 DS-GCP20Q11-E nanoemulsion-compatible vehicle for 
MTT assay 
 
The DS-GCP20Q11-E nanoemulsion was considered stable when there was no 
phase separation or aggregation seen upon addition into the medium. The formulation 
stability in various mediums was found different. Formulations in complete DMEM 
growth medium at 1:9 v/v ratio were stable up to 4 hours after which time creaming layer 
was observed on the surface, whereas in PBS 1X, Hanks’ Balanced Salt Solution (HBBS) 
1X, and 5% glucose (dextrose), the nanoemulsions were stable for more than 4 hours 
when added into the medium at the same 1:9 ratios.  
At this point, it appeared the best vehicle to use was either the PBS, HBBS 1X 
and 5% glucose since the formulations were stable in those media for longer time than in 
DMEM. Therefore, prior to the MTT assay for determination of cell cytotoxicity of the 
drug treatments against the MIAPaCa-2 cell lines, effects of the various medium on its 
own on the cells viability was determined from the MTT assay using the method 
described in the previous sections. This was done to select the most suitable medium or 
vehicle which was not compromising the viability of the cells on its own and compatible 
with the drug formulation for the treatment. The cells grown in 96-well, flat bottom plates 
were incubated with either DMEM (control), HBBS 1X, HBBS 0.1X, HBBS 0.01X, PBS 
1X, PBS 0.1X, PBS 0.01X, or 5% glucose for 4 hours. The procedure of adding MTT 
reagent into the plate up until measuring the absorbance and determination of the cell 
viability were done as described previously (Section 4.3.3 and 4.3.4). 
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4.5.1 Results and discussion 
 
 
Figure 43: Cell viability (%) upon exposure to different DS-GCP20Q11-E-compatible 
vehicles for 4 hours. 
 
Cell viability in DMEM growth medium was made as reference in which all cells 
would survive throughout the incubation period (100% cell viability). The results (Figure 
43) showed only half of cell population survived in the HBBS 1X (57.3%) and PBS 1X 
48.54%) after incubation for 4 hours. The viability was even lower in 5% glucose 
(16.4%). Lower concentrations of HBBS and PBS were also tested in order to see if their 
cell viability would be the same as 1X concentration cell viability. It was found that the 
viability was however further decreased with incubation in lower concentration buffers. 
This might due to the higher amount of Milli-Q water content used in more diluted buffers 
which increases the osmolarity difference between the cells and the vehicle, leading to 
more cell burst caused by osmosis. These results had led to the use of DMEM medium as 
the vehicle for all treatments used in the MTT cell cytotoxicity assay as it had no effect 
on the cell viability on its own. The incubation period of the cells with the treatments 
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could only be done for 4 hours as the nanoemulsion was only stable up until such period 
before phase separation occur in the DMEM medium.  
The instability of the formulation in DMEM after 4 hours might due to the activity 
of proteins in the cell culture medium against the nanoparticle physicochemistry. 
Nanoparticles tend to be covered with protein corona upon contact with biological 
medium. In blood, different biological molecules compete to adsorb on the surface of 
nanoparticles with majority of them are the proteins and small portions of lipids. Over 
time, the corona will be replaced by the higher affinity proteins (Vroman et al., 1980). 
This activity is driven by protein-nanoparticle binding affinities and protein-protein 
interactions. The protein corona alters size and surface composition of the nanoparticles, 
giving a new biological identity that could trigger physiological response such as 
agglomeration, transport, circulation lifetime and toxicity thus affecting the particle 
stability. Structure and composition of corona depends on physicochemical property of 
nanomaterials (e.g. size, shape, surface charge and duration of exposure) (Rahman et al., 
2013). 
Drop in surface charge and increase in hydrodynamic size has been reported in 
nanoparticles exposed to cell culture media containing 10% FBS (Casals et al., 2010). In 
a nano-biointeraction study of gold nanoparticles with commonly used cell culture media 
DMEM and Roswell Park Memorial Institute medium (RPMI) supplemented with FBS, 
it was found that DMEM caused formation of time-dependent larger, more abundant and 
stable protein corona compared to RPMI medium (Casals et al., 2010). This shows that 
protein-nanoparticle interaction also depends on the different cellular media components. 
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4.6 Conclusions 
Presence of copper in the treatment of DS whether with or without encapsulation 
with GCPQ had a significant effect on reducing the cell viability of the human pancreatic 
cancer MIAPaCa-2 cell lines after only 4 hours’ incubation period with the treatment. 
However, in comparison to the non-encapsulated DS, the encapsulation of DS with GCPQ 
with the presence of copper ions produced more significant cytotoxicity effect against the 
cancer cells. This gave an insight and better understanding of the possible effect that could 
be observed if the DS-GCP20Q11-E nanoemulsions reach the cancerous target site in the 
in vivo model. 
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5 Pharmacokinetics of disulfiram nanoemulsion 
 
 
Chapter 5 
 
Pharmacokinetics of 
disulfiram nanoemulsion 
 
5.1 Pharmacokinetics in nanomedicine development  
By definition, the pharmacokinetics of a drug is the study of the drug’s absorption, 
distribution, metabolism and elimination in human, as well as in animals over a period of 
time (Benet and Zia-Amirhosseini, 1995).  Absorption and distribution involves the 
process of the drug molecules entering the blood stream from the administration site and 
when the drug molecules are disseminated throughout the fluid and tissues in the body, 
respectively. Metabolism is when the drug is transformed into parent-derived metabolites, 
whereas elimination is the process of drug excretion from the body (Yáñez et al., 2011).  
Determination of pharmacokinetic profile is a crucial part in understanding the 
fate of a newly developed or modified drug formulation. This will determine if the new 
formulation is either the same efficacy, improved, or downgraded in comparison to the 
original formulation.  Apart from that, pharmacokinetics is also important (1) to support 
the preclinical toxicology in animals as the drug level in plasma or tissues are usually 
more reliable and predictive to extrapolate the toxicity data in human; (2) for correct use 
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of the drug formulations in therapy by knowing the best route of administration and dose 
regimen to exert the maximum effect from the drug (Urso et al., 2002). 
Assessment of bioavailability by measuring the amounts or concentrations of the 
drug in blood, tissues, urine or other fluids at different times after the administration gives 
information on the release of drug in the physiological fluid, its permeability and possible 
pre-systemic metabolism (Aulton and Taylor, 2013).  This is possible by constructing the 
concentration-time profile of the drug. After single dose of the drug is administered orally 
or parenterally, serial blood samples are withdrawn at specific time points and plasma 
samples are assayed for construction of the plasma concentration-time curve.  
The most important part of a pharmacokinetic study is to be able to use a proper 
technique for selective and efficient detection of the drug and its associated metabolites 
in biological samples. The bioanalytical methods must be fully validated, standardized 
and characterized to yield reliable results. The application of mass spectrometry alongside 
with liquid chromatography is common in pharmacokinetic analysis because of the 
complex nature of the sample matrix and the need for high sensitivity to be able to detect 
low concentration of analyte. 
The hypothesis was that the DS-GCP20Q11-E nanoemulsions would increase the 
bioavailability of DS in the blood circulation by improving the drug absorption in the gut 
whilst protecting the drug against degradation. This study was hence conducted to 
compare the plasma drug level in mice administered with either free DS or the DS-
GCP20Q11-E nanoemulsions by application of the sensitive and robust liquid 
chromatography with tandem mass spectrometry (LC-MS/MS) technique for detection of 
the analytes. 
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5.2 Principal of LC-MS/MS analysis  
LC-MS/MS has been used widely for quantification of small molecule drugs in 
biological samples. The coupling of LC unit with mass spectrometry (MS) improves the 
sensitivity, specificity and accuracy of compound detection in samples with many 
interferences such as blood and plasma. The advantages of using MS as the detector 
compared to other LC detectors such as ultraviolet-visible (UV-Vis), fluorescence or 
refractive index detectors is that the MS capable of not only giving signal strength data 
but also spectral data as a function of time. The ability of the method to precisely isolate 
and distinguish the analyte spectra of choice from the background components improves 
the specificity of the analysis and increases the sensitivity of the analyte detection.  
In general, the principles of MS involve molecule ionizations at the ion source 
chambers, followed by sorting and identifying the generated ions according to the mass-
to-charge (m/z) ratios. The analyte molecules are usually ionized by a technique called 
atmospheric pressure ionization (API) where analytes are ionized at atmospheric pressure 
before analyte ions are mechanically and electrostatically separated from neutral 
molecules. The most commonly used API is the electrospray ionization (ESI) where 
analytes in solution are sprayed (nebulized) into a chamber at atmospheric pressure in 
presence of heated drying nitrogen gas and strong electrostatic field (Figure 44). The 
heated drying gas evaporates the solvent in the droplets causing an increase in the charge 
concentration in the droplets, whereas the electrostatic field causes dissociation of analyte 
molecules as the repulsive force between same charge ions increases thus ejecting 
(desorbed) the ions into gas phase (Kang, 2012). The ‘soft’ ionization by API mainly 
creates molecular ions (M+ or M-), protonated molecules [M + H]+ and simple adduct ions 
such as [M + Na]+. The ions then pass through capillary into the mass analyser. 
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Figure 44: Schematic diagram of electrospray ionization (ESI) 
 
The use of quadrupole type of mass analyser allows scanning of m/z values across 
a range of mass spectrum. A quadrupole consists of a set of four parallel metal rods 
arranged in a square. Voltages are applied to the rods in varying frequencies to allow 
generation of electromagnetic fields which later on determines m/z ratios of ions that can 
pass through the filter.  One example of widely used tandem mass spectrometry is the 
triple quadrupole mass spectrometer which allows monitoring of specific m/z values only 
rather than scanning the whole ions that are unrelated to the analysis.  
In triple quadrupole (also known as quadrupole/quadrupole/time-of-flight) 
(Figure 45), the first quadrupole (Q1) selects the precursor ion, followed by the second 
quadrupole (Q2) where collision-induced dissociation (CID) of the precursor ion occurs 
in the collision cell. This to allow the fragmentation of the analyte ions by collision with 
inert gas such as nitrogen. The dissociated and fragmented ions are then transmitted to 
the third quadrupole (Q3) to generate spectrum of resulting product ions with respect to 
the precursor ions (Madeira and Florêncio, 2012). 
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Figure 45: MS/MS in a triple quadrupole mass spectrometer  
 
When the first and third quadrupoles are set to monitor specific m/z values 
simultaneously in which panels of precursor/product ion pairs are set, the process is called 
selected reaction monitoring (SRM). Multiple reaction monitoring (MRM) happens when 
the triple quadrupole MS instrument running multiple SRMs for the same precursor ions. 
Several advantages of multiple-stage MS are 1) specificity of the analysis is greatly 
enhanced as the first stage of MS (first quadrupole) discards nonanalyte ions, 2) chemical 
background is mostly removed at the second stage MS (third quadrupole) hence avoiding 
the isobaric interference of the same exact mass as the fragmented ions of the analytes 
(Watson and Sparkman, 2008). 
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5.3 LC-MS/MS for DS and MeDDC analysis 
Determination of DS bioavailability upon administration of the nanoemulsions to 
the animal subjects was done by the application LC-MS/MS analysis. Optimization of the 
analysis method from mouse plasma samples was carried out for detection of two main 
analytes; the parent drug disulfiram and its major metabolite, S-methyl-N,N-
diethyldithiocarbamate (MeDDC), along with the internal standard, diphenhydramine 
(DPH). 
 
5.3.1 Materials 
Item Supplier / Manufacturer 
Sodium chloride Sigma-Aldrich Company Limited, Dorset, UK 
Sodium acetate 
Diethylene triamine 
pentaacetic acid 
Methanol 
Absolute ethanol 
Diphenhydramine 
hydrochloride 
Acetonitrile (LCMS grade) 
Water (LCMS grade) 
Methyl 
diethyldithiocarbamate 
Santa Cruz Biotechnology, Inc., California, USA 
Formic acid Fisher Scientific Limited, Leicestershire, UK 
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5.3.2 Methodology 
5.3.2.1 Instrumentation and analytical conditions 
The LC-MS/MS experiments were conducted using Agilent 1260 Infinity LC 
(Agilent Technologies, California, USA) connected to Agilent 6460 Triple Quadrapole 
LC/MS system with ESI source equipped with Agilent Jet Stream technology.  The data 
acquisition, quantitative and qualitative analysis for both liquid chromatography (LC) and 
mass spectrometry units were performed using Agilent MassHunter Workstation 
software. 
The chromatographic separations were performed using Phenomenex OnyxTM 
Monolithic C18 analytical column (50 x 2 mm, 130Å) connected to Phenomenex OnyxTM 
Monolithic C18 guard column (5 x 2 mm, 130Å) (Phenomenex, Torrance, California, 
USA). The column temperature was maintained at 30°C. The LC run was carried out by 
injecting 5 µl of sample into the mobile phase of water added with 0.1% formic acid (A) 
and acetonitrile (B) under gradient elution of 5 minutes’ runtime. The gradient conditions 
were as follows: B was increased from 5 to 95% at 1 minute and stayed at the same value 
for 1.5 minutes. At 2.5 minutes, B was decreased back to 5% to be at the original ratio for 
re-equilibration of the column until stop time at 5 minutes. The flow was kept constant at 
0.4 ml/min.  
The tandem mass spectrometry was done under positive ion mode (positive ESI). 
The source parameters used were as follows: nitrogen as collision gas, gas temperature at 
300°C, gas flow at 5 l/min, nebulizer at 45 psi, sheath gas heater and gas flow at 250°C 
and 11 l/min, respectively and capillary voltage at 3.5 kV. Detection of the analytes was 
done using MRM scan type to monitor transitions of precursor-product ion of DS at m/z 
297.1>116.1, MeDDC at m/z 164.06>116, and DPH as the internal standard (IS) at m/z 
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256>167 with fragmentor voltage at 73 V for both DS and DPH and 45 V for MeDDC, 
collision energy 9 V for all analytes.  
 
5.3.2.2 Preparation of cold stabilizing agent 
For 10 ml of stabilizing agent, 90 mg of sodium chloride, 64 mg of sodium acetate, 
and 80 mg of diethylene triamine pentaacetic acid (DTPA) were mix altogether in 10 ml 
of Milli-Q water and stirred until all substances were dissolved. The pH was measured to 
ensure it was at pH 4.5. The solution was kept at 4⁰C until use. 
 
5.3.2.3 Preparation of drug stock solution 
DS and MeDDC stock solutions were prepared in absolute ethanol at 100 µg/ml. 
The stocks were then diluted further for preparation of calibration curve to have final 
concentrations of 10, 20, 40, 60, 80, 100, 200, 400, 600, 800 ng/ml upon addition into 
mouse plasma. DPH was added into methanol (extraction solvent) to have final 
concentration of 1.0 ng/ml in the plasma samples. 
 
5.3.2.4 Preparation of calibration standards and quality control (QC) 
Blood from animal subjects was collected in K2EDTA blood tubes. The blood was 
then transferred into 1.5 ml microcentrifuge tube, added with equal volume of cold 
stabilizing agent and centrifuged for 5 minutes at 10,000 g to obtain the stabilized plasma 
which was later kept at -80⁰C until use. 
An amount of 50 µl stabilized plasma was put into 1.5 ml microcentrifuge tubes 
and kept on ice at all times.  Drug stock solutions (5 µl) containing different 
concentrations of both DS and MeDDC was added into the plasma samples to have final 
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concentration of 10, 20, 40, 60, 80, 100, 200, 400, 600, 800 ng/ml for the calibration 
standards and 15, 75 and 750 ng/ml for the QC samples. The samples were vortexed for 
10 seconds. The samples were then added with 150 µl of methanol (3x the volume of 
plasma) containing the IS and vortexed vigorously for 10 minutes for drug extraction, 
followed by centrifugation at 10,000 g for 5 minutes to precipitate the protein. The 
methanol supernatant (100 µl) was collected carefully without disturbing the pellet and 
placed into a new tube. Tubes were then immediately placed on dry ice to avoid 
unnecessary drug degradation. The samples were analysed with LC-MS/MS as soon as 
possible. The samples were brought to room temperature 5 minutes before sampling. 
 
5.3.2.5 Preparation of experimental samples for analysis  
For experimental samples, fresh blood samples from animals were immediately 
processed for drug extraction upon collection. The drug extraction process involved was 
the same as described before (Section 5.3.2.4) except for the addition of drug stock 
solutions which was omitted in this procedure.  
 
5.3.3 Statistical analysis 
All statistical analyses in this chapter were performed using IBM SPSS Statistics 
for Windows, Version 22.0 (IBM Corp, Armonk, New York, USA). Comparison of more 
than two groups was done using One-way ANOVA with Tukey’s multiple comparison 
test for the post-hoc analysis, whereas comparison between two groups was done using 
Independent-samples t-test (Student’s t-test). Data was presented as mean ± standard 
deviation with significance value of p < 0.05. 
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5.3.4 LC-MS/MS method validation 
5.3.4.1 Validation procedures 
The LC-MS/MS method was validated based on selectivity, linearity, accuracy, 
precision, recovery, and stability (Tiwari and Tiwari, 2010).  
Selectivity analysis was done to ensure no interference to the analyte peak from 
other components in the samples at its retention time which enables differentiation and 
quantification of the analyte. The selectivity of the method was validated by analysing 
samples of blank stabilized plasma spiked with either IS (1 ng/ml), DS or MeDDC, where 
the concentration of DS and MeDDC was at the lower limit of quantification (LLOQ) 
level.  
The samples for calibration standards were prepared in triplicate. The calibration 
curves (y = ax + b) were constructed by plotting peak area ratios of the drug to the IS (y) 
versus the drugs concentration (x). The linearity of the plots was assessed in the range of 
eleven concentrations levels from 5 to 800 ng/ml altogether with blank plasma spiked 
with only the IS (zero plasma). The percentage of coefficient of variation (CV%) for every 
drug concentration was calculated for determination of the LLOQ. LLOQ was determined 
as the lowest concentration of calibration standard at which precision was less than 20% 
and accuracy within 20% of the added drug concentration. 
Precision and accuracy of the method was determined by analysing QC samples 
at low, medium and high concentrations of the drug (15, 75 and 750 ng/ml of either DS 
or MeDDC, respectively). The QC samples were prepared in 5 replicates and measured 
intra-day (within the same day) and inter-day (on different days for three consecutive 
days). The accuracy was expressed as percentage of relative error (%RE), while precision 
as percentage of coefficient of variation (%CV). The precision at each concentration 
should not exceed 15%. Calculations were performed as in the formulas below:  
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%RE = ([Found drug – added drug]) / added drug) x 100 
%CV = (Standard deviation / Mean) x 100 
 
Recovery of DS and MeDDC from the extraction method was determined by 
comparing analyte mean peak area of extracted QC samples (pre-extraction spike) to the 
samples of extracted blank plasma spiked with drugs at the same concentration as the QC 
samples (post-extraction spike). Matrix effects (%ME) were determined by comparing 
the mean peak area of post-extraction spike samples to the ones also containing equivalent 
drug concentrations as the QC but prepared in ethanol (no extraction).  %ME less than 
100% could represent ionization suppression, whereas %ME at or more than 100% could 
represent no ionization suppression or ionization enhancement occurred. Samples per 
concentration were also prepared in 5 replicates (n=5). 
Stability of processed samples (post-extraction) in methanol was assessed by 
measuring DS and MeDDC level 1) before (Day 0) and after storage at -80°C for three 
days (Day 3) and 2) at room temperature (in the autosampler) and in the dry ice (-79°) for 
up to two and a half hours prior to the injection into the LC-MS/MS instrument. QC 
samples at 750 ng/ml were prepared in 5 replicates (n=5).  
 
5.3.4.2 Results 
5.3.4.2.1 Optimization of mass spectrometry and chromatographic conditions  
The initial optimization of DS and MeDDC with the MS was to find the optimum 
precursor and product ion for DS and MeDDC. Standard solution of DS or MeDDC was 
injected into the MS unit without the LC column and Agilent MassHunter Optimizer 
software was used to rapidly determine the precursor and product ion (m/z values) with 
the most abundance at both positive and negative ion mode. Later on, the software 
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automatically optimized the fragmentor voltage and collision energy for each of the m/z 
values provided. Here it was found that precursor ion 297.1 and product ion 116.1 was 
the most abundant for DS (Figure 46A) whereas precursor ion 164.06 and product ion 
116 was for the MeDDC (Figure 46B). The rest of the MS parameters including for the 
source was optimized manually later on to maximize the signal response of the analytes. 
The liquid chromatography condition was set to have good separation and distinct 
peaks of all three DS, MeDDC and IS analytes within reasonable run time per analysis. It 
was found that acetonitrile was better in providing sharper peaks of the analytes compared 
to other organic phase such as methanol. Addition of 0.1% formic acid into the water 
phase enhanced the ionization of the analytes. Gradient elution was also used instead of 
isocratic for better separation of the hydrophobic analytes from the endogenous 
substances present in the samples. The selection of diphenhydramine as the internal 
standard was based on the work done by Zhang et al. (2013) and was chosen for its 
stability in plasma and peak is detectable within the set run time of 5 minutes with no 
interference with DS and MeDDC peaks. 
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(A) 
 
(B) 
Figure 46: MS/MS spectrum of disulfiram (A) and MeDDC (B) from the positive 
mode ESI. 
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5.3.4.2.2 Selectivity 
The selectivity (specificity) of the method was proven by the chromatograms 
showing dinstict peaks of DS and MeDDC at retention time 2.6 minutes (Figure 47D) and 
2.4 minutes (Figure 47E), respectively. Zero plasma (blank plasma spiked with only IS) 
showed a peak representing DPH analyte at retention time 2.0 minutes (Figure 47C). 
Blank plasma samples also showed no prominent peak at the DS and MeDDC retention 
times (Figure 47A and B, respectively). The results prove that the processing method 
prevented the interference from possible endegenous components and impurities present 
in the samples to the analyte peaks.  
 
(A) Blank plasma DS 
 
 
(B) Blank plasma MeDDC 
 
  
(C) Zero plasma   
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(D) DS at LLOQ (10 ng/ml)  
 
 
(E) MeDDC at LLOQ (10 ng/ml) 
 
 
Figure 47: Chromatograms of blank plasma for DS and MeDDC (A and B, respectively), 
zero plasma (C), and DS and MeDDC at LLOQ level of 10 ng/ml (D and E, respectively). 
 
5.3.4.2.3 Linearity 
The calibration curve was linear in the range concentration of 5 to 800 ng/ml for 
both DS and MeDDC with regression equation of y = 0.0017x + 0.0221 and y = 0.0009x 
+ 0.0089, respectively. The curves also showed good linearity with R2 values of 0.9887 
and 0.9960 for DS and MeDDC, respectively. The lower limit of detection (LLOD) for 
both drugs was found to be at 5 ng/ml, whereas the LLOQ was determined to be at 10 
ng/ml since the %CV at 5 ng/ml for both DS and MeDDC were more than acceptable 
value of 20% (67% and 56%, respectively) (Table 19). 
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 Drug 
concentration 
(ng/ml) 
%CV 
DS MeDDC 
LLOD 5 67 56 
LLOQ 10 10 3 
 
Table 19: LLOD and LLOQ of DS and MeDDC 
 
5.3.4.2.4 Accuracy and precision 
The intra-day and inter-day results for determination of accuracy and precision of 
the method is displayed in Table 20. Both %RE and %CV were not more than 15%, which 
is the value recommended by the Food and Drug Administration (FDA) (2001) guidance.  
 
Drug Added 
drug 
(ng/ml) 
Intra-day Inter-day 
Found drug 
(ng/ml) 
%RE %CV Found drug 
(ng/ml) 
%RE %CV 
DS 15 15.77 ± 1.26 5.16 7.99 14.31 ± 1.56 -4.60 10.90 
75 73.55 ± 6.61 -1.93 8.98 72.05 ± 4.72 -3.94 6.56 
750 743.76 ± 
23.41 
-0.83 3.15 732.87 ± 17.89 -2.28 2.44 
MeDDC 15 14.69 ± 1.39 -2.06 9.44 15.55 ± 0.74 3.66 4.76 
75 743.76 ± 
23.41 
0.41 3.16 73.50 ± 2.92 -1.99 3.98 
750 756.12 ± 
16.32 
0.82 2.16 749.31 ± 19.50 -0.09 2.60 
 
Table 20: Intra-day and inter-day analysis of the QC samples for determination of 
precision and accuracy of the LC-MS/MS assay. Data were presented as mean ± SD (n = 
5). 
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5.3.4.2.5 Recovery and matrix effects 
 
Table 21 summarizes the extraction recovery of DS and MeDDC from plasma 
samples and the matrix effects on both drugs following the processing method of the 
samples. The mean recovery of the IS at single concentration (1 ng/ml) was 108%. The 
recovery results of both drugs suggest the extraction method for DS and MeDDC is 
acceptable to be used in preparing plasma samples for analysis. The high recovery values 
for MeDDC (> 100%) at all concentrations might be attributed to the pipetting error 
during preparation of post-extraction spike samples. The high %ME values at 15 ng/ml 
DS and MeDDC (123% and 118%, respectively) indicates the biological matrix causes 
no ion suppression at such concentration. The effect was however increased at higher 
concentration of drugs.  
 
Drug 
concentration 
(ng/ml) 
Recovery (%) %ME 
DS MeDDC DS MeDDC 
15 70 147 123 118 
75 65 139 42 89 
750 75 154 12 49 
 
Table 21: Extraction recovery and matrix effects (ME%) of DS and MeDDC from plasma. 
 
 
 
 
 
146 
 
5.3.4.2.6 Post-extraction stability 
Storage of processed samples at -80°C for 3 days caused reduction of all DS, IS 
(DPH) and MeDDC concentrations (Figure 48). However, only MeDDC level was 
significantly reduced to nearly half of the Day 0 concentration.  
 
 
* Significant compared to MeDDC on Day 0. 
Figure 48: DS, IS and MeDDC stability in reconstitution solvent methanol on Day 0 and 
Day 3. Data were presented as mean ± SD (n = 3). 
 
Post-extraction samples kept at room temperature were found to be unstable as 
both DS and MeDDC showed gradual decrease in drug concentration over time. The 
labile DS showed sharper drop in drug level than MeDDC (Figure 49B) with more than 
half the original drug content lost within an hour (Figure 49A). The IS concentration also 
dropped to 84% over duration of 2.5 hours at RT (Figure 49C).   Meanwhile, at freezing 
temperature of -79°C on dry ice, drug level of DS, MeDCC and IS was found consistent 
throughout the experiment period. This indicates the activity of the endogenous substance 
in the samples that causes the drug instability can be blocked in the subfreezing condition. 
The results also proved the integrity of DPH as IS since it was very stable with no sudden 
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drug degradation at different temperatures and also not affected by the presence of 
biological matrices.  
 
 
Figure 49A 
 
 
Figure 49B 
 
 
 
Figure 49C 
 
Figure 49: DS, MeDDC and IS stability in post-extraction methanol (Figure 49A, B and 
C, respectively) at room temperature (RT) and -79°C. 
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5.3.4.3 Discussion and conclusion 
 Zhang et al. (2013) were the first and the only one to publish detail LC-MS/MS 
methodology for the detection of DS in the plasma. The methodology uses the tedious, 
slower and high in cost solid phase extraction (SPE) method for the extraction of the drug, 
rather than the simpler and effective protein precipitation (PP) technique used in the 
present study. The LLOQ for DS in Zhang’s method was however reported lower (0.6 
ng/ml) than the LLOQ found in the present study (10 ng/ml). This perhaps due to the 
more efficient SPE method in extracting the drug as other DS LLOQ value from PP 
technique applied in the extraction method was also higher (15 ng/ml) (Spivak et al., 
2014). It is therefore down to the preference of the analyst on whether to have a robust 
and simple technique of sample preparation but modest limit detection of the drug, or 
costlier and laborious preparation for more sensitive detection of the lower drug amount. 
DS is known as a very labile drug and prone to degradation in the smallest amount 
of protein present in the samples (Cobby et al., 1977, Agarwal et al., 1986). The use of 
stabilized plasma to minimize the rapid degradation of DS in plasma samples for 
analytical measurement was first attempted by Johansson (1988) and later on by Zhang 
et al. (2013) with modifications to the former method stabilizing agents for more practical 
approach of the sample preparation. The stabilizing agent was composed of DTPA as 
chelating agent (chelates plasma protein bound cupric ion) and prepared in acidic 
condition to acidify the plasma in order to stop the interference of various thiols in the 
blood. 
Despite the addition of stabilizing agent to reduce DS degradation rate by the 
activity of the proteins and protein removal during the PP technique, drug degradation 
was still observed in the processed samples with marked activity seen at room 
temperature. The drug degradation process however was found halted when the processed 
samples stored at sub-zero temperature. This drug degradative prevention step was 
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therefore applied in the present study by keeping the processed samples on dry ice the 
whole time prior to the LCMS analysis apart from the immediate blood sample processing 
upon collection from the animals.  
MeDDC is one of the major metabolites produced from the metabolism of DS. 
Unlike the polar DDC, MeDDC is highly hydrophobic (Faiman et al., 1983) and therefore 
easier to be measured simultaneously alongside with DS using the hydrophobic-based C18 
column during the liquid chromatography run. MeDDC is also rapidly metabolized from 
DDC (Faiman et al., 1980, Faiman et al., 1978) thus making it a suitable choice of DS 
metabolite to be measured.  
In conclusion, a validated LC-MS/MS method was successfully developed and 
optimized for simultaneous detection of DS and MeDDC analytes in mouse plasma 
samples. This method was later on used in the analysis for determination of 
pharmacokinetic profile of the DS-GCP20Q11-E nanoemulsion in animal model. 
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5.4 Oral pharmacokinetic profile of DS-GCP20Q11-E 
The objective of the study was to determine the pharmacokinetic profile of DS 
and MeDDC following oral administration of either DS-GCP20Q11-E nanoemulsions 
(encapsulated DS) or DS in soybean oil (free DS) in the mouse model. 
 
5.4.1 Methodology 
5.4.1.1 Animals 
The animal experiments were carried out under license from the Home Office and 
by the policies and regulations stated in Animals and Scientific Acts 1986 UK. All 
animals were housed at UCL School of Pharmacy Biological Service Unit (BSU) and the 
animal handling and care for scientific research was implemented as recommended by 
the BSU guidelines.  
Female CD-1 mouse (Charles River, Kent, UK), 17-21 g were maintained in 
controlled room conditions with ambient temperature at 22-25°C, relative humidity at 55-
60% and 12-hour light and dark cycles. Food and water were given ad libitum to the 
animals. All animals were acclimatized for a week prior to the start of experiments. 
 
5.4.1.2 Experimental procedure 
Animals were randomly divided into two groups of 28 based on the type of 
treatment given: 1) DS-GCP20Q11-E with 40% oil content, 2) DS in soybean oil (20 
mg/ml). The single oral administration of the treatment was given at a dosage of 70 mg/kg 
using oral gavage needle. Animals were then euthanized at 7 different time points (n = 4 
per time point) of 15 minutes, 30 minutes, 60 minutes, 90 minutes, 2 hours, 4 hours and 
8 hours by CO2 asphyxiation. The blood was then immediately taken by cardiac puncture 
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and collected into K2EDTA blood tubes. The blood samples were processed immediately 
upon collection as described previously in Section 5.3.2.5 for LC-MS/MS analysis.  
 
5.4.1.3 Pharmacokinetic analysis 
Pharmacokinetic parameters were determined using PK solver software (Zhang et 
al., 2010) with implementation of noncompartmental analysis. The following parameters 
were used to evaluate the treatments: (1) elimination half-life (t1/2) is the time for the 
concentration of the drug to reach half of its initial amount; (2) Tmax is the time at which 
the maximum drug concentration in the plasma is reached; (3) Cmax is the maximum drug 
concentration in the plasma; (4) Area under curve (AUC) is the total area under the plasma 
drug concentration–time curve and AUC0-t is the AUC from zero (0) hour to time of last 
quantifiable concentration (t). 
 
5.4.2 Results and discussion 
The developed and validated LC-MS/MS method was applied to analyse the 
pharmacokinetic profile of both treatments in mouse plasma. The graph of plasma 
concentration-time profile for oral administration of DS in SB oil and DS-GCP20Q11-E 
are displayed in Figure 50a and Figure 50b respectively.  
Based on the qualitative visual examination of the data, there was presence of 
double peaks in the plasma concentration-time profile for DS analyte in both DS in SB 
oil and DS-GCP20Q11-E treatments, whereas for MeDDC metabolite, it only occurred 
in the DS-GCP20Q11-E treatment. The quantitative analysis of DS and MeDDC plasma 
concentration data (Table 22) was conducted to determine the location (T1max and T2max) 
and magnitude (C1max and C2max) of the two peaks (Table 22). The T1max for DS and 
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MeDDC appeared to happen earlier (15 minutes) in group treated with free DS (DS in SB 
oil) compared to the encapsulated DS (DS-GCP20Q11-E) group (30 minutes). The 
situation was also the same for the T2max of DS with 90 minutes for the free DS compared 
120 minutes for the encapsulated DS group. The delayed Tmax in encapsulated DS group 
could be related to the fact that DS in the formulation is encapsulated and it takes time to 
be released into the blood. The two peaks phenomenon of MeDDC was however seen 
only with the DS-GCP20Q11-E treatment, with C1max was found significantly higher than 
C2max, whereas for the DS in SB oil treatment, only one peak was seen of which gradually 
decline over time.  
Nevertheless, the AUC value measured from t = 0 hour to t = 8 hours (AUC0-8hr) 
which represents an index of overall drug exposure in the blood circulation were found 
significantly higher in free DS group for both analytes (almost 60 times higher for DS 
level) compared to the encapsulated DS group. The very low DS detection level 
throughout the study could have contributed to the inability to calculate the t1/2 for DS in 
the DS-GCP20Q11-E group. 
 
 
 
 
153 
 
 
Figure 50a 
 
 
Figure 50b 
a MeDDC was significantly higher compared to DS level in DS in SB oil group 
b MeDDC was significantly higher compared to DS level in DS-GCP20Q11-E group 
c DS was significantly higher compared to DS level in DS-GCP20Q11-E group 
d MeDDC was significantly higher compared to MeDDC level in DS-GCP20Q11-E group 
 
 
Figure 50: Plasma concentration–time profile for DS in SB oil and DS-GCP20Q11-E oral 
treatment (a and b, respectively). Data were presented as mean ± SD (n = 4). 
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Parameter Unit DS-GCP20Q11-E DS in SB oil 
DS MeDDC DS MeDDC 
t1/2 min N/A 72 44 83 
T1max min 30 30 15 15 
C1max ng/ml 0.538 80.772 40.937 144.993 
T2max min 120 120 90 N/A 
C2max ng/ml 1.694 22.481 45.908 N/A 
AUC0-8hr ng/ml.min 104.428 5193.796 6909.827 11000.036 
 
Table 22: Pharmacokinetic parameters for single oral administration of DS-GCP20Q11-
E and DS in SB oil. N/A = not available. 
 
The multipeaks phenomenon in plasma concentration-time profile of drugs 
following oral administration has been reported previously for several types of oral drug 
that shares no common structure similarities such as alprazolam, cimetidine and talinolol 
(Wang et al., 1999, Oberle and Amidon, 1987, Weitschies et al., 2005). Some common 
factors speculated for this occurrence are: 1) variability in gastric emptying and intestinal 
flow rates (Oberle and Amidon, 1987); 2) enterohepatic recycling (Roberts et al., 2002); 
and 3) presence of absorption sites along the gastrointestinal tract (Gramatte et al., 1994). 
 The first DS peak in the free DS treatment profile could be caused by the rapid 
absorption of the drug due to its high hydrophobicity along the gastrointestinal tract 
especially in the stomach where tissue absorption of the drug is the highest within 30 
minutes post-administration (Faiman et al., 1980). Faiman and colleagues (1980) also 
reported the plasma Tmax for both DS and MeDDC was 5 hours following oral 7 mg/kg 
DS administration to the rats, which was later than the T1max found in the present study. 
Perhaps the use of oil as the DS solvent promoted the earlier rapid DS absorption into the 
blood circulation. The oral PK study of DS in the human male volunteers following 500 
mg DS dosage reported a plasma Tmax at 5 hours for DS and 8 hours for MeDDC (Jensen 
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and Faiman, 1980). The following absorption in the intestinal tract could have caused the 
second peak. Despite the two distinct phases of DS absorption, the MeDDC level was 
seen highest only at the first peak which later on steadily decreased due to being 
metabolized into other forms of metabolite (e.g. MeDTC) or due to elimination. 
 The occurrence of two peaks for DS analyte in DS-GCP20Q11-E group can be 
rendered negligible as the values were lower than the LLOQ. This low DS level detection 
in the plasma could be attributed to the fast absorption of the formulation in the 
gastrointestinal wall, even faster than the rate of absorption when the drug is in SB oil 
free form due to the highly positive charge of GCPQ encapsulating the drug (Ensign et 
al., 2012), causing faster transportation of the nanoemulsion to the liver. This could 
explain the high C1max value of MeDDC first peak with the formulation treatment as it 
was highly formed from the parent drug during the time course of the first peak. The 
conversion of DDC metabolite into MeDDC is rapid in the liver and kidney. The two 
peaks scenario of DDC pharmacokinetic profile following oral administration has been 
reported previously (Faiman et al., 1984). Enterohepatic recycling was believed to play a 
role based on the evidence of subsequent hydrolysis of DDC-glucuronide found in the 
gastrointestinal tract that led to the second peak formation.  
The bigger values of MeDDC found in the plasma compared to DS is likely due 
to MeDDC considerably more stable than DS (Scappaticci et al., 1990). MeDDC does 
not go through covalent disulphide interchange like DS does to inhibit ALDH activity 
(Kitson, 1976). DS was also found able to stop the activity of microsomal esterases 
enzyme (Zemaitis and Greene, 1976) which responsible for metabolising MeDDC into 
methyl mercaptan and thiocarboxylic acid (Eneanya et al., 1981). This blockage of 
enzyme by DS could lead to the rise of the MeDDC level in the plasma, represented by 
the high MeDDC AUC value compared to DS AUC for both treatments. 
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 Lower AUC of DS in animals given with the DS-GCP20Q11-E compared to the 
DS in SB oil could be caused by the properties of GCPQ. Following oral administration 
of deuterated GCPQ in mice, the GCPQ was found only localised at the enzyme-rich 
mucus lining in the gut instead of in the villi of the jejunum (Garrett et al., 2012). This 
gives an opportunity for the nanoparticles to release the drug at the gut wall and drug 
being absorbed through the epithelial cells into the villi thus into the blood circulation. In 
the case of disulfiram, the drug should be absorbed in the gut encapsulated by the GCPQ 
polymer in the nanoparticle form and not as free drug in order for its protection against 
blood proteins. If the drug is released from the nanoparticles at the mucus layer, even if 
the drug is highly penetrating the epithelial wall into the villi, the drug would be degraded 
as soon as it is in contact with the blood.  
 In another finding (Serrano et al., 2015) based on a different technique applied 
that detects individual polymer molecules of GCPQ instead of detecting signals from self-
assembled nanoparticle (Garrett et al., 2012), GCPQ nanoparticles were found absorbed 
via enterocytes into the intestinal villi. The nanoparticles were also found in the liver and 
lungs. This has also been observed in formulation of GCPQ with peptides (Lalatsa et al., 
2012a). If the same situation happens to DS-GCPQ, the low DS detection in the plasma 
could only happened because of the DS-GCP20Q11-E nanoemulsion was rapidly 
absorbed by tissue upon reaching the systemic circulation.  
 Meanwhile, higher DS detection in the plasma when the drug is given in SB oil 
medium could be related to increased absorption of the highly lipophilic drug-oil 
combination into the lymphatic system in the gut. Lymphatic circulation is known for 
transportation of dietary lipids such as triglycerides and many lipophilic substances such 
as chylomicrons (Dixon, 2010), the lipoprotein that carries dietary lipid before eventually 
released into the blood circulation at the thoracic duct (Trevaskis et al., 2015). Soybean 
oil is composed of long-chain triglycerides (Goulet et al., 2010) and various components 
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of fatty acids such as palmitic acid, oleic acids, linoleic acid and linolenic acid (Baughman 
and Jamieson, 1922). DS in SB oil could have accessed the lymphatic circulation via 
association with lipid absorption and lipoprotein assembly pathways across the intestinal 
enterocytes. Drug administration with long-chain lipids has been reported effective in 
promoting lymphatic transportation (Caliph et al., 2000). One major advantage of 
intestinal lymphatic transport is that it circumvents hepatic first-pass metabolism 
(Trevaskis et al., 2015). This would have substantially improved oral bioavailability of 
DS as less amount of the drug is metabolized in the liver. 
 
5.4.3 Conclusions 
The administration of DS-GCP20Q11-E via oral route was found as not the ideal 
route of administration in the attempt to elevate DS level in the blood circulation of the 
animals. It is uncertain whether the cause of the low level of DS in the plasma is due to 
the lack of absorption in the GIT, degradation upon contact with the GIT fluid and blood 
components, or the nanoemulsion was rapidly absorbed by the surrounding tissue in the 
body. Another solution in the attempt to elevate the DS level in plasma is to study the 
drug bioavailability upon administration of the formulation via the intravenous route. 
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5.5 DS-GCP20Q11-E stability in mouse plasma 
Prior to the intravenous pharmacokinetic study of DS-GCP20Q11-E in animal 
model, stability of the nanoemulsion formulations in plasma was tested in vitro by 
comparing it to the stability of the non-encapsulated DS in the same environment. 
 
5.5.1 Methodology 
DS-GCP20Q11-E formulations at 5% oil was used in the experiment, whereas for 
DS solution (without polymer), it was prepared at 1mg/ml in 0.5% DMSO. Mouse plasma 
diluted to 50% of initial concentration using 0.9% w/v sodium chloride solution was 
prepared in bulk (approximately 8 ml) prior to the experiment. An amount of 995 µl of 
the diluted plasma was placed in a 1.5 ml microcentrifuge tube and placed in 37°C water 
bath for at least 30 minutes. As soon as the temperature of plasma stabilized, 5 µl of either 
DS-GCP20Q11-E 5% oil or 1 mg/ml DS solution in DMSO was added into the plasma. 
Samples were prepared in triplicate for each treatment. Plasma samples added with the 
test substances were placed in the temperature-controlled water bath (37°C) at all times. 
A small sample of plasma (50 µl) was taken from each tube at time point 0, 10, 30, 60 
and 120 minutes and immediately processed according to the drug extraction method 
described previously for LC-MS/MS analysis. 
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5.5.2 Results and discussion 
Figure 51 shows the percentage of DS drug entrapment derived from analysis of 
DS drug level from plasma samples added with either DS solution in 0.5% DMSO or DS-
GCP20Q11-E at 5% oil for 2-hours period. The result showed significant decline in DS 
level in plasma with both treatments, with sharper drop seen in plasma with the 
nanoemulsions compared to plasma added with the naked DS. The t1/2 for DS-
GCP20Q11-E formulation and DS in DMSO was 7 minutes and 49 minutes, respectively. 
 
 
a,b Significant compared to drug entrapment at 0 hour for DS and DS-GCP20Q11-E 5%, 
respectively. 
Figure 51: Stability of DS and DS-GCP20Q11-E 5% oil in diluted mouse plasma (in 
vitro). 
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The plasma was diluted to reduce the activity of protein and other endogenous 
components against the drug in order to see the rate of possible degradation of the drug 
upon contact with the plasma (Lalatsa et al., 2012a). The rapid decrease of DS level in 
the plasma added with DS-GCP20Q11-E formulation suggests the instability of the 
nanoparticle upon exposure to the components in the plasma. This instability had been 
observed previously when the formulations were incubated in the SIF, in which medium 
DS concentration was also decreased over time. The presence of multiple endogenous 
enzymes in both SIF and plasma was believed to be the cause of the lack of stability of 
the nanoparticles. 
The instability of the particles might be due to the formation of protein corona 
around the surface of the particle, as discussed previously in Section 4.5.1 regarding the 
probable cause of nanoparticle instability in DMEM medium. There are over several 
thousand different types of protein in the blood that compete for the limited attachment 
space on the nanoparticle surface (Monopoli et al., 2011). This increases the chance of 
protein adsorption to the nanoparticles thus promotes more configuration change to the 
particle’s surface morphology. Albumin, fibrinogen, apolipoprotein and immunoglobulin 
G (IgG) are the proteins most commonly present in the corona (Aggarwal et al., 2009) as 
there are high abundance of these proteins in the blood plasma. The protein corona 
formation is however not permanently fixed and composition is due to change depending 
on the kinetic rate of the adsorption and desorption of the protein, as well as upon 
movement of particle from one site to the other such as from the blood circulation into 
the tissue. This is due to the different relative abundance for different types of protein. 
This suggests that the nanoparticle behaviour from in vitro data does not necessarily 
predict the exact same activity happening in vivo for the same nanoparticles (Rahman et 
al., 2013).  
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5.6 Intravenous pharmacokinetic profile of DS-GCP20Q11-E 
Pharmacokinetic profile of a drug formulation via intravenous (IV) administration 
is commonly used as a reference to compare with the pharmacokinetic profile of other 
routes of administrations such as oral and subcutaneous administration. This is due to the 
absence of barrier via the IV route that could limit the absorption and distribution of the 
drug as the drug is directly introduced into the systemic system.  The IV route could also 
provide an enhanced level of drug that could be of therapeutic benefit. The objective of 
this study was to determine if the DS level in plasma is improved and maintained at 
acceptable level upon administration of the DS-GCP20Q11-E nanoemulsions through the 
IV route.  
 
5.6.1 DS-GCPQ formulation evaluation for IV administration 
5.6.1.1 Methodology 
The DS-GCP20Q11-E formulation was modified to suit the requirement for the 
IV administration by preparing it in 5% w/v glucose instead of Milli-Q water. The 
preparation of DS-GCP20Q11-E formulations at different oil content (5, 10, 20, 30, 40 
and 50% oil) was the same as described previously (Section 3.4.4.1) except for using the 
sterile 5% w/v glucose (Hameln Pharmaceuticals Limited, Gloucester, UK) as the 
aqueous phase to replace Milli-Q water (Table 16). Freshly prepared formulations at each 
oil content were prepared in triplicate for the characterization. All formulations were 
characterized by analysing the mean drug entrapment (%), particle size and PDI, as well 
as the zeta potential, as described previously.  
Another characterization of the DS-GCP20Q11-E in 5% w/v glucose at different 
oil content was the measurement of viscosity as this could affect administration with small 
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bore needles. Viscosity was measured using Bohlin Gemini Rheometer (Malvern 
Instruments, Malvern, UK). A stainless-steel cone and plate at 4° angle and 40 mm 
diameter (CP 4/40) was used for the measurement at 25°C over the shear rate range of 
0.01 to 100 s-1. Apparent viscosity was measured under the shear rate of 100 s-1.  
 
5.6.1.2 Results and discussion 
The purpose of preparing the formulation in 5% glucose is to avoid the osmolarity 
difference between formulations and blood constituents upon its administration into the 
blood circulations that could lead to cell rupture or haemolysis. The formulations were 
also prepared and kept in sterile condition at all times to avoid any exposure of the bacteria 
or harmful foreign particles into the formulations that could be transferred to the test 
subjects.  
The resulting dispersion of DS-GCP20Q11-E in 5% glucose at all oil content 
appeared uniform, milky white in colour and more viscous towards higher amount of oil 
content. The result shows all formulations at different oil content having 100% drug 
entrapment (Figure 52).  
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Figure 52: Percentage of drug encapsulation of freshly prepared DS-GCP20Q11-E in 5% 
glucose formulations at 5, 10, 20, 30, 40 and 50% oil content. Data were presented as 
mean ± SD (n = 3). 
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The mean particle size of the formulations (Figure 53) showed an increasing 
pattern of size towards higher amount oil content, similar to the pattern seen in DS-
GCP20Q11-E nanoemulsion prepared in Milli-Q water. Both the size and PDI values 
were also found significantly different among different oil content formulations (P < 
0.05).  
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* Significant compared to mean particle size of any other formulations with different oil content 
Figure 53: Particle size of freshly prepared DS-GCP20Q11-E in 5% glucose formulations 
at 5, 10, 20, 30, 40 and 50% oil content. Data were presented as mean ± SD (n = 3). 
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a Significant compared to mean PDI value of 10, 30 and 40% oil content formulations  
b Significant compared to mean PDI value of 10 and 40% oil content formulations  
 
Figure 54: PDI values of freshly prepared DS-GCP20Q11-E in 5% glucose formulations 
at 5, 10, 20, 30, 40 and 50% oil content. Data were presented as mean ± SD (n = 3). 
 
The zeta potential measurements showed highly positive surface charge in all 
formulations (pH 4 to 5). It appeared however that the charge was decreasing in 
formulations having higher amount of oil (Figure 55).  
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a Significant compared to mean zeta potential of 10% oil content formulations  
b Significant compared to mean zeta potential of 30% oil content formulations  
c Significant compared to mean zeta potential of any other formulations with different oil content  
 
Figure 55: Zeta potential (mean ± SD, n = 3) of freshly prepared DS-GCP20Q11-E in 5% 
glucose formulations at 5, 10, 20, 30, 40 and 50% oil content.  
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Apparent viscosity is defined by the shear stress applied to the fluid divided by 
the shear rate. The apparent viscosity at highest shear rate of 100s-1 was chosen to 
compare formulations with different oil content because of measurement at maximum 
torque by the rheometer gives high accuracy of the reading (Ngan et al., 2014). Based on 
the graph in Figure 56, the apparent viscosity was increased towards higher content of oil 
in the DS-GCP20Q11-E nanoemulsion. 
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Figure 56: Apparent viscosity of DS-GCP20Q11-E nanoemulsion in 5% glucose at 
different oil content at shear rate 100s-1.  
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Figure 57: Rheological behaviour of DS-GCP20Q11-E nanoemulsion in 5% glucose at 
different oil content at shear rate between 0.01 to 100s-1.  
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Figure 57 shows the DS-GCP20Q11-E nanoemulsions having the flow behaviour 
of shear thinning (pseudoplastic) at higher shear rate. This means more occurrence of 
fluid system when subjected to external pressure, which is a desirable character for easier 
administration from the syringe during the intravenous bolus injection. During the shear 
thinning, as the shear rate increases, the polymer chains are more uniformly aligned, 
causing the viscosity to decrease accordingly (Likavčan et al., 2014). It could also mean 
that the polymeric nanoparticles network of GCPQ is broken at high shear rates, as 
reported previously in our group (Chooi et al., 2014). In comparison to other formulations, 
only formulation at 50% oil showed a distinct yield stress (amount of stress needed for 
the dispersion to flow) peak at shear rate 0.018 s-1. This is a common situation in highly 
concentrated nanoemulsions when subjected to small shear deformation as they exhibit 
strong elastic response (Pal, 1999). The absence of yield stress peak means no force 
needed for the dispersion to flow.  
In summary, it can be concluded that the drug entrapment, particle size and 
particle size distribution of DS-GCP20Q11-E in 5% glucose showed no distinct 
differences compared to the ones prepared in Milli-Q water. This formulation was 
therefore used for the IV pharmacokinetic study in mouse model. 
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5.6.2 Intravenous pharmacokinetic study of DS-GCP20Q11-E in mice 
5.6.2.1 Methodology  
The animals condition used was as described previously in Section 5.4.1.1. 
Animals were given with single IV administration of DS-GCP20Q11-E in 5% glucose 
with 20% oil content (4 mg/ml DS) at 20 mg/kg dose via the tail vein injection. Animals 
were then euthanized at 5 different time points (n = 5 per time point) of 5 minutes, 15 
minutes, 30 minutes, 1 hour and 2 hours by the CO2 asphyxiation. The blood was then 
immediately taken by cardiac puncture and collected into K2EDTA blood tubes. The 
blood samples were processed immediately upon collection as described previously in 
Section 5.3.2.5 for LC-MS/MS analysis. The pharmacokinetic analysis done was as 
described in Section 5.4.1.3. 
 
5.6.2.2 Results and discussion 
The developed and validated LC-MS/MS method was used to determine the 
pharmacokinetic profile of DS in mouse plasma from the IV administration of DS-
GCP20Q11-E in 5% glucose. In this study, there was no DS control group (non-
encapsulated) to be used as a comparison to the formulation group since DS is routinely 
given to the subjects through oral routes only. As the DS-GCP20Q11-E at 40% oil was 
too viscous and difficult to be administered IV through the mouse tail vein because of 
high backpressure, DS-GCP20Q11-E in 5% glucose at 20% oil (4 mg/ml DS) was used 
in the dosing regimen. 
The plasma concentration-time profile of the single IV administration of the 
formulation in shown in Figure 58. Qualitative visual examination of the graph showed a 
gradual decline of both analytes concentration within one-hour post-injection with plasma 
DS level continuously decreased until end of observation period of t = 2 hours. MeDDC 
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level was however seen increased starting from t = 1 hour onwards. The decrease in DS 
level might be attributed to the action of MPS mechanism eliminating the nanoparticles 
as positively-charged nanoparticles was reported having higher rate of opsonisation 
compared to ones with neutral charge (Roser et al., 1998). It could also mean that the 
nanoparticles are rapidly absorbed into the tissues.  
 
 
* MeDDC was significantly higher compared to DS level at t = 2 hours  
 
Figure 58: Plasma concentration – time profile of DS-GCP20Q11-E in 5% glucose 
intravenous treatment. Data were presented as mean ± SD (n = 5). 
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Parameter Unit DS-GCP20Q11-E 
DS MeDDC 
t1/2 min 17 110 
Tmax min 5 5 
Cmax ng/ml 645.593 376.573 
AUC0-2hr ng/ml.min 13348.471 16883.166 
 
Table 23: Pharmacokinetic parameters for single IV administration of DS-GCP20Q11-E 
in 5% glucose. 
 
The pharmacokinetic parameters for IV administration of DS-GCP20Q11-E are 
shown in Table 23. Despite the gradual decline of the drug level, DS t1/2 at 17 mins was 
longer than previously reported (6 mins) for IV administration (Liu et al., 2014). The 
improved AUC value of DS from IV administration (13348.471 ng/ml.min) compared to 
oral administration (104.428 ng/ml.min) could due to the avoidance of the first-pass 
metabolism through the IV route. This was supported by findings from Serrano et al. 
(2015) in which very low levels of GCPQ nanoparticles has been found in the liver and 
none in the spleen following an IV administration. There was also a slight elevation of 
MeDDC level, higher than the DS level at time point 120 minutes. The elevation of 
MeDDC level might due to the late release of DS from some of the nanoparticles, causing 
parts of the administered DS being converted into MeDDC in the liver at later time than 
the rest of the drug. 
For the DS anticancer study, the DS-GCP20Q11-E nanoemulsion was one of the 
few DS nanoparticle formulations made for IV administration route. Two of the reported 
studies investigated the effects of DS nanoparticles from the IV administration against 
breast cancer xenograft development in mice. A liposome-encapsulated disulfiram 
formulation was developed by Liu and colleagues (2014) while in the other study, a 
folate-receptor-targeted PLGA-PEG nanoparticle for encapsulation of DS was developed 
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by Fasehee and colleagues (2016a) for the passive (EPR effect) and active (folate 
receptor) tumour targeting. A DS-loaded lipid emulsion was formulated by Chen and 
colleagues (2015) aiming for an IV route delivery. The lipid emulsion made of mixture 
of medium chain triglycerides, glycerine, oleic acid, soybean lecithin and non-ionic 
surfactant Poloxamer 188 was yet to be tested for the in vivo stability. Unfortunately, no 
PK data of the nanoparticle formulations were disclosed in any of the studies.  
 
5.6.2.3 Conclusions 
The IV route of administration of DS-GCP20Q11-E was able to improve the DS 
bioavailability in the blood circulation of the test animals by prolonging the half-life and 
increasing the AUC level of the drug. At the present moment, IV administration was seen 
as the better choice of route of administration for the nanoemulsion formulation to be 
given to the animals in the pharmacodynamics study, which will be covered in the next 
chapter. 
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6 In vivo anticancer study of disulfiram nanoemulsion 
 
 
Chapter 6 
 
In vivo anticancer study of 
disulfiram nanoemulsion 
 
6.1 Overview 
In the previous chapter, the pharmacokinetic aspect of the DS-GCP20Q11-E 
formulations following both oral and intravenous administration to the mice were 
determined with the conclusion that these nanoparticles could be administered 
intravenously. The drug dose and percentage of oil content of the nanoemulsions that 
could be used were also determined. This chapter evaluates the pharmacodynamic aspect 
of DS-GCP20Q11-E nanoemulsions on the development of xenograft tumour of 
pancreatic cancer in mouse model using the dose regimens pre-determined in the 
pharmacokinetic study.  
Pharmacodynamic studies explore the relationship between concentration of the 
drug at the site of action and the observed resulting effect in a set time course (Meibohm 
and Derendorf, 1997, Derendorf and Meibohm, 1999). In a simpler way, 
pharmacokinetics explores what the body does to the drug, while pharmacodynamics is 
about what the drug does to the body to produce the pharmacological effect (Yáñez et al., 
2011).  
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6.2 Pancreatic cancer as the chosen type of malignancy 
Pancreatic cancer is one of the high mortality-type of cancer with five-year 
survival rate of less than 5% and the median survival measured in months (Bailey et al., 
2016, Guerra and Barbacid, 2013). The most common factor contributing to the poor 
prognosis is the late diagnosis of the disease, at an advanced state of the tumour 
development with metastasis outside of the pancreas (Hidalgo, 2010, Vincent et al., 
2011).  
Patients at an early (local) stage of cancer usually have surgery to remove the 
resectable tumours. Nevertheless, even after the tumour removal, the patients frequently 
still need to have postoperative administration chemotherapy to minimize the risk of 
systemic spread. Drugs of choice include fluorouracil and leucovorin or gemcitabine 
(Burris et al., 1997). These are also commonly used to treat advanced pancreatic cancer 
to improve overall survival (Hidalgo, 2010) but with limited benefit. This is why the 
development of more effective, safer anticancer drugs important in the treatment of 
pancreatic cancer so that the adverse effects of anticancer drug treatments do not outweigh 
the effects coming from the disease itself, especially during the treatment of early stage 
tumours. 
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6.3 Xenograft tumour model for pancreatic tumour 
Murine tumour xenograft model has been used widely as a cancer model in 
preclinical studies to provide significant advances in the understanding of this family of 
diseases (Huynh et al., 2011). Rodent models are used to recapitulate the human disease 
for evaluation of chemopreventive and therapeutic measures. The most common 
xenograft models use cultured pancreatic cancer cells, which are available in more than 
25 types of cultured cell lines. Some of the regularly used parental cell lines include 
MIAPaCa-2, Panc-1, AsPC-1, Capan-2 and BxPC-3 (Ding et al., 2010). 
The subcutaneous xenograft models using cultured cells involve implanting cells 
or tissues in the subcutaneous pocket under the skin, usually at the flank area on either 
side of the animals near the hind legs or along the animal’s back. For this cell implantation 
to grow and not undergoing rejection from the host, athymic nude mice are commonly 
used as these animals have defective development of the thymus and hair follicles, thus 
lack of T-lymphocytes and hair (Fidler, 1986). In other words, the immunocompromised 
nude mice will not be able to reject foreign cells and tissues because of absence of these 
immune cells. 
There are several advantages of this subcutaneous xenograft in vivo system. Since 
the implanted cells under the skin develop into palpable solid tumours, this enables the 
tumour size and volume to be estimated by direct measurement of the tumour dimensions 
(Dai et al., 2015). The tumour mass and its general morphology can also be assessed at 
the end of the experiment after the tumours are resected from the host. The histopathology 
of the tumours also maintains the morphological phenotype of the primary tumour from 
human despite being grown in rodents. The simple implantation technique into the mice 
at the heterotopic sites reduces cost, lowers the incidence of complications from the 
procedure and provides convenience for cell manipulation by limited skill personnel to 
achieve successful engraftments (Kim et al., 2009). 
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Nevertheless, there are also limitations for this approach. There is probable risk 
of genetic instability to the cancer cell lines after several multiples passages. This 
adaptation of neoplastic cells to the in vitro conditions with long periods of successive 
passages may resulted in gain or loss of genetic alterations, which might be different form 
the parental tumours (Ding et al., 2010). The systemic environment of the 
immunocompromised mouse also does not allow evaluation of the host’s immune system 
contribution to the growth modulation of the tumours. Subcutaneous xenograft tumours 
also rarely metastasize and usually show local growth only (Fidler, 1986), therefore they 
fail to truly imitate the invasive nature of pancreatic cancer in human. 
Despite of all the weaknesses surrounding this approach of in vivo model, it is still 
commonly used for studies involving evaluations of drug formulation effect and 
determination of tumour growth and invasion. It is undoubtedly a simple, fast, reliable 
and inexpensive method compared to others such as orthotopic xenograft implantation 
and genetically engineered models as a way to reach defined end point evaluation of an 
experiment. 
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6.4 Materials 
Item Supplier / Manufacturer 
MIAPaCa-2 (CRL-1420) American Type Culture Collection, Rockville, 
Maryland, USA. 
Copper gluconate Sigma-Aldrich Company Limited, Dorset, UK 
 Dulbecco’s Modified Eagle’s 
Medium (DMEM), high 
glucose with L-glutamine 
Dulbecco’s Phosphate 
Buffered Saline 
Fetal bovine serum 
Sodium pyruvate, 100 mM Gibco Life Technologies, Bleiswijk, Netherlands 
Trypsin-
ethylenediaminetetraacetic 
acid (EDTA), 0.25%, phenol 
red 
Gibco Life Technologies, Paisley, Scotland 
Corning® Matrigel® Matrix Corning, New York, USA 
Glucose intravenous infusion 
50% w/v 
Hameln Pharmaceuticals Limited, Gloucester, UK 
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6.5 Methodology 
6.5.1 Animals 
The animal experiments were carried out under ethical approval from the Home 
Office, as described previously in Chapter 5, Section 5.4.1.1. Fifteen female CD-1 nude 
mice (Charles River, Kent, UK) of 17-21 g were kept in the individually ventilated cages 
(IVCs) with constant temperature and humidity monitoring according to the UCL School 
of Pharmacy BSU guidelines. Food and water were given ad libitum to the animals. All 
animals were acclimatized for a week prior to the start of experiment. 
 
6.5.2 MIAPaCa-2 cells preparation and pancreatic xenograft 
implantation 
Similar to the cell conditions described previously in Chapter 4, Section 4.3.1, the 
MIAPaCa-2 cancer cells were grown for at least 2 weeks prior to the use for implantation 
in the complete DMEM growth medium (DMEM added with 10% v/v fetal bovine serum 
and 1 mM sodium pyruvate), maintained in CO2 incubator with 5% CO2 at 37°C. Cells 
that were grown in 175 cm2 cell culture flask and reached 90% confluency were used 
after the amount of cells was determined with the flow cytometer.  
Cells for the implantation were prepared in a combination of blank growth 
medium (DMEM medium without FBS and sodium pyruvate) and Matrigel at 1:1 ratio, 
containing 2x106 cells in 100 µl suspension (2x107 cells per ml). Cells were first removed 
from complete growth medium by centrifuging the cell suspension at 1000-2000 g for 3 
minutes at 4°C, removing the supernatant (complete growth medium) and adding the 
blank growth medium into the cells. The centrifugation and replacement with blank 
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growth medium was repeated twice. Prior to the mix, frozen Matrigel from -50°C freezer 
was thawed into liquid form and then kept on ice (Matrigel solidifies into gel above 10°C). 
After mixing the cell suspension in blank growth medium with the Matrigel, the cell 
mixture was kept on ice at all times prior to the injection. 
The freshly prepared MIAPaCa-2 cell mixture was injected subcutaneously into 
the right flank of the mouse at the volume of 100 µl per flank using 25G needle and 1 ml 
syringe. The day of implantation was determined as Day 0. The animals were monitored 
daily for the first tumour appearance, bodyweight change and health condition. Once 
tumours were detected in all mice, animals were randomly divided into 3 groups (n = 5). 
 
6.5.3 Experimental design for DS-GCP20Q11-E and DS in SB oil 
treatments 
Treatment was started when the tumour reached a palpable size of approximately 
6-7 mm in diameter. The tumour diameter was measured using a vernier calliper. For the 
treatments, Group 1 was the control group (no treatment); Group 2 for the treatment of 
intravenous 20 mg/kg DS-GCP20Q11-E at 20% oil content in 5% glucose (IV DS-GCPQ) 
with oral 11.4 mg/kg copper gluconate (Oral Cu); and Group 3 for the treatment of oral 
20 mg/kg DS in SB oil (Oral DS) with Oral Cu. Treatments were given once every two 
days, along with the subsequent monitoring of tumour growth and bodyweight of the 
animals. Treatments were terminated in all groups after the total amount 10 intravenous 
injections were given to the mice in Group 2. Afterwards, the tumour growth was 
continuously measured until it reached maximum diameter of 13 mm, at which point the 
study was terminated (Figure 59). Mice were euthanized with CO2 asphyxiation. The 
tumours were then excised, measured for tumour volume and weight and fixed in 10% 
formalin. The tumour volume (mm3) was calculated as (width2 x length)/2.  
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Figure 59: Simplified diagram to summarize the flow of experiment for the 
pharmacodynamics study of DS-GCP20Q11-E using pancreatic xenograft tumour model. 
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6.5.4 Statistical analysis 
Data presented as mean ± standard deviation was analysed using One-way 
ANOVA with Tukey’s multiple comparison test for the post-hoc analysis, using IBM 
SPSS Statistics for Windows, Version 22.0 (IBM Corp, Armonk, New York, USA). 
Analysis of survival data was performed using GraphPad Prism version 5.00 for Windows 
(GraphPad Software, San Diego, California, USA). The survival of animals was 
determined using Kaplan-Meier analysis with Log rank (Mantel-Cox) test for comparison 
of two survival curves. The differences were considered significant when value of p < 
0.05. 
6.6 Results 
6.6.1 Bodyweight 
Figure 60 shows the bodyweight of all animals in all groups throughout the period 
of experiment. There was no significant difference in bodyweight change for each 
individual animal in all groups upon tumour implantation and administration of the 
treatments.  
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(C) 
Figure 60: Bodyweight changes in individual animal throughout the study (A, B and C) 
of control, IV DS-GCPQ + Oral Cu, and Oral DS + Oral Cu group, respectively. 
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6.6.2 Tumour incidence, volume and weight 
Treatments were started on Day 8 when the palpable tumour in mice reached 
approximately between 6 to 7 mm in diameter. The data (Figure 61) displays the mean 
tumour volume in each group vs. day of post-tumour implantation, with a few exceptions; 
Day 32 and 34 for IV DS-GCPQ + Oral Cu and Day 34 for Oral DS + Oral Cu group 
displayed volume from one animal only. All tumours, with or without treatments, showed 
a gradual increase in tumour volume over time (Figure 62 A, B, and C). Despite lower 
mean tumour weight seen in IV DS-GCPQ + Oral Cu group (Table 24), the weights were 
not significantly different among the treatment groups (p>0.05).  
 
 
Figure 61: Mean tumour volume measured from Day 8 until end of study in all 3 groups.  
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(C) 
Figure 62: Tumour volume progression in individual mouse for IV DS-GCPQ + Oral Cu 
(A), Oral DS + Oral DS (B), and control (C) group measured from Day 8 until end of 
study. 
 
 
Group 
Tumour weight (g) 
Mean SD 
Control 260.2 48.8 
IV DS-GCPQ + Oral Cu 183.4 52.1 
Oral DS + Oral DS 204.2 59.0 
 
Table 24: Mean tumour weight (g) in all three groups measured upon excision from the 
flank of the animals during post-mortem. 
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6.6.3 Survival 
Treatments were started on Day 8 and ended on Day 26 which was equivalent to 
the total amount of 10 IV injections given to the animals in IV DS-GCPQ + Oral Cu 
group. The median survival time for animals received IV DS-GCPQ + Oral Cu, Oral DS 
+ Oral Cu and control group was 30, 32 and 25 days, respectively (Figure 63). 
Statistically, the median survival time in animals received no treatment (control) was 
significantly shorter compared to the values in both IV DS-GCPQ + Oral Cu and Oral DS 
+ Oral Cu treatment groups (p = 0.0305, p = 0.0031, respectively). There was no 
significant difference in the survival time values between the two treatment groups. 
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Figure 63: Kaplan-Meier survival curve of nude mice bearing pancreatic xenograft 
tumours. 
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6.7 Discussion 
The analysis of animal survival is commonly used to measure clinical outcomes. 
Since the humane practice of the experiment only allows the animals to bear single 
tumour up to certain size only (maximum of 13 mm in diameter for the present case), this 
was used as a surrogate marker and endpoint to study the anticancer effects of DS-
GCP20Q11-E nanoemulsion treatments.  
Based on this modified survival study, the treatment of DS with copper 
supplementation showed significant effect in increasing the survival of the animals 
bearing MIAPaCa-2 xenograft pancreatic tumour. It has been shown that both oral and 
IV treatment of DS produced the effect of tumour growth suppression, rendering IV route 
as the less preferable choice for route of administration of the drug. The method of 
administering DS in soybean oil is however only feasible in this experiment for easy oral 
administration of DS via oral gavage to the mice. This approach is less desirable in human 
as the drug is more conveniently and commonly taken in solid form of capsules or tablets.  
Since the oral pharmacokinetic of DS-GCP20Q11-E revealed very low DS level 
in the mouse plasma, study of the anticancer effect following oral route of DS-
GCP20Q11-E administration was omitted. Perhaps with better understanding of DS-
GCP20Q11-E fate in the body following oral administration, such as investigating the DS 
level or nanoparticle deposition in the main organs and other tissues, oral DS-GCP20Q11-
E administration to study its effect on tumour progression can be taken into consideration 
in the future studies. No significant bodyweight change in control and treated animals 
means the tumour burden did not induce health deterioration effect and the treatments not 
producing toxicity or any adverse side effects, respectively, to the animals.  
 The effectiveness of DS in suppressing the progression and growth of pancreatic 
cancer xenografts has been reported by many for the past several years. DS with copper 
has been made into a complex for the intraperitoneal (i.p.) treatment against SW1990 
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cells subcutaneous pancreatic tumour xenograft in nude mice (Han et al., 2013). The 
treatment was able to inhibit 62.8% of the tumour growth when compared to control. The 
positive effect was also achieved when disulfiram administered in combination with other 
active ingredients. Combined treatments of gemcitabine and disulfiram with zinc sulphate 
via intraperitoneal administration were able to reduce mean tumour mass of PaCa44 cells 
subcutaneous pancreatic xenograft in nude mice to 40-fold compared to control after 4 
weeks of treatments (Dalla Pozza et al., 2011). In another study involving treatments with 
oral DS and intraperitoneal of low-dose gemcitabine, the growth of the CFPAC-1 
xenograft tumour was significantly suppressed which was comparable to the effects of 
10-times higher dose of gemcitabine treatment (Kim et al., 2013). Another combined 
treatment of disulfiram was with arsenic trioxide and ascorbic acid (AAA), where the 
intraperitoneal injection of the combination had caused 61% reduction in mean tumour 
size and eliminated tumours in 30% of nude mice with PANC-1 xenografts (Dinnen et 
al., 2013). Intraperitoneal treatment of DDC, the reduced metabolite of disulfiram with 
12-O-tetradecanoylphorbol-13-acetate was also found strongly inhibited the growth of 
PANC-1 xenograft tumours (Huang et al., 2015). 
Copper is an essential ingredient in elevating the anticancer property of DS. It 
would be practical to administer copper intravenously along with the DS-GCP20Q11-E 
formulation. Since there was lack of information on the possible interactions between the 
copper ions and the particles of the nanoemulsions in the blood environment, the copper 
was administered orally in the form of copper gluconate. Copper (cupric) gluconate is a 
widely available salt as a dietary supplement and is one of the Generally Regarded as Safe 
(GRAS) substance (FDA, 2015). In fact, it has also been used in the Phase 1 clinical trials 
for the study of DS against hepatic metastases from solid tumours (ClinicalTrials.gov 
Identifier NCT00742911). As the copper is capable of forming complex with DS in vivo 
(Johansson, 1992), it is possible to have the copper and DS complex formed in the tissues 
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such as in the liver or to a greater extent in the tumour. Accumulation of copper in cancer 
cells is high (Gupte and Mumper, 2009). The supplementation of copper gluconate was 
therefore assumed helping to increase the bioavailability of copper in the blood 
circulation and in the tumour microenvironment thus aid the anticancer activity of the 
DS-GCP20Q11-E without causing unnecessary toxicity from the copper overdose.   
The DS-GCP20Q11-E formulation was able to show positive effects against the 
development of the pancreatic tumour xenograft. Nevertheless, there are still a lot of 
improvement that could be made to fully utilize the benefits of the nanoemulsion. To take 
advantage of the high drug loading that can be put into the nanoemulsion, it is worthwhile 
to attempt for combination of DS with other potent hydrophobic anticancer drugs such as 
gemcitabine into the formulation for a more potent anticancer activity. For a more precise 
imitation of the actual pancreatic cancer environment and its metastatic nature, the 
anticancer activity of the formulation could also be tested using the murine orthotopic 
model of the pancreatic cancer by direct injection of the pancreatic cancer cells into the 
proximal portion of the pancreas (Alves et al., 2001) or into the common bile duct (Tsuji 
et al., 2006). It is no doubt that the orthotopic method requires expertise and more 
challenging to be executed, but the significance of the outcome from such study is 
invaluable for better mimics of the pancreatic cancer in human. 
 
6.8 Conclusions 
The treatment of DS-GCP20Q11-E with copper was able to produce a significant 
inhibition effect against the progression of MIAPaCa-2 cells subcutaneous xenograft 
tumour growth when the nanoemulsion is given intravenously to the nude mice. The 
treatment was also found not causing any toxicological effects to the animals even after 
it was given over the period of 23 days. This showed that the DS-GCP20Q11-E has the 
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ability to alleviate the rapid progression of pancreatic cancer without causing harmful side 
effects from its continuous use in a set period of time. This therefore suggests that the 
DS-GCP20Q11-E nanoemulsion has the potential to be studied further as a safe adjuvant 
for chemotherapeutic treatment.  
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7 Conclusion 
 
 
Chapter 7 
 
Conclusion 
 
In order to improve the delivery system of DS, the aim was to develop a 
nanoparticle formulation by incorporating the drug with chitosan-derived GCPQ 
polymer. Two batches of GCPQ had been synthesized from two different sources of 
glycol chitosan via step-by-step process of acid degradation, palmitoylation and 
quaternisation. Despite the same synthesis procedure applied, the NMR spectroscopy 
showed different P% but same Q% between the GCP10Q11 and GCP20Q11 polymers, 
which led to two different molecular weights of 15,100 and 24,890 kDa respectively, 
based on the GCP-MALLS analysis. There was possibility that the lower P% and 
molecular weight of GCP10Q11 was caused by the GC used had less primary amine 
group available (higher N-acetylation degree) for the conjugation with palmitic acid chain 
synthesis to happen in comparison to the GC for GCP20Q11. Apart from that, the 
influence of random conjugation reactions is also a factor that cannot be ruled out.  
The polymeric micelles formulation approach was unable to give high DE% for 
both DS-GCP10Q11 and DS-GCP20Q11 formulations (3-4% DE% only), despite the 
attempt to use different drug-to-polymer ratio of 1:5 and 1:10 w/w, higher palmitoylated 
GCPQ and high-powered probe sonication procedure. The range of particle size (166-275 
and 112-295 nm) and particle size distribution (0.3-0.4 and 0.53-0.68) of DS-GCP10Q11 
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and DS-GCP20Q11 respectively, were however within the acceptable criteria for a 
nanoparticle formulation. The presence of undissolved DS crystals in the formulation 
upon naked eye observation and TEM imaging proved the incomplete solubilisation of 
DS by the polymer and explained the low drug encapsulation into the nanoparticles.  
In the attempt to increase the DS encapsulation while maintaining other optimum 
nanoparticle criteria, the formulation of DS with higher palmitoylation GCP20Q11 into 
nanoemulsions showed promising results. Incorporation of soybean oil into the DS-
GCP20Q11-E formulation produced a milky white and homogenous nanoemulsion with 
DE% as high as 100% at 1:10 drug to polymer ratio after a 15-minutes probe sonication. 
At 5% oil content, the nanoparticle criteria were found ideal with particle size of 183.2 ± 
5.9 nm, PDI of 0.17 ± 0.01 and zeta potential of 50.9 ± 1.3 at pH 4.54. Despite the low 
PDI, TEM images however revealed heterogeneous particle size distribution between 9 
to 100 nm.  
DS-GCP20Q11-E at higher content of oil (10, 20, 30, 40 and 50% oil) was 
investigated to determine the maximum limits of oil-drug loading of the nanoemulsions. 
Results showed high DE% in all formulations (95-100%). It was found that with 
increasing oil content (5-50%) the mean particle increased, as did overall polydispersity 
(190 to 359 nm and 0.14 to 0.21, respectively). The colloidal and drug load stability of 
formulations at all oil content were seen improved when stored at 4°C compared to room 
temperature. DS-GCP20Q11-E at 5% oil showed no significant change in 1) particle size 
and PDI values upon exposure to acidic and basic pH solution; 2) DE% in phosphate and 
HCl buffer up to 4 hours, and; 3) DE% upon incubation in simulated gastric fluid for 4 
hours.  
The potential of the nanoemulsions formulation to be developed for oral delivery 
was studied by conducting the in vivo oral pharmacokinetic study of DS-GCP20Q11-E in 
a mouse model. The oral administration of DS-GCP20Q11-E at 40% oil, 70 mg/kg dose 
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was however showed low DS level in the mouse plasma compared to control group (DS 
in soybean oil) with AUC of 104.428 compared to 6909.827 ng/ml.min, respectively. The 
change of route of administration to intravenous was able to improve the pharmacokinetic 
profile of DS-GCP20Q11-E even upon administration of lower oil content formulations 
and lower dosage (20% oil and 20 mg/kg DS, respectively). This was proved by the 
increased IV’s AUC value (13348.471 ng/ml.min) ~ over 100-fold of the oral AUC value, 
as well as better DS t1/2 compared to the other previously reported DS IV nanoparticle 
formulation.  
Presence of copper in the treatment increases the potency of DS-GCP20Q11-E 
nanoemulsions, as shown by the significant low IC50 values of the treatment compared to 
the ones without copper in the in vitro cellular toxicity experiment against MIAPaCa-2 
cancer cell lines. This finding was later implemented in the treatment regime to 
investigate DS-GCP20Q11-E anticancer activity against the development of pancreatic 
cancer xenograft tumour. Improved survival days of the tumour-bearing animals was seen 
in groups treated with continuous IV treatment of DS-GCP20Q11-E, as well as oral DS 
in soybean oil. Treated animals also showed no significant changes in bodyweight 
throughout the study, suggesting no toxicity or side effects from the prolonged 
administration of the DS formulations. 
In conclusion, the DS-GCP20Q11-E nanoemulsion was found capable of 
protecting the drug in the blood circulation to some extent and delivered the drug load to 
the tumour site. Additional feature of the nanoemulsions was the ability to be loaded with 
high amount of oil thus high amount of drug without compromising the colloidal stability 
of the nanoparticle formulation. This could help reaching the therapeutic dose needed for 
the treatment without the risk of toxicity from the use of high surfactant/emulsifier 
amount to stabilize the drug formulation. This proves the potential of the newly found 
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DS-GCP20Q11-E nanoemulsions to be used or developed further for cancer therapeutic 
purposes. 
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8 e recommendations 
Future recommendations 
 
Polymeric micelles formulation of DS and GCPQ could probably be improved by 
adding cosurfactant into the formulation such as the biodegradable PEG for avoidance of 
the MPS elimination, or by adding ligands for tumour site active targeting. For drug 
release study, the ultracentrifugation method is not suitable for nanoemulsions. Therefore, 
the release study could be done using the dialysis tube method. The low level of DS found 
in the mouse plasma following the oral administration of the formulation would be better 
understood by analysing the DS level in the main organs such as the liver, kidney, lung 
and brain, as well as fat tissues since DS is known to deposit more in the fatty deposits in 
the body. For the investigation of DS-GCP20Q11-E anticancer activity, it would be useful 
to add treatment group of oral DS-GCP20Q11-E administration for the equal comparison 
with the effects seen in the oral DS in soybean oil group. The anticancer study of the 
nanoemulsions could also be attempted on other types of cancer such as the brain cancer, 
where the transport of the nanoemulsion through the blood brain barrier could be 
investigated. 
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